A Novel Model System to Study the Role of Catecholamines in Cardiac Lineage Commitment of Embryonic Stem Cells and Functional Response to Proarrhythmic Drugs by Lehmann, Martin
  
 
 
A Novel Model System to Study the Role of 
Catecholamines in Cardiac Lineage Commitment of 
Embryonic Stem Cells and Functional Response to 
Proarrhythmic Drugs 
 
 
 
 
 
 
I n a u g u r a l  D i s s e r t a t i o n 
zur 
Erlangung des Doktorgrades 
Dr. nat. med. 
der Medizinischen Fakultät 
und 
der Mathematisch-Naturwissenschaftlichen Fakultät 
der Universität zu Köln 
 
vorgelegt von 
 
Martin Lehmann 
aus Hoyerswerda 
 
 
 
 
Köln 2014 
  
  
 
Berichterstatter/Berichterstatterin:   Prof. Dr. M. Paulsson 
Prof. Dr. G. Plickert 
 
Tag der letzten mündlichen Prüfung: 11.02.2014  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
„Die einzige Quelle des Wissens ist Erfahrung.“ 
(A. Einstein) 
  
  
 
  
  
 
 
 
 
Meinen Eltern und meiner Familie 
  
  
 
 Table of Content 
I 
 
I Table of Content 
 
I Table of Content ................................................................................................................ I 
II Table of Figures .............................................................................................................. VI 
III Abbreviations ............................................................................................................... VIII 
IV Abstract ........................................................................................................................ XIII 
V Zusammenfassung ........................................................................................................ XV 
1 Introduction ...................................................................................................................... 1 
1.1 Pluripotent stem cells ................................................................................................... 1 
1.1.1 Embryonic stem (ES) cells ................................................................................... 1 
1.1.2 Induced pluripotent stem cells (iPSCs) ................................................................ 1 
1.1.3 Direct reprogramming .......................................................................................... 3 
1.2 Application fields of ES and iPS cells ......................................................................... 3 
1.3 Catecholamines ............................................................................................................ 4 
1.3.1 Catecholaminergic regulation of the heart function ............................................. 4 
1.3.2 Synthesis ............................................................................................................... 4 
1.3.3 Characterization, Function and Distribution of Adrenoceptors ........................... 7 
1.3.4 Cellular effects of adrenoceptor signal transduction ............................................ 9 
1.3.5 Reserpine action ................................................................................................... 9 
1.4 Embryonic heart development ................................................................................... 10 
1.4.1 Specification of myo- and endocardial precursors ............................................. 10 
1.4.2 Development of the tubular heart ....................................................................... 11 
1.4.3 Looping of the tubular heart ............................................................................... 11 
1.4.4 Development of the four-chambered heart ......................................................... 12 
1.5 Electrophysiology of the heart ................................................................................... 13 
1.5.1 Resting membrane potential ............................................................................... 13 
1.5.2 The cardiac action potential (AP) ....................................................................... 13 
Table of Content 
II 
 
1.6 Microelectrode arrays (MEA) ................................................................................... 16 
1.6.1 Extracellular vs. intracellular recordings ........................................................... 16 
1.6.2 Comparison of APs and FPs ............................................................................... 17 
1.6.3 Technical MEA Applications ............................................................................. 18 
1.7 Aims of the work ....................................................................................................... 18 
1.7.1 The role of catecholamines in cardiac lineage commitment in mouse ES cells. 19 
1.7.2 MEA-based QT-screen using pluripotent stem cell derived CMs ..................... 19 
2 Materials and Methods .................................................................................................. 21 
2.1 Cell culture ................................................................................................................ 21 
2.1.1 Feeder culture and inactivation .......................................................................... 21 
2.1.2 ICR-feeder (Charles Rivers Laboratories, Germany)......................................... 21 
2.1.3 neomycin-resistant mouse embryonic fibroblasts (NEO-feeder) ....................... 21 
2.1.4 CF1-feeder (Charles Rivers Laboratories, Germany) ........................................ 22 
2.1.5 Murine embryonic stem cells (mESCs; D3 aPIG44) ......................................... 22 
2.1.6 Puromycin purification of cardiomyocytes ........................................................ 23 
2.1.7 Rhesus monkey embryonic stem cells (rESCs; R366.4 and MF12) .................. 23 
2.1.8 Human embryonic and induced pluripotent stem cells (hESCs and hiPSCs) .... 25 
2.1.9 EB size assay ...................................................................................................... 25 
2.1.10 Ratio of beating clusters ..................................................................................... 25 
2.2 Flow cytometry .......................................................................................................... 26 
2.2.1 Cell preparation .................................................................................................. 26 
2.2.2 Measurement ...................................................................................................... 26 
2.3 Immunohistochemistry .............................................................................................. 26 
2.3.1 Cryosliced EBs ................................................................................................... 26 
2.3.2 Single cells/ whole EBs ...................................................................................... 27 
2.3.3 Permeabilization and immunostaining procedures ............................................ 27 
2.4 Molecular biology ...................................................................................................... 27 
2.4.1 RNA Isolation .................................................................................................... 27 
 Table of Content 
III 
 
2.4.2 DNase I digestion of RNA isolations ................................................................. 28 
2.4.3 cDNA Synthesis ................................................................................................. 28 
2.4.4 Semiquantitative-RT-PCR ................................................................................. 28 
2.4.5 Quantitative-RT-PCR ......................................................................................... 29 
2.4.6 Agarose gel electrophoresis ............................................................................... 29 
2.5 Extracellular recordings using Microelectrode Arrays (MEA) ................................. 30 
2.6 Impedance measurement ........................................................................................... 31 
2.6.1 Cell preparation .................................................................................................. 31 
2.6.2 Measurement procedure ..................................................................................... 32 
2.7 Data analysis .............................................................................................................. 32 
3 Results ............................................................................................................................. 33 
3.1 The role of catecholamines in cardiac lineage commitment in mouse ES cells ........ 33 
3.1.1 Cell culture and morphology .............................................................................. 33 
3.1.2 Reserpine application protocols ......................................................................... 33 
3.1.3 Reserpine reduces numbers of beating clusters .................................................. 35 
3.1.4 Quantification of CMs in EBs using flowcytometry .......................................... 36 
3.1.5 Reserpine inhibits expression of cardiac marker proteins .................................. 38 
3.1.6 Effects of reserpine on proliferation and cell viability ....................................... 40 
3.1.7 Reserpine effects on gene expression - Quantitative Real Time-PCR (qRT-PCR) 
  ............................................................................................................................ 43 
3.1.8 Expression of α- and β-adrenergic receptor subtypes ........................................ 48 
3.1.9 Positive effects on neuronal differentiation........................................................ 49 
3.1.10 Immunohistochemical stainings for β-III-tubulin and DBH .............................. 50 
3.1.11 Functional expression of the adrenergic and muscarinic system ....................... 51 
3.1.12 Prove of reserpine’s catecholamine depleting action ......................................... 54 
3.1.13 Isoproterenol (ISO) partially rescues the long-term effects of reserpine ........... 56 
3.1.14 α- and β-AR antagonists mimic the reserpine effect .......................................... 58 
3.2 MEA-based QT-screen using pluripotent stem cell derived CMs ............................. 61 
Table of Content 
IV 
 
3.2.1 Rhesus monkey cell culture ................................................................................ 61 
3.2.2 rESC differentiation using mass culture and END2 protocols ........................... 62 
3.2.3 rESC differentiation applying activinA/BMP4 .................................................. 62 
3.2.4 Summary of the optimized differentiation ......................................................... 64 
3.2.5 Efficiency of the optimized differentiation ........................................................ 65 
3.2.6 rESCMs express cardiac αActinin ..................................................................... 66 
3.2.7 Negative FPDur/ frequency (FP/f) correlation in hESCMs under physiologic 
conditions ........................................................................................................... 67 
3.2.8 Negative FP/f correlation in hiPSCMs under physiologic conditions ............... 70 
3.2.9 Negative FP/f correlation during negative chronotropic stimulation ................. 71 
3.2.10 FP/f correlation during successive positive and negative chronotropic 
stimulations ........................................................................................................ 71 
3.2.11 Effects of class III antiarrhythmic drugs on FP/f correlations in hESCMs and 
rESCMs .............................................................................................................. 72 
4 Discussion ........................................................................................................................ 76 
4.1 Role of catecholamines in cardiac lineage commitment in mouse ES cells .............. 76 
4.1.1 Effects of reserpine on cardiac differentiation ................................................... 77 
4.1.2 Underlying mechanisms ..................................................................................... 81 
4.1.3 Effects on neuronal Differentiation .................................................................... 83 
4.1.4 Conclusions ........................................................................................................ 85 
4.2 MEA-based QT-screen using pluripotent stem cell-derived CMs ............................ 86 
4.2.1 Optimization of rESC culture and differentiation .............................................. 86 
4.2.2 Qualitative classification of drug effects by FP/f correlation ............................ 87 
4.2.3 Limitations and suggested improvements .......................................................... 88 
4.2.4 Conclusions ........................................................................................................ 90 
VI References ................................................................................................................... XVII 
VII Primers ................................................................................................................ XXXIV 
VIII Antibodies ............................................................................................................. XXXV 
 Table of Content 
V 
 
IX Materials ................................................................................................................ XXXVI 
X Curriculum Vitae .......................................................................................................... XL 
XI Declaration ................................................................................................................... XLI 
XII Publications .............................................................................................................. XLII 
XIII Danksagungen ......................................................................................................... XLIII 
 
 
Table of Figures 
VI 
 
II Table of Figures 
Figure 1.1: Schematic overview of catecholamine synthesis and corresponding enzymes ....... 5 
Figure 1.2: Correlation of APs and ECG intervals and segments ............................................ 16 
Figure 1.3: Linear relationship between APD90 and FPDur ....................................................... 18 
Figure 2.1: Depiction of common FP features ......................................................................... 31 
Figure 3.1: Colony of pluripotent D3 αPIG44 ES cells ........................................................... 33 
Figure 3.2: Scheme of culture protocols .................................................................................. 34 
Figure 3.3: eGFP positive cardiomyocyte containing EBs representative of the time course of 
differentiation ........................................................................................................................... 35 
Figure 3.4: Visual counting of beating clusters ........................................................................ 36 
Figure 3.5: Flowcytometry for CM quantification ................................................................... 38 
Figure 3.6: Immonhistochemical staining for cardiac markers ................................................ 40 
Figure 3.7: Cross-section areas during the course of differentiation ....................................... 41 
Figure 3.8: Impedance measurements to exclude cytotoxic effects of reserpine on CMs ....... 43 
Figure 3.9: qRT-PCR results of Zfp42 (Rex1), Oct4, Nanog and Fgf-5 .................................. 44 
Figure 3.10: qRT-PCR results of cardiac marker genes Myh6, Mlc2a and mesodermal markers 
Nkx2-5, T-bra and Gata4 ......................................................................................................... 46 
Figure 3.11: qRT-PCR results of catecholamine synthesis genes Th, Ddc, Dbh and Pnmt ..... 47 
Figure 3.12: qRT-PCR results of endodermal and ectodermal /neuronal marker genes .......... 48 
Figure 3.13: Time course of α- and β-AR subtype expression ................................................ 49 
Figure 3.14: Neuronal cells in reserpine-treated EBs .............................................................. 50 
Figure 3.15: Immunohistochemical staining with anti-β-III-tubulin and anti-DBH antibodies
 .................................................................................................................................................. 51 
Figure 3.16: Comparison of β-adrenergic and muscarinic modulation of beating rate in control 
and reserpine-treated ES cell-derived cardiomyocytes ............................................................ 53 
Figure 3.17: Effect of catecholamines on spontaneously beating clusters of EBs after acute 
application of reserpine ............................................................................................................ 55 
Figure 3.18: Long-term rescue experiment with ISO .............................................................. 57 
Figure 3.19: Isoprenaline long-term rescue effect on neuronal development .......................... 58 
Figure 3.20: Blocking of α- and β-ARs mimics the reserpine-induced effect on 
cardiomyogenesis ..................................................................................................................... 60 
Figure 3.21: Alkaline phosphatase staining of R366.4 and MF12 rESCs ................................ 61 
 Table of Figures 
VII 
 
Figure 3.22: Optimization of rESCM differentiation by mass culture and END2 differentiation 
protocols ................................................................................................................................... 62 
Figure 3.23: Optimization of rESCM differentiation protocols by activinA and BMP4 ......... 64 
Figure 3.24: Scheme of the rESC cardiac differentiation protocol using growth factors 
activinA and BMP4 for MEA QT-screen ................................................................................ 65 
Figure 3.25: Efficiency of rESC differentiation into contracting EBs ..................................... 66 
Figure 3.26: Anti-αActinin immunohistochemical staining of an rESC-derived contracting EB
 .................................................................................................................................................. 67 
Figure 3.27: Negative FP/f correlation in H1 hESCMs under physiological positive 
chronotropic conditions ............................................................................................................ 69 
Figure 3.28: Negative FP/f-correlation in hiPSCMs under physiological positive chronotropic 
conditions FPDur/frequency plots representative of ISO treatment of NP0017, NP0014c5 and 
Royan d25-35 hiPSCMs. .......................................................................................................... 70 
Figure 3.29: Negative FP/f correlation in hESCMs under physiologic positive chronotropic 
conditions FPDur/frequency plots representative of CCH treatment of H1 d25-35 hESCMs. .. 71 
Figure 3.30: Negative FP/f correlation in hESCMs under physiologic positive and negative 
chronotropic conditions ............................................................................................................ 72 
Figure 3.31: Positive FP/f correlation in hESCMs and rESCMs induced by class III 
antiarrhythmic drug application ............................................................................................... 73 
Figure 3.32: Positive FP/f correlation in hESCMs and rESCMs induced by different 
antiarrhythmic drug applications .............................................................................................. 74 
Figure 4.1: Illustration of drug effect classification based on positive and negative FP/f 
correlations ............................................................................................................................... 87 
 
 
Abbreviations 
VIII 
 
III Abbreviations 
% percent 
°C degree celsius 
µ (SI-prefix) micro (10-6) 
AA arachidonic acid  
AADC aromatic L-amino acid decarboxylase (see DDC) 
Afp alpha-fetoprotein (gene name) 
Alb albumin (gene name) 
AP action potential 
APD action potential duration 
APD90 action potential duration at 90 % repolarization 
APDur action potential duration 
AR adrenoceptor/adrenergic receptor 
ATP adenosine-5'-triphosphate 
AV-node  atrioventricular node 
bFGF basic fibroblast growth factor 
β-ME β-Mercaptoethanol  
BMP bone morphogenic protein 
bp base pairs 
Ca2+ calcium ion 
cAMP cyclic adenosine-5'-monophosphate 
CCH carbachol 
cDNA complementary deoxyribonucleic acid (DNA) 
cGMP cyclic guanosine-5'-monophosphate 
CI cell index 
CICR Ca2+-induced Ca2+-release  
Cl- chloride ion 
CO2 carbondioxide 
COMT catechol-O-methyltransferase  
ct cycle threshold 
cTnT cardiac troponinT 
d day of differentiation 
DA dopamine 
DAG diacylglycerol 
DBH dopamine-β-hydroxylase  
DDC L-dopa-decarboxylase (see AADC) 
DMEM Dulbecco's Modified Eagle Medium  
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNase deoxyribonuclease 
DOPA 3,4-dihydroxyphenylalanine  
E embryonic day (e.g. E9, etc.) 
 Abbreviations 
IX 
 
EB embryoid body 
ECG electrocardiogram 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent protein 
EPI epinephrine/adrenaline 
ES (cell)/ESC embryonic stem cell 
ESCM embryonic stem cell-derived cardiomyocyte 
EtBr ethidium bromide 
FBS fetal bovine serum  
FGF fibroblast growth factor 
Fgf-5 gene name 
Fig. figure 
Foxa2 forkhead box A2 (gene name)  
FP field potential 
FP/f  FPDur/ frequency 
FPDur field potential duration 
FPmax field potential maximum 
FPmin field potential minimum 
g gramm 
G418 neomycin 
Gapdh glyceraldehyde-3-phosphate dehydrogenase (gene name) 
Gata4 Gata binding factor 4 (gene name)  
GFP green fluorescent protein 
Gi inhibitory G-protein 
GPCR G protein-coupled receptor  
G-protein guanosine nucleotide-binding protein 
Gs stimulating G-Protein 
H2O water 
hESCM human embryonic stem cell-derived cardiomyocyte 
HMMA vanillylmandelic acid  
Hnf4a hepatocyte nuclear factor 4a (gene name) 
hr hour 
HVA homovanillic acid  
Hz Hertz 
I (membrane) current (e.g. IKr, ICaL, etc.) 
ICA (cells) intrinsic cardiac adrenergic (cells) 
ICM inner cell mass (of blastocyst) 
IHC immunohistochemistry 
IMDM Iscove's Modified Dulbecco's Medium 
IP3 inositol 1,4,5-trisphosphate 
iPS (cell)/iPSC induced pluripoten stem cell 
iPSCM induced pluripoten stem cell-derived cardiomyocyte 
ISI interspike interval 
Abbreviations 
X 
 
ISO isoproterenol/isoprenaline 
k (SI-prefix) kilo (103) 
K+ potassium ion 
KO-DMEM Knock-out™ Dulbecco’s Modified Eagle Medium  
l litre 
LDCG large dense core granule 
L-DOPA L-Dihydroxyphenylalanine  
LDVC large dense core vesicle 
LIF leukemia inhibitory factor  
M mol/liter 
m meter 
m (SI-prefix) milli (10-3) 
MAB monoclonal antibody 
MAO monoamine oxidase  
Map2 microtubule-associated protein 2  (gene name) 
MEA microelectrode array 
MEF mouse embryonic fibroblast 
mESCM mouse embryonic stem cell-derived cardiomyocyte 
Mg2+ magnesium ion 
min minute 
Mlc2a myosin light chain 2a (gene name)  
mRNA messenger ribonucleic acid 
Myh6 myosin heavy chain 6 (gene name)  
n number of samples 
n (SI-prefix) nano (10-9) 
Na+ sodium ion 
Nanog gene name 
NCAM neuronal cell adhesion molecule 
NE norepinephrine/noradrenaline 
NEAA non-essential amino acids  
Nes nestin (gene name) 
NH4Cl ammonium chloride 
Nkx2-5 homebox protein Nkx2-5 (gene name)  
NO nitric oxide  
Nodal gene name 
Oct4/Oct3/4 gene name 
PBS phosphate-buffered saline 
PCR polymerase chain reaction 
PD parkinson’s disease  
Pen/Strep Penicillin/Steptomycin  
PI propidium iodide 
PNMT phenylethanolamine N-methyltransferase  
Prod# product number 
 Abbreviations 
XI 
 
Puro puromycin 
qRT-PCR quantitative real-time polymerase chain reaction 
Res reserpine 
rESCM rhesus monkey embryonic stem cell-derived cardiomyocyte 
RNA ribonucleic acid 
RNase ribonuclease 
RP resting potential 
RQ relative quantity 
RR-interval  ECG-derived time interval between two R-peaks 
s.e.m. standard error of the means 
SA-node  sinoatrial-node 
SD standard deviation 
sec second 
Sox17 gene name 
sqRT-PCR semiquantitative reverse-transcription polymerase chain reaction 
SR sarcoplasmatic reticulum  
SR Serum replacement 
SV synaptic vesicles 
TAE (-buffer) Tris base, acidic acid, EDTA (-buffer) 
T-bra T brachyury (gene name)  
TdP torsade de pointes 
TGF-β tumor growth factor-β 
TH tyrosine hydroxylase  
Tris Tris-(hyrdomethyl)-aminomethane 
Tubb3 β-III-tubulin (gene name) 
U enzyme units 
V Volt 
v/v volume per volume 
VAT vesicular amine transporter 
VMA vanillylmandelic acid  
VMAT vesicular monoamine transporters 
w/o without 
w/v weight per volume 
Wnt gene name 
x g gravitation [m/s2] 
Zfp42(Rex1) gene name 
 
  
Abbreviations 
XII 
 
Abstract 
XIII 
 
IV Abstract 
Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the 
blastocyst. These cells possess the ability to differentiate into all cell types of the three germ-
layers and to proliferate indefinitely. In defined conditions ES cells are committed to the 
mesodermal lineage and differentiate, amongst other cell types, into cardiomyocytes (CMs). 
The processes underlying mesodermal and subsequent cardiac differentiation are yet only 
partially understood. Catecholamine release is well known to modulate heart rate and force in 
adult mammals. Despite first evidence, only little is known about an involvement of 
catecholamines during embryonic heart development. Therefore the work aimed to investigate 
in more detail whether catecholamines are involved in the process of ES cell cardiac 
differentiation in vitro. 
 Effects of catecholamine depletion induced by reserpine were investigated during 
murine D3 αPIG44 ES cell differentiation. Reserpine is a drug blocking vesicular storage of 
monoamines, and as a result depletes cells of the catecholamines norepinephrine and 
epinephrine. Cardiac differentiation was assessed by quantification of beating clusters, 
immunocytochemistry, molecular biology, flowcytometry and pharmacological approaches. 
Proliferation and cytotoxicity was evaluated by embryoid body cross-section measurements 
and impedance monitoring, while functional characterization of CMs was performed using 
extracellular field potential (FP) recordings with microelectrode arrays (MEAs). Involvement 
of β-adrenoceptor signaling was studied differentiating ES cells in the presence of reserpine 
and isoproterenol. To further discriminate between drug-specific effects of reserpine and 
catecholamine action via adrenergic receptors we applied the unspecific α- and β-receptor 
antagonists phentolamine and propranolol during differentiation. 
 Reserpine treatment led to a remarkable reduction of beating cardiac clusters, down-
regulation of cardiac proteins α−actinin and troponinT and delayed mesodermal and cardiac 
gene expression. In more detail, the average ratio of ~40% spontaneously beating control 
clusters was significantly reduced by 100%, 91.1% and 20.0% on days 10, 12, and 14, 
respectively. In line, significant reduction by 71.6% (n=11) of eGFP expressing CMs after 
reserpine treatment was revealed by flowcytometry. Reserpine neither reduced EB size nor 
acted cytotoxic on CMs, while an increased numbers of neuronal cells were observed. MEA 
measurements with reserpine-treated EBs showed lower FP frequencies and weak 
responsiveness to adrenergic and muscarinic stimulation. Co-application of isoproterenol and 
reserpine during differentiation partially rescued cardiac development. The developmental 
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inhibition after α- and β-adrenergic blocker application mimicked developmental changes 
with reserpine and proved an involvement of adrenergic receptors in the process. We 
conclude that catecholamines and adrenergic signaling play a critical role during cardiac 
development in ES cells. 
 Since we experienced the ES cell/MEA model as useful for pharmacological 
approaches, we wondered as a next step whether pluripotent ES cell-derived CMs could be 
used for safety pharmacological drug screening with cardio-active compounds. 
Concentration/response was tested in rhesus monkey and human ES cell- and human induced 
pluripotent stem cell-derived CMs (rESCMs, hESCMs and, hiPSCMs, respectively) for 
different drugs at increasing concentrations. 
 Empirical observation under physiologic positive and negative chronotropic drug-
stimulation showed negative correlations of FP duration (FPDur) and beating frequency 
(negative FP/f correlation). Negative FP/f correlation persisted independent of cell lines in 
hESCMs and hiPSCMs. In contrast, FP/f correlations changed to positive values in the 
presence of E4031 and sotalol in a concentration-dependent manner.  
 Therefore, it was concluded that safety pharmacological drug-screening is feasible 
using ES cell-derived CMs and MEAs independent of cell lines and species origin. 
Furthermore a novel method to qualitatively evaluate QT-time/repolarization prolonging drug 
effects based on FP/f correlations is sugested. The results may help to reduce cost-intensive 
clinical trials and, above all, to reduce the number of animal experiments.  
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V Zusammenfassung 
Embryonale Stammzellen werden aus der inneren Zellmasse von Blastozysten gewonnen. 
Diese Zellen besitzen die Eigenschaft in alle Zelltypen der drei Keimblätter zu differenzieren 
und unendlich zu proliferieren. Unter den geeigneten Bedingungen lassen sich aus 
embryonalen Stammzellen mesodermale Zellen generieren, die neben anderen Zellen, zu 
Kardiomyozyten differenzieren. Die Prozesse, die mesodermaler und anschließender kardialer 
Differenzierung zugrunde liegen sind jedoch erst teilweise erforscht. Man weiß, dass über 
Katecholamineausschüttung die Herzfrequenz und die Kontraktionskraft des Herzens in 
adulten Säugetieren reguliert wird. Obwohl vorläufige Ergebnisse darauf hindeuten, weiß man 
allerdings erst sehr wenig ob Katecholamine während der embryonalen Herzentwicklung eine 
Rolle spielen. Daher soll in dieser Arbeit detailliert untersucht werden, ob Katecholamine in 
vitro am Prozess der kardialen Differenzierung von Stammzellen beteiligt sind. 
 Die Effekte, die durch Reserpin-induzierte Katecholamin-Verarmung hervorgerufen 
wurden, sollten während der Differenzierung muriner embryonaler D3 αPIG44 Stammzellen 
untersucht werden. Reserpin blockiert den vesikulären Transport von Katecholaminen, und 
als Folge verarmen die Zellen an Noradrenalin und Adrenalin. Die Auswirkungen auf die 
kardiale Differenzierung wurden durch die Quantifizierung kontrahierender Cluster, 
immunhistochemischer und molekularbiologischer Methoden, sowie Durchflusszytometrie 
und pharmakologischer Methoden ermittelt. Die Prolifertation und Zytotoxizitätseffekte 
wurden jeweils mit Hilfe von Querschnittsflächen-Messungen von Embryonalkörpern (EBs) 
beziehungsweise Impedanz Messungen untersucht, wohingegen man extrazelluläre 
Feldpotential (FP) Messungen durch Microelektroden Arrays (MEA) dazu benutzte, die 
Funktionalität der Kardiomyozyten zu prüfen. β-Adrenozeptor vermittelte Signale als Ursache 
der beobachteten Prozesse, wurde durch Differenzierung der Stammzellen unter gleichzeitiger 
Zugabe von Reserpin und Isoproterenol (ISO) untersucht. Um darüber hinaus zwischen 
Reserpin-spezifischen Effekten und Katecholamin-vermittelter α- und β-Adrenozeptor 
Wirkung zu unterscheiden, wurden die Stammzellen während der Differenzierung den 
entsprechenden Antagonisten, Phentolamin und Propranolol, ausgesetzt.  
 Reserpin führte zu einer deutlichen Reduktion schlagender kardialer Cluster und zu 
herab-regulierter Expression der kardialen Proteine α-Actinin und TroponinT sowie 
mesodermaler und kardialer Gene. Im Detail beobachtete man, dass die in Kontrol EBs bei 
ungefähr 40% liegende Rate schlagender Areale an den Tagen 10, 12 und 14 signifikant um 
entsprechend 100%, 91,1% und 20% reduziert waren. Genauso zeigten Durchflusszytometrie 
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Experimente eine Reduzierung eGFP-exprimierender Kardiomyozyten um 71,6%. Reserpin 
hatte weder einen Einfluss auf die EB Größe noch auf Zytotoxizität, jedoch wurde 
interessanterweise eine erhöhte Anzahl von Neuronen beobachtet. Die MEA Versuche 
ergaben verringerte Schlagraten in Reserpin-behandelten EBs und sehr geringe 
Empfindlichkeit gegenüber adrenerger und muskarinerger Stimulation. Eine co-Applikation 
von Reserpin mit ISO bewirkte einen partiellen „Rescue“ der kardialen Entwicklung. 
Außerdem beobachtete man, dass die kardiale Entwicklungsverzögerung nach α- und β-
Blocker Behandlung in hohem Maß der Verzögerung nach der Reserpin Behandlung glich. 
Dadurch konnte der Einfluss der adrenergen Rezeptoren gezeigt werden. Es lässt sich daher 
aus dieser Arbeit schlussfolgern, dass Katecholamine eine kritische Rolle bei der 
Herzentwicklung spielen und dass adrenerge Rezeptoren daran beteiligt sind. 
 Da sich das ES Zell/MEA Modell als sehr geeignet für pharmakologische 
Untersuchungen erwiesen hat, stellte sich die Frage ob man pluripotente Stammzellen für 
sicherheitspharmakologische Screenings kardioaktiver Substanzen nutzen kann. Die 
Kombination von Stammzellen als unbegrenzte Quelle für Kardiomyozyten zu dienen mit 
dem Vorteil der MEA-Technik über lange Zeiträume extrazellulär ableiten zu können, stellt 
eine ideale Methode für Drogen-Screens dar. Die konzentrationsabhängige Antwort 
verschiedener Drogen wurde daher an verschiedene Rhesusaffen und humanen embryonalen 
und induziert-pluripotenten Stammzell-abgeleiteten Kardiomyozyten (entsprechend rESCMs, 
hESCMs und hiPSCMs) getestet.  
 Unter physiologisch positiven und negativen chronotropen Bedingungen beobachtete 
man eine negative Korrelation zwischen der FP Dauer (FPDur) und der Schlagfrequenz 
(negative FP/f Korrelation). Negative FP/f Korrelation wurden unabhängig voneinander bei 
ESCMs und iPSCMs beobachtet. Im Gegensatz dazu änderte die Zugabe von E4031 und 
Sotalol die FP/f Korrelation zu positiven Werten.  
 Anhand der empirischen Daten kann man zeigen, dass ein 
sicherheitspharmakologischer Screen, basierend auf pluripotenten Stammzellen und dem 
MEA System, unabhängig von Zelllinie und Spezies durchgeführt werden kann. Im Rahmen 
dieser Arbeit schlagen wir eine neue graphische Methode der qualitativen Evaluierung 
substanz-abhängiger QT-Zeit- bzw. Repolarisations-Effekte vor. Die Ergebnisse daraus 
können in Zukunft dazu beitragen, Kosten bei der Medikamentenforschung einzusparen und, 
vor Allem, die Zahl an Versuchstieren deutlich zu verringern.
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1 Introduction  
1.1 Pluripotent stem cells 
1.1.1 Embryonic stem (ES) cells 
Embryonic stem (ES) cells are derived from the inner cell mass (ICM) of an early blastocyst. 
These cells are pluripotent, i.e. they possess the ability to differentiate into all cells of an 
embryo except for extra-embryonic tissues (e.g. the trophoblast). Pluripotent ES cells are, 
thus, characterized by their ability to differentiate into cells of the three germ-layers 
(endoderm, mesoderm and ectoderm) and further by their property to be propagated 
indefinitely [Evans and Kaufman 1981, Martin 1981, Thomson, Kalishman et al. 1995, 
Thomson, Itskovitz-Eldor et al. 1998, Itskovitz-Eldor, Schuldiner et al. 2000]. Due to these 
characteristics ES cells provide a great tool to study embryogenesis in vitro. Underlying 
mechanisms or signaling pathways crucial for ES cell development into mature cells can 
easily be accessed using this relatively simple model. Furthermore, ES cells are thought to 
hold great promise for cell replacement therapy of a variety of degenerative diseases like 
Parkinson’s disease, cardiac infarction and diabetes mellitus. However, there is a number of 
obstacles to overcome before pluripotent cells and their derivatives will be used for clinical 
approaches. A major issue of the medical application of pluripotent cells is that current 
differentiation protocols lead to a mixture of randomly occurring cells, even if the used 
protocol favors a certain direction of cell-type differentiation. Amongst the other cells there is 
a high probability of remaining pluripotent cells which, after transplantation, have a high 
potential for teratocarcinoma formation [Thomson, Kalishman et al. 1995, Thomson and 
Marshall 1998]. And moreover, if for example donor stem cell-derived somatic cells of a 
certain kind are transplanted into a host (allogenic transfer), the host’s immune system can 
recognize the donor cells as foreign and will induce a variety of immune reactions potentially 
leading to transplant rejection [Thomson, Itskovitz-Eldor et al. 1998].  
1.1.2 Induced pluripotent stem cells (iPSCs) 
A breakthrough in regard of the issue of immune rejection, hindering clinical application, was 
the work of S. Yamanaka, his colleagues and other groups. They showed that somatic cells 
can be reprogrammed into a pluripotent state and being indistinguishable to pluripotent ES 
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cells derived from embryos [Takahashi and Yamanaka 2006, Takahashi, Tanabe et al. 2007, 
Wernig, Meissner et al. 2007]. They found that only four factors, OCT4 (also called OCT3/4 
or POU5f1), SOX2, c-MYC, and KLF4 (“Yamanaka factors”) are sufficient to reprogram 
somatic cells into a pluripotent state. Using a different set of reprogramming factors (OCT4, 
SOX2, NANOG, and LIN28) also led to successful somatic cell reprogramming [Yu, 
Vodyanik et al. 2007]. These cells are known today as induced pluripotent stem (iPS) cells 
possessing typical characteristics of ES cells, and amongst those, the ability to differentiate 
into cells of all three germ-layers. The possibility of reprogramming to generate patient-
specific iPS cells was a critical step toward clinical application of pluripotent cell derivatives, 
because immune rejection could be overcome by this approach. Very recently, however, the 
supposed advantage of histocompatibility of iPSCs was challenged. A study showed that also 
syngeneic iPSCs were rejected after transplantation [Zhao, Zhang et al. 2011]. Nevertheless, 
controversial debate, especially considering the immunogenicity of iPSC-derived 
differentiated cells, is still going on [Okita, Nagata et al. 2011, Araki, Uda et al. 2013]. 
However, iPS cells still inherit the risk of teratoma formation after transplantation 
[Takahashi and Yamanaka 2006, Wernig, Meissner et al. 2007, Yu, Vodyanik et al. 2007, 
Yoshida and Yamanaka 2010]. Less than 2 years after the first successful generation of iPS 
cells using the Yamanaka factors, an improved iPS generation protocol was established 
omitting the oncogene c-Myc leading to reduced tumor formation in chimeric offspring 
[Nakagawa, Koyanagi et al. 2008, Pera and Hasegawa 2008, Wernig, Meissner et al. 2008]. 
Another study revealed that exogenous expression of only Oct4 was enough for 
reprogramming neural stem cells into pluripotent cells, which could again be differentiated, 
not only into neuronal lineage cells, but also into cardiomyocytes and endothelial cells [Kim, 
Sebastiano et al. 2009]. This meant a further advance toward clinical application of 
pluripotent cells. Still, the viral vectors used for transfection of the pluripotency factors 
represent an important issue, because they integrate into the genome randomly and potentially 
lead to insertional mutagenesis. Methods for non-integrative reprogramming such as episomal 
plasmids [Okita, Matsumura et al. 2011], proteins [Kim, Kim et al. 2009, Zhou, Wu et al. 
2009] and mRNA [Warren, Manos et al. 2010, Warren, Ni et al. 2012] have already been 
established. Ultimately, e.g. small molecules for reprogramming would help to make 
pluripotent stem cell therapy considerably safer. 
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1.1.3 Direct reprogramming 
Within the last 5 years first results of trans-differentiation of one somatic cell-type directly 
into another somatic cell-type were presented [Feng, Desbordes et al. 2008, Ieda, Fu et al. 
2010, Vierbuchen, Ostermeier et al. 2010]. As suggested, cell types can be converted into cell 
lines of another type. Even though it is at the very beginning, at the moment this research field 
is the most promising one, because it circumvents the afore-mentioned major risks of 
pluripotent cell usage for the treatment of diseases. Trans-differentiated cells supposedly 
avoid the risk of teratoma formation because they will obviate pluripotent cell states, and if 
the technique is established cells for syngeneic transplantation can be produced within a short 
period of time [Feng, Desbordes et al. 2008, Ieda, Fu et al. 2010, Vierbuchen, Ostermeier et 
al. 2010].   
1.2 Application fields of ES and iPS cells 
ES as well as iPS cells are used as models to study embryogenesis. Especially iPS cells will 
be valuable tools for studies involving material of human origin, since ethical considerations 
are avoided when compared to ES cells. One possible field beside basic research on 
embryogenesis could certainly be the usage of human iPS cells for drug screening [Khan, 
Lyon et al. 2013]. In this way possible side-effects can be prognosed in vitro, thus, reducing 
the number of experimental animals needed for clinical trials. Possibly harmful or un-
specifically acting compounds could be identified early, if negative effects on tissue-specific 
committed cells, derived from human iPS cells, are detected. One part of this thesis focusses 
on exactly this question. We have analyzed and will discuss if cardio-active drug effects can 
reliably be forecasted using microelectrode arrays (MEA). Another application area for iPS 
cells is the investigation of the pathophysiology of genetic diseases. Therefore, patient-
specific fibroblasts were reprogrammed and subsequently differentiated into the cell types 
affected by the disease. Cardiomyocytes, for example, were generated to analyze if the 
pathological symptoms seen in patients can be recapitulated phenotypically [Moretti, Bellin et 
al. 2010, Fatima, Xu et al. 2011, Itzhaki, Maizels et al. 2011]. These approaches will help to 
understand mechanisms of diseases, to develop new drugs and to optimize treatment strategies 
[Jung, Moretti et al. 2012]. 
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1.3 Catecholamines 
1.3.1 Catecholaminergic regulation of the heart function 
It is well known that catecholamine secretion induces several physiological changes 
increasing the performance of the organism in response to dangerous or acute stress situations 
(fight-or-flight response [Cannon 1920]). These changes are attributed to the sympathetic 
nervous system and regulate cardiac output as well as vasoconstriction subsequently 
influencing blood pressure. Moreover, also respiration, digestion, the pupillary response, 
urinary excretion and sexual arousal are regulated by that system. Already in 1895, George 
Oliver and Edward Albert Schäfer showed the pharmacological effect of a supra-renal extract 
on blood pressure [Oliver and Schafer 1895]. Shortly after that Thomas Renton Elliot found 
that a substance could be produced from the adrenal medulla, which mimicked the effects of 
the sympathetic nervous system. Then, in 1904 adrenalin synthesis was accomplished by F. 
Stolz. It took many years until in 1931 a study on isolated embryonic chick hearts and cardiac 
tissue cultures showed that adrenaline (and also acetylcholine) affects pre-innervation stage 
cardiac isolates and thus suggested that an “intermediate receptive substance” (i.e. receptors) 
confers the adrenalin signal [Markowitz 1931]. Today we know that adrenoceptors 
(adrenergic receptors, ARs) and their second messengers are responsible for signal 
transduction of NE and EPI across the membrane of the affected cell.  
1.3.2 Synthesis 
The biogenic amines Dopamine (DA), Norepinephrine (NE) and Epinephrine (EPI) are 
synthesized in amine-handling cells in different organs of the body in mammals, e.g. neurons 
in the central and peripheral nervous system and in chromaffin cells of the adrenal medulla in 
the kidneys. While DA functions as the principal neurotransmitter in those parts of the central 
nervous system associated with motor control, its β-hyrdoxylated form, NE, is produced in 
the adrenergic central and peripheral nervous system. The addition of a methyl group to the 
amino group of NE forming EPI finally takes place in the adrenal medulla [Molinoff and 
Axelrod 1971, Peaston and Weinkove 2004]. Amine-handling cells are characterized by the 
expression of proteins related to I) amine synthesis, II) plasma membrane transport for release 
and recycling of amines from the extracellular space and III) intracellular transport of amines 
for vesicular storage (reviewed in [Weihe and Eiden 2000]). 
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1.3.2.1 Catecholamine synthesis cascade 
Catecholamine synthesis is schematically depicted in Fig. 1.1 with the amino acid tyrosine as 
a precursor which is converted into L-Dihydroxyphenylalanine (L-DOPA), DA, NE and EPI 
by the sequential action of the enzymes tyrosine hydroxylase (TH), aromatic L-amino acid 
decarboxylase/L-dopa-decarboxylase (AADC/DDC), dopamine-β-hydroxylase (DBH) and 
phenylethanolamine N-methyltransferase (PNMT) . The TH-catalyzed first step within the 
anabolic cascade is the rate-limiting one. 
 
1.3.2.2 Plasma membrane transport for release and recycling of amines from the 
extracellular space 
During the synaptic transmission process, catecholamines, acting as neurotransmitters, are 
released from the presynaptic membrane by exocytosis into the synaptic cleft. After release, 
binding of catecholamines to post-synaptic receptors subsequently induces signal transduction 
and allows information propagation from one cell to the other. As important as the 
information propagation, however, is the termination of the signal transduction by an active 
re-uptake of the amines into the presynaptic membrane (Na+-gradient dependent). How 
important this re-uptake process and the termination of the signaling for a normal function of 
e.g. the brain is, can be understood by the dramatic effects induced by specific re-uptake 
 
Figure 1.1: Schematic overview of catecholamine synthesis and corresponding enzymes 
Adopted from Encycloaedia Britannica. 
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inhibitors like cocaine and amphetamines. After re-uptake amines are either recycled by 
transport into storage vesicles or degraded by the action of monoamine oxidase (MAO) and 
catechol-O-methyltransferase (COMT) (reviewed in [Eisenhofer, Kopin et al. 2004, Peaston 
and Weinkove 2004]).  
Only a small fraction of released catecholamines reaches circulation [Bravo, Tarazi et 
al. 1979], while the majority of the catecholamines is metabolized in the cytosol of neuronal 
or extra-neuronal cells as well as in the adrenal medulla. During the metabolic degradation of 
catecholamines which are circulating in the body or are re-uptaken by cells, a number of 
cytotoxic metabolites are formed. While NE and EPI are metabolized to vanillylmandelic acid 
(HMMA/VMA), DA is metabolized to homovanillic acid (HVA). These metabolites are then 
transported to the liver via the blood-stream, before both are eliminated from the system by 
the kidneys (reviewed in [Eisenhofer, Kopin et al. 2004]).  
1.3.2.3 Intracellular transport of Catecholamines for vesicular storage 
The intracellular transport of catecholamines in the cells of the adrenergic central and 
peripheral nervous system and the adrenergic medulla is accomplished by expression of 
Vesicular Amine Transporters (VATs). Vesicular transport of dopamine is also one of the 
rate-limiting steps in catecholamine synthesis. In catecholaminergic cells two types of VATs 
are found depending on the organ or cell type they are located at and are called VMATs 
(Vesicular Monoamine Transporters). While VMAT1 expressing cells are found in peripheral 
neuroendocrine cells including the adrenal chromaffin cells (in the adrenal medulla in the 
kidney), VMAT2 expression is found in all aminergic neurons, some neurons of the guts and 
in cells of the immune system (e.g. mast cells [Weihe and Eiden 2000]). Monoamine uptake 
by VMATs can potently be blocked by reserpine and tetrabenazine [Erickson, Eiden et al. 
1992, Schuldiner 1994]. 
Monoamines are not only stored in synaptic vesicles (SVs), but also in large dense 
core vesicles (LDCVs) which are analogous to large dense core granules (LDCGs) in 
neuroendocrine cells [Liu, Krantz et al. 1999, Torrealba and Carrasco 2004]. Both kinds 
represent different types of secretory vesicles and show distinct differences, e.g. their 
subcellular sites of release (reviewed in [Fei, Grygoruk et al. 2008]). VMAT2 was found to be 
localized in SVs as well as LDCVs. Therefore subcellular VMAT2 localization can regulate 
the site of monoamine release, showing its importance for the regulation of catecholamine 
effects [Nirenberg, Liu et al. 1995, Nirenberg, Chan et al. 1996, Nirenberg, Chan et al. 1997]. 
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1.3.3 Characterization, Function and Distribution of Adrenoceptors 
ARs are the targets of the catecholamines epinephrine (adrenaline; EPI) and norepinephrine 
(noradrenaline; NE) and are found in a variety of tissues within the body. Catecholamine 
binding induces a sympathetic response (‘flight-or-fight’ response) with the general result of 
increased heart rate and force, pupil dilation and energy mobilization preparing the body for 
improved physiological performance [Bylund, Eikenberg et al. 1994]. Effects of 
catecholamines in the mammalian body are mediated by the two major classes of adrenergic 
receptors: alpha- and beta-adrenoceptors (α-ARs and β-ARs; [Powell and Slater 1958]), 
which are both known to belong to the G protein-coupled receptor superfamily (GPCRs) 
[Caron and Lefkowitz 1993]. Several receptor-subtypes of both classes were identified and 
their specific tissue distribution and cellular localization, their distinct pharmacological 
properties and their different downstream signaling mechanisms explain the variety of actions 
conferred by catecholamines. ARs are very well investigated because of their widely 
diversified properties, the following paragraphs will give a rough overview over this complex 
field.  
1.3.3.1 α-Adrenoceptors 
α-ARs are usually found in nerve terminals of the central and peripheral sympathetic nervous 
system and are divided into two subclasses, the α1-ARs and α2-ARs. The α1-ARs subclass 
was further shown to consist of three receptor subtypes (α1A, α1B and α1D; [Hieble, Bylund et 
al. 1995]) and the α2-AR subclass constitutes another three subtypes (α2A, α2B, α2C; [Lorenz, 
Lomasney et al. 1990, Bylund 1992]). Each subtype has specific pharmacological properties 
and amino acid sequences [Bylund, Eikenberg et al. 1994, Zhong and Minneman 1999]. 
Originally, α-ARs were classified based on their anatomical localization [Langer 1974]. 
While α1-ARs are located postsynaptically, α2-ARs are mostly found presynaptically, even 
though also postsynaptic localization is found. More recently, however, α-ARs and their 
subtypes were classified by their pharmacological properties and radio-ligand binding 
(reviewed in [Bylund, Eikenberg et al. 1994]). 
All α1-ARs have certain common features: 1.) They are equally activated by NE and 
EPI, 2.) they are sensitive to blockade by prazosin, 3.) they show a low affinity to α2-ARs 
antagonists yohimbine and rauwolscine, 4.) the activation of each subtype leads to increased 
intracellular Ca2+ (reviewed in [Bylund, Eikenberg et al. 1994]). In the central nervous system 
α1-ARs have excitatory functions on postsynaptic membranes of neurons, whereas, α1-ARs in 
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the periphery are situated on vascular and non-vascular smooth muscle cells and are 
responsible for their tone. Furthermore, α1-ARs were found in the liver responsible for 
glycogenolysis and potassium release and, in the heart where they exert inotropic effects 
[Jensen, Swigart et al. 2009, Wang, Yeh et al. 2010].  
Also α2-ARs have common properties: 1.) they are activated by NE and EPI, 2.) they 
are blocked by yohimbine and rauwolscine [Bylund 1992, Bylund, Eikenberg et al. 1994]. α2-
ARs rather serve as an inhibitory system [Stevens, Kuramasu et al. 2004]. On nerve terminals 
they are found presynaptically, acting as ‘autoreceptors’ or ‘heteroreceptors’ [Starke 1987, 
Boehm and Huck 1995, Starke 2001]. Activating presynaptic α2-ARs with NE or EPI, in turn 
leads to a feedback inhibition of catecholamine (‘autoreceptor’) or other neurotransmitter 
(‘heteroreceptor’) release from neuron terminals. Similarly, EPI release from chromaffin cells 
is regulated in an autoreceptor feedback loop [Gilsbach, Brede et al. 2007]. α2-ARs were also 
found outside the central nervous system, acting in e.g. vascular smooth muscle controlling 
blood pressure [Link, Desai et al. 1996, Gilsbach, Albarran-Juarez et al. 2011]. 
Upon stimulation of all three α1-subtypes, the Gq/11 signaling pathway is activated, 
generating the second messengers inositol-(1,4,5)-triphosphate and diacylglycerol (DAG) by 
activation of phospholipase C. Furthermore,  Ca2+ from intracellular stores and especially the 
sarcoplasmatic reticulum (SR) is mobilized upon α1-AR stimulation [Chen and Minneman 
2005]. In contrast, stimulation of the α2-ARs leads to activation of the inhibitory G-protein 
(Gi) pathway, subsequently inhibiting the activity of the adenylate cyclase enzyme and 
reducing the cAMP levels in affected cells. Reduced Ca2+ influx during action potentials, in 
turn, reduces the release of NE [Limbird 1988].  
1.3.3.2 β-Adrenoceptors 
The β-AR subfamily was initially divided into β1- and β2-receptors classified for their affinity 
to their natural agonists, NE and EPI. While β1-ARs showed equal affinity for NE and EPI, 
β2-ARs show lower affinity for NE than for EPI [Lands, Arnold et al. 1967]. Furthermore, at 
least one more β-AR subtype (β3) was identified having pharmacological properties distinct 
from the other two β-AR agonists [Arch, Ainsworth et al. 1984, Bond and Clarke 1988]. 
Having an equally strong affinity to the synthetic catecholamine, isoprenaline activation, is 
one of the common properties of all three subtypes. Also antagonisation with propranolol is 
found in all subtypes, however, β3-ARs are less sensitive to this antagonist. Moreover, β-ARs 
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are primarily associated with stimulating G-protein (Gs) signaling, activating adenylyl cyclase 
and producing cAMP as a second messenger.  
β1-ARs are located mainly in the heart and adipose tissue. Especially their localization 
in the heart makes them clinically relevant, because upon stimulation they mediate increases 
in heart rate (chronotropy) and force of contraction (inotropy). Furthermore, they stimulate 
renin secretion, relaxation of coronary arteries and gastrointestinal smooth muscle. In 
contrast, β2-ARs are responsible for relaxation of vascular, uterine and airway smooth muscle. 
Also prejunctional β-ARs, responsible for NE release modulation in sympathetic nerve 
terminals, seem to be of the β2-AR subtype (reviewed in [Bylund, Eikenberg et al. 1994]). β3-
ARs have also been found in adipocytes and, furthermore in the ileum [Arch, Ainsworth et al. 
1984, Bond and Clarke 1988]. Nevertheless, β-AR subtypes (as well as α-AR subtypes) are 
distributed throughout the body and are not exclusively limited to specific tissues and, even 
more, the distribution is highly species-dependent.  
1.3.4 Cellular effects of adrenoceptor signal transduction 
Upon catecholamine binding to respective receptor subtypes, dissociation of the G-protein 
heterotrimers regulates a variety of second messengers, e.g. cAMP, cGMP, Ca2+, inositol 
1,4,5-trisphosphate (IP3), diacylglycerol (DAG) nitric oxide (NO), arachidonic acid (AA), etc. 
Subsequently, protein kinases and phosphatases regulate the phosphorylation status of 
proteins involved in almost all areas of cellular function. These functions can roughly be 
divided into short-term and long-term modulating effects. Short-term effects include e.g. ion 
channel activity, receptor sensitivity, general metabolism or neurotransmitter synthesis and 
release, whereas, long-term modulations include synthesis of channels, receptors and 
intracellular messengers, synaptogenesis and generally gene expression [Keys and Koch 
2004, Zheng, Han et al. 2004].  
1.3.5 Reserpine action 
Reserpine was originally a drug used for the treatment of hypertension, but was soon shown 
to produce hypokinesia and akinesia as well as other symptoms like rigidity of skeletal 
muscles, tremor and postural flexion in different treated animal species by changing the 
catecholamine levels in the brain [Flach 1955, Jurna and Lanzer 1969, Morrison and Webster 
1973, Wagner and Anderson 1982]. Inducing these symptoms, resembling human Parkinson’s 
disease (PD), reserpine provided one of the first transient pharmacological PD models. In turn 
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the decreased motor activity could be counteracted by the administration of 3,4-
dihydroxyphenylalanine (L-DOPA) and that was the basis for the L-DOPA substitution 
therapy of PD [Carlsson, Lindqvist et al. 1957]. Even though, reserpine is not clinically 
relevant anymore because of its strong psychiatric side-effects, including lethargy and 
depression [Freis 1954, Freis and Ari 1954], it has been established as a potent drug inhibiting 
VMAT catalyzed vesicular transport of catecholamines leading to a depletion of 
catecholamine stores and at the same time preventing re-uptake of catecholamines [Carlsson, 
Lindqvist et al. 1957, Schuldiner 1994, Bezard, Imbert et al. 1998, Bezard and Przedborski 
2011]. The plasma half-life of catecholamines is very short (1-2 min) because secreted 
extracellular catecholamines are quickly degraded by the action of MAO and COMT. 
Catecholamines, that after release are re-uptaken into the cytosol or are leaking from storage 
vesicles, are also degraded by the activity of MAO and COMT. Thus, if reserpine is present 
and completely inhibits vesicular transport, it prevents new synthesis of NE and EPI and cells 
will be depleted of those within a short period of time. As a consequence there will be no 
extracellular catecholamines left for the paracrine effects of these substances.  
1.4 Embryonic heart development 
The heart is the first organ to be functionally active in vertebrate embryos. During the 
embryonic development the heart keeps contracting to guarantee circulation, while it is 
constantly remodeled until it finally becomes the four-chambered organ. Heart development 
can roughly be divided into four main phases:  
1.4.1 Specification of myo- and endocardial precursors  
After implantation the three germ layers are formed. In mice the specification of myo- and 
endocardial precursors is completed within the heart forming fields of the anterior lateral plate 
mesoderm. Growth factors from different families are involved in this process, i.e. non-
canonical Wnt signaling, FGF- and BMP-signaling as well as inhibitors of Wnt/β-Catenin 
signaling (reviewed in [Brand 2003, Brade, Manner et al. 2006]). Committed cells of the heart 
forming field form the cardiogenic crescent. These cells express the earliest cardiac marker, 
homeodomain transcription factor Nkx2.5. All myo- and endocardial precursors derive from 
two heart fields: the primary and the secondary heart field. While the first heart field was 
found to provide cardiomyocytes for the left atria and ventricles, the secondary heart field 
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mainly contributes the cells for the right ventricle and the outflow tract [Stalsberg and 
DeHaan 1969, Brade, Manner et al. 2006].  
1.4.2 Development of the tubular heart 
This stage is characterized by folding processes of the cardiac field subsequently forming the 
tubular heart. In more detail, during gastrulation and neurulation the primary and secondary 
heart fields (located at both sides of the embryo midline), fold toward the embryo midline and 
merge ventrally to form the linear heart tube [Manasek 1968, Brade, Manner et al. 2006, 
Manner 2006]. At the linear heart tube stage, the tube is rather short and consists of the 
embryonic ventricles only. From this short linear heart tube stage continuous merging of the 
heart-forming fields progresses, adding the remaining elements of the embryonic heart to the 
arterial and venous pole of the linear heart tube. This heart tube finally forms the sinus 
venosus, a primitive atrium and ventricle, the bulbus cordis, and the aortic arches [Brade, 
Manner et al. 2006]. As a result of these events the heart is relocated ventrally. The wall of the 
linear heart tube is already composed of myocardial cells (outer layer) and endocardial cells 
(inner layer). After folding and relocation the tubular heart shows first peristaltic contractions 
[Moorman and Lamers 1994]. Also a pacemaking region in the sinus venosus region was 
described [Brade, Manner et al. 2006, Christoffels and Moorman 2009]. In humans this 
process takes place in the fourth week of pregnancy.  
1.4.3 Looping of the tubular heart 
During this stage, principally the already formed tubular heart elongates faster than the 
surrounding pericardial cavity, resulting in the formation of a loop (looping heart tube). 
Thereby, the heart tube undergoes positional and morphological changes bringing the future 
sections of the definitive heart into their topographical proximity [Brade, Manner et al. 2006]. 
Several functional parts of the final heart are already established at this time: The sinus 
venosus forming the inflow tract; the atrium primitivum later forming the atria and the left 
ventricle, respectively; the bulbus cordis forming the right ventricle, the truncus arteriosus 
which will finally form the aorta; and the aortic arches as the outflow tract [Moorman and 
Lamers 1994]. Also during this stage, the looping heart tube becomes colonized by primarily 
extracardiac progenitor cells, subsequently leading to the division of the outflow tract into 
systemic and pulmonary paths, as well as the entire coronary vasculature [Manner, Perez-
Pomares et al. 2001, Brade, Manner et al. 2006].   
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1.4.4 Development of the four-chambered heart 
The final step of the heart development is the formation of the four-chambered heart from the 
looping heart-tube with its single undivided lumen. Transformation into the four-chambered 
heart is accompanied by several major morphological changes, including ballooning of the 
atria and ventricles, remodeling of the inner heart curvature and the outflow tract, valve 
formation at atrioventricular and ventriculo-arterial junctions and the formation of septa 
between the four chambers [Christoffels, Habets et al. 2000, Brade, Manner et al. 2006]. 
Amongst several other signaling molecules, the Wnt/β-catenin pathways are involved in these 
remodeling processes [Brade, Manner et al. 2006]. In a final step, the terminal conduction 
system develops. Thereby, the peristaltic contraction of the heart tube is transformed into the 
conduction and contraction pattern of the mature four-chambered heart [Christoffels and 
Moorman 2009]. 
 
In conclusion, the development of a complex organ like the heart is well investigated. The 
general developmental steps (as described above) are well conserved between species. 
Nevertheless, looking into more detail there are various aspects of heart development that 
differ between species, are discussed controversially or are just not investigated yet. The 
findings of e.g. BMP signaling committing mesodermal cells into myo- and endocardial 
precursor cells laid the basis for approaches to translate these cardiac inducing signaling 
pathways into ES cell differentiation. For example, activinA and BMP4 (in addition to bFGF) 
were found to induce cardiomyocyte development during human ES cell differentiation 
[Yang, Soonpaa et al. 2008]. Moreover, several studies showed that activin/Nodal/TGF-β, 
Wnt, and BMP pathways all play pivotal roles in the establishment of the cardiovascular 
system [Conlon, Lyons et al. 1994, Haegel, Larue et al. 1995, Gadue, Huber et al. 2006, 
Klaus, Saga et al. 2007]. However, a variety of cardiac cell fate determining stimuli like 
different growth factors, growth factor inhibitors, signaling molecules and further e.g. 
mechanical or electrical stimulation, are still to be investigated to establish optimal conditions 
for cardiac differentiation in vitro.   
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1.5 Electrophysiology of the heart 
1.5.1 Resting membrane potential  
The resting membrane potential (RP) is characterized by a specific distribution of ions along 
the cell membrane. Due to selective permeability of the membrane ions are distributed 
unequally. In the cytoplasm potassium ions (K+) and organic ions (e.g. proteins, other organic 
molecules) are found in high concentration. In lower concentrations also sodium ions (Na+) 
are present inside the cells. On the outside of the membrane we find high concentrations of 
Na+ and chloride (Cl-) as well as low concentrations of K+. Altogether, the cytoplasm contains 
more negative charges than the outside of the membrane, resulting in a difference of the 
distribution of charges which can be detected by e.g. the patch-clamp method as an electric 
potential across the cell membrane. The resting potential is usually between -70 to -90 mV. 
The membrane’s selective permeability is due to Na+- and K+- channel proteins in the 
membrane. Even in the resting state of a cell, the membrane is permeable for both cations, but 
the membrane permeability is significantly higher for K+ than for Na+. On the other side, the 
permeability for Cl- and organic anions is extremely low and can thus be neglected here. 
However, over time Na+ and K+ would be passively transported along their electrochemical 
gradient resulting in an equilibrium state and vanishing of the membrane potential. The 
electrochemical gradient itself is defined by the two forces responsible for the movement of 
ions across the membrane. One force results from the concentration gradient of Na+ and K+ 
between the inside and outside of the membrane, while the other force results from the 
electromagnetic interaction between the charge carriers. To stabilize the membrane potential, 
the Na+/K+-ATPase actively transports three Na+ to the outside and two K+ to the inside of the 
membrane under constant ATP-consumption to uphold the unequal ion distribution.  
1.5.2 The cardiac action potential (AP) 
1.5.2.1 AP formation and contraction of the myocard 
AP formation in the heart mainly depends on voltage-gated Na+-, K+-, Ca2+- and to a minor 
degree also Cl--ion channels. The initial depolarization is carried by a Na+-current into the cell 
resulting in a very fast reversal of the membrane potential (phase 0). Phase 1 of the AP is 
characterized by the activation of K+-channels initiating repolarization. The channels open to 
release K+ from the cytosol resulting in short currents called Ito (transient outward) and IKur 
(ultra-rapid) [Boyle and Nerbonne 1991]. K+-channels are also important in phase 2 
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(plateauphase) and phase 3 (repolarization). Two types of IK currents are detected, the faster 
component is the IKr while the second and slower component is called IKs [Sanguinetti and 
Jurkiewicz 1990, Sanguinetti and Jurkiewicz 1991]. HERG-K+-channel open probabilities are 
responsible for the IKr current [Abbott, Sesti et al. 1999]. However, in phase 2 most prominent 
are the Ca2+-currents (ICa-L and ICa-T) which are responsible for the plateau phase of the AP. 
Ca2+ influx through L-type Ca2+-channels (ICa in the sarcolemma) induce Ca2+-release through 
ryanodine receptors (in the SR membrane), thereby increasing intracellular Ca2+ and delaying 
the depolarization. This process is called Ca2+-induced Ca2+-release (CICR) and triggers the 
excitation-contraction coupling, finally leading to the contraction of actin and myosin 
filaments and shortening of sarcomeres. During systolic myocard contraction these processes 
provide the force for the ejection of blood [Fabiato 1983, Bers 2002]. In contrast, in early 
human ESCMs and iPSCMs excitation-contraction coupling was found to be dependent on 
transsarcolemmal Ca2+ influx rather than on SR-release [Dolnikov, Shilkrut et al. 2006]. 
Finally repolarization is completed by the IK1-current in Phase 4, before the RP is stabilized 
and a new AP can be triggered during the diastole. 
1.5.2.2 In cells of the conduction system 
Cells of the SA-node (sinoatrial-node), the AV-node (atrioventricular node), bundle of His, 
tawara’s branches, and purkinje fibres show certain differences in comparison to the working 
myocard. Especially, the cells of the SA- and AV-node show a particularly slow upstroke 
velocity of the initial depolarization and their RP is less negative. Their depolarization is 
further mainly carried by a slow Ca2+ influx. Additionally, conduction system APs do not 
possess a pronounced plateau phase due to their relatively weakly developed sarcoplasmatic 
reticulum. All cells of the conduction system show spontaneous depolarization without 
external stimulation. The leakage channel allowing for spontaneous depolarization is an 
unspecific anion channel known as the “funny channel” (If). This property enables the 
conduction system cells to work as pacemakers controlling the heart rate. Amongst the cells 
of the conduction system sinus node cells show the highest spontaneous frequency with 
decreasing frequencies along the conduction path (i.e. SA-node > AV-node > bundle of His > 
etc.). In case of e.g. a SA-node failure (e.g. SA block), the AV-node can replace the 
pacemaking activity, however, exerting lower pacing frequency. The autonomic nervous 
system strongly innervates the SA-node. In this way the autonomic system is able to adjust 
the heart rate to adapt to changing conditions. Sympathetic stimulation increases, while 
parasympathetic stimulation decreases heart rate through the β-adrenergic and muscarinic 
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receptors, respectively. Upon receptor stimulation by e.g. catecholamines, cAMP and protein 
kinases induce phosphorylation of the If-channel, increasing the velocity of the spontaneous 
depolarization and with that the heart rate (reviewed in [Baruscotti, Bucchi et al. 2005]). 
 In Fig. 1.2 the shapes of APs generated by different cells within the heart are depicted. 
APs can explicitly be distinguished by end-diastolic depolarization (phase 4), their upstoke 
velocity and the presence and duration of the plateau. A heart cycle consists of the diastolic 
and the systolic phase during which excitation spreads throughout the heart. Depending on 
their function, cardiac cells from conduction system, atria and ventricles generate APs at 
different time-points of the heart cycle. The excitation spread can be monitored by an 
electrocardiography (ECG) and is represented by its intervals and segments (P-wave, QRS-
complex, T-wave and sometimes U-wave). The QT-interval represents the excitation of the 
ventricles and their recovery. Prolongation of the QT-interval increases the risk of ventricular 
tachyarrhythmias (e.g. TdP; [Antzelevitch, Shimizu et al. 1999]). QT-interval shortening and 
resulting decreased refractory time, on the other side, increases the risk of reentry induced 
cardiac fibrillation [Halbach 2006]. The right panel of Fig. 1.2 depicts AP shapes and 
correlates them to distinct ECG intervals. Ventricular APDur corresponds to the QT-interval of 
the ECG. In paragraph 1.6.2 the relationship of APs and field potentials (FPs) recorded from 
MEAs and their significance for this work will further be discussed.  
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1.6 Microelectrode arrays (MEA) 
1.6.1 Extracellular vs. intracellular recordings 
Extracellular recordings of field potentials (FPs) using the microelectrode array (MEA) 
technique provide a number of advantages over intracellular recordings like voltage or current 
clamp and sharp-electrode measurements. One of the most useful advantages of the MEA 
technique for this work was the fact that it is non-invasive. It therefore allows long recording 
periods (up to several days) where either different drug concentrations or even different drugs 
at different concentrations can be applied sequentially to the same preparation (EBs in our 
case). Analyzing drug effects in identical preparations helps to exclude possible preparation-
to-preparation or cell-to-cell differences to improve the reliability of conclusions. Even more, 
being a non-invasive method guarantees that the recordings are not disturbed by 
 
Figure 1.2: Correlation of APs and ECG intervals and segments 
APs as they would be recorded from cells of the respective part of the heart. Furthermore, the figure shows the 
involvement of the functional parts of the heart during a heart cycle presented by the ECG. Different cells 
generate APs in a coordinated order throughout a heart cycle to guarantee contraction of the heart and ejection 
of blood. As can be seen, AP durations correlate to respective ECG intervals and segments (From 
http://www2.hs-esslingen.de/~johiller/elektrokardiogramm/pics/ekg29.gif). 
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infringements of cell membranes and subsequently changed electrical physiology of cells. The 
MEA technique further enables to measure multi-cellular and whole tissue preparations, like  
retinal tissue, heart and brain slices, and for this work, EBs [Hammerle, Egert et al. 1994, 
Egert, Heck et al. 2002, Halbach, Egert et al. 2003, Halbach, Pillekamp et al. 2006]. Because 
MEAs allow simultaneous monitoring of 60 measurement electrodes that are spatially 
separated from each other (8x8 grid with an inter-electrode distance of 200 µm), tissue 
preparations can be analyzed in respect to 2-dimensonal signal propagation and conduction 
velocity. This aspect is only insufficently accessible using traditional intracellular recording 
techniques [Halbach, Egert et al. 2003]. 
 Using MEAs, cell preparations are cultivated in culture dishes containing the substrate 
integrated extracellular electrodes and can directly be monitored in the same dishes. Also 
complicated positioning of the electrodes and penetration of cells, as needed for 
transmembrane recordings, is not necessary. Thus, in comparison to intracellular recordings 
of the transmembrane potential, MEA recordings are less work-intensive and, hence, easier to 
handle. 
1.6.2 Comparison of APs and FPs 
Compared to intracellular transmembrane potential recordings, a certain downside remains 
using the MEA technique. Detailed monitoring of single ion channel activity with e.g. patch 
clamp techniques or monitoring of populations of specific ion channels like from whole-cell 
voltage clamp recordings cannot be accomplished with MEA. Nevertheless, previous work 
has shown a linear relationship of FPDur and APD90 recorded by the current clamp sharp 
electrode technique (see Fig. 1.3;  [Halbach, Egert et al. 2003, Halbach 2006]). This 
relationship allows the estimation of alterations of the cardiac electrical physiology based on 
FPs similar to AP analysis. Repolarization modulating drug effects, which this work will 
focus on, can thus be extracted from MEA recordings and drug effects can be analyzed based 
on FPDur. As discussed in section 1.5.2 and depicted in Fig. 1.2, durations of APs and ECG 
intervals correlate. Accordingly, also ECG interval modulations may indirectly be estimated 
by FPDur measurements. 
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1.6.3 Technical MEA Applications 
Drug development is a cost intensive factor for the pharmaceutical industry. The MEA 
technology with its versatile applications provides different kinds of information on cellular 
electrical functions. As described in paragraph 1.5.2.2 and 1.6.2 and Fig. 1.2 and 1.3, FPs 
provide information that allow conclusions to be drawn on drug-effects on APDur and the 
phases of the ECG. Thus, MEAs provide a valuable platform for drug screening purposes. For 
example, compounds with possible cardio-active side effects can be sorted out before they are 
tested in cost-intensive clinical trials and, at the same time help reducing the number of 
experimental animals being used.  
1.7 Aims of the work 
The current work was conducted to study aspects of embryonic stem cell differentiation into 
cardiac myocytes. Numerous scientists have produced great knowledge on the field of 
embryonic stem cells within the last 15 to 20 years. Because the field of stem cell research is 
broadly diversified, the work itself was subdivided into two separate parts investigating two 
rather independent aspects.  
 
Figure 1.3: Linear relationship between APD90 and FPDur  
Left: Overlay of an action potential from intracellular recording (black) and a FP recorded by MEA (grey). 
Right: Comparison of APD90 and FPDur. Each dot represents a value pair of APD90 and FPDur recorded from the 
same position of the same preparation to showcase the comparability of both parameters. Both graphs were 
taken from the doctoral thesis of Dr. M. Halbach, University Hospital Cologne [Halbach 2006]. 
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1.7.1 The role of catecholamines in cardiac lineage commitment in mouse ES cells 
The first part was aimed to describe the role of the important class of catecholamines on the 
differentiation of ES cells, focusing on their role on CM development. Using reserpine 
enabled us to deplete ES cells of catecholamines during the course of differentiation. Several 
microscopy, molecular biology, flow cytometry techniques and immunohistochemical 
stainings were applied for the descriptive analysis. Beside effects on cardiomyogenesis, this 
work also assessed the expression of pluripotency, catecholamine synthesis and AR genes as 
well as germ-layer markers. To exclude cytotoxic effects of reserpine EB cross-section areas 
were measured and a newly developed impedance cytotoxicity assay was used. Functional 
MEA experiments were employed to investigate the role of catecholamines on the 
electrophysiology during the course of CM development. Strengthening the conclusion that 
catecholamines and not reserpine per se was responsible for the observation of reduced 
cardiac development, we tested whether α- and β-AR antagonists mimicked the reserpine 
effect and if AR stimulation rescued the reduced cardiomyogenesis when co-applied with 
reserpine.  
1.7.2 MEA-based QT-screen using pluripotent stem cell derived CMs  
The second part represents series of experiments aimed to investigate the possibility of using 
the MEA system as a platform for safety-pharmacological screening of drugs with cardiac 
side effects. One such side effect is known to be life-threatening torsade de pointes (TdP) 
tachycardia [Selzer and Wray 1964]. TdP is caused by a variety of factors amplifying 
electrical heterogeneities in the ventricular myocardium. Drugs with antiarrhythmic agent 
class III actions (potassium channel blockers) reduce the net repolarizing currents and change 
the spatial dispersion of repolarization within the ventricular myocardium and can therefore 
result in QT-prolongation and the development of polymorphic reentrant ventricular 
tachycardia causing TdP [Antzelevitch 2005]. These drug-induced repolarization prolonging 
effects can be monitored using MEAs. Combining the advantage of long-time recording 
provided by MEAs with the advantages of pluripotent stem cell-derived cardiomyocytes, we 
sought to empirically investigate the applicability of that system for drug screenings to 
identify cardio-active side effects. For this purpose several rhesus monkey and human ES 
(rES and hES) cell lines as well as human induced pluripotent stem (hiPS) cells were 
differentiated into CMs. We initially simulated positive and negative chronotropy with 
specific substances to describe the physiological correlation of FPDur and the beating rate. As 
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the proof of concept,  EBs containing beating cardiac clusters were treated with different 
concentrations of class III antiarrhythmic agents to investigate if cardiac repolarization 
prolongation can be qualitatively accessed using our MEA-based analysis system. The 
correlation of FPDur and beating rate under the influence of different drugs was further tested 
in CM lines proving a general feasibility of the screen. 
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2 Materials and Methods  
2.1 Cell culture 
Cell culture work was conducted in sterile conditions under laminar-flow work benches. If not 
delivered in a sterile condition by the manufacturer, materials and solutions used for cell 
culture work were sterilized by autoclaving or sterile-filtration. 
2.1.1 Feeder culture and inactivation 
ES cells in culture differentiate spontaneously. Keeping them in a pluripotent state is crucial 
to guarantee that the initial cell material for differentiations is comparable. Therefore, besides 
the addition of growth factors, which contribute to cellular growth and proliferation, a 
cultivation of ES cells on confluent feeder layers is crucial, as those cells secrete factors that 
support the cells in an undifferentiated state.  
2.1.2 ICR-feeder (Charles Rivers Laboratories, Germany) 
Purpose: rESC (R366.4 and MF12) propagation 
Medium: Dulbeccos Modified Eagle Medium (DMEM), fetal bovine serum (FBS; 10%, v/v), 
L-glutamine (2 mM) and non-essential amino acids (NEAA; 1x). Medium and supplements 
were purchased from Invitrogen, Karlsruhe, Germany. 
After thawing, ICR-feeders were seeded on cell culture dishes and passaged by enzymatical 
dissociation (trypsine) to expand the culture for 2 passages. Finally, ICR-feeders were 
mitotically inactivated using mitomycin C (10 µg/ml; Sigma-Aldrich, Taufkirchen, Germany) 
for 2-4 hrs. After the inactivation step and cell counting (life/dead staining with Trypan blue 
in a Neubauer counting chamber), ICR-feeders were seeded at a density of 40,000 cells/cm2 
for further use. 
2.1.3 neomycin-resistant mouse embryonic fibroblasts (NEO-feeder) 
Purpose: rESC (R366.4 and MF12) and mESC (αPIG) propagation 
Medium: DMEM, fetal bovine serum (FBS; 10%, v/v), L-glutamine (2 mM), non-essential 
amino acids (NEAA; 1x), β-ME (100 µM), Penicillin/Steptomycin (Pen/Strep; 100 µg/ml and 
100 U/ml, respectively). 
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Mitotically inactivated NEO-feeders (mitomycin C, 10 µg/ml, see above) were seeded at a 
density of 40,000 cells/cm2. 
2.1.4 CF1-feeder (Charles Rivers Laboratories, Germany) 
Purpose: hESC (H1, H9) and hiPSC propagation 
Medium: DMEM, fetal bovine serum (FBS; 10% v/v), L-glutamine (2 mM) and non-essential 
amino acids (NEAA; 1x), Pen/Strep (100 µg/ml and 100 U/ml, respectively).  
Mitotically inactivated CF1-feeders (by radiation with 30 Gray) were provided  
at a density of 12,000-20,000 cells/cm2. 
2.1.5 Murine embryonic stem cells (mESCs; D3 aPIG44) 
2.1.5.1 Cell propagation 
The murine D3 αPIG 44 ES cell line was passaged as published earlier [Kolossov, Lu et al. 
2005]. Passage numbers 15-40 were cultivated on NEO-feeders in IMDM supplemented with 
fetal bovine serum (FBS; 15% v/v), β-ME (50 µM), non-essential amino acids (1x), leukemia 
inhibitory factor (LIF; 100 U/ml) and G418 (Neomycin; 0.5 mg/ml). Cells were passaged 
every 2-3 days by enzymatic dissociation of the mESC for 5 min (0.05%% Trypsin/EDTA) at 
37°C. Afterwards 0.5*106 single cells were plated on fresh NEO-feeders. 
2.1.5.2 Cardiac Differentiation 
Differentiation was initialized following a mass culture protocol [Frenzel, Abdullah et al. 
2009]. 1*106  of the enzymatically dissociated cells were cultivated in bacteriological dishes 
under constant horizontal shaking at 37°C in 5% CO2 atmosphere in IMDM supplemented 
with: FBS (20%; v/v), β-ME (100 µM), and non-essential amino acids (1x) for the control 
group. For the solvent control and reserpine-treated group, dimethylsulfoxide (DMSO; 
1:1,000 v/v) or reserpine (10 µM in DMSO 1:1,000) was added, respectively. 2 days after the 
onset of differentiation the culture was split distributing 1,000 EBs per 10 cm bacteriological 
dish and maintained at 37°C in 5% CO2 atmosphere under constant horizontal shaking. 
Afterwards, two separate differentiation protocols were used. In the first protocol, reserpine 
was added every second day with medium changes every 6 days (chronic application ‘d2’; 
Fig. 3.2) , in the second protocol reserpine was added every four days including medium 
changes at these days (chronic application ‘d4’; Fig. 3.2). DMSO was applied and refreshed 
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like reserpine and served as a second control to exclude unspecific effects of the reserpine 
solvent.  
2.1.6 Puromycin purification of cardiomyocytes 
The D3-derived αPIG44 murine ES cell line expresses enhanced green fluorescent protein 
(eGFP) and a puromycin resistance gene under control of the cardiac specific alpha myosin 
heavy chain (αMHC) promoter [Kolossov, Fleischmann et al. 1998]. For purification, day 10 
EBs were treated with 8 µg/ml puromycin and maintained at 37°C in 5% CO2 atmosphere on 
a horizontal shaker. Puromycin and medium was changed every 2 days. For most of our 
experiments purified clusters were harvested at day 14. 
2.1.7 Rhesus monkey embryonic stem cells (rESCs; R366.4 and MF12) 
The two cell lines were kindly provided in frozen stocks by Prof. U. Martin (Head of the 
Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover, 
Germany). R366.4 was derived from macaca mulatta, while the MF12 line was derived from 
macaca fascicularis. 
2.1.7.1 Cell propagation 
Rhesus monkey embryonic stem cells were originally isolated by J.A. Thomson and 
colleagues in 1995 and karyotyped 42, XY, normal [Thomson, Kalishman et al. 1995]. For 
passages we followed a protocol adopted from K. Schwanke and colleagues [Schwanke, 
Wunderlich et al. 2006]. RESCs growing as multi-cellular mono-layered colonies, were 
cultivated on ICR- and NEO-feeders in Knock-out™ Dulbecco’s Modified Eagle Medium 
(Knockout™ -DMEM; Gibco) supplemented with Knockout™-Serum Replacement (20% 
v/v), β-ME (100 µM), non-essential amino acids (1x), L-glutamine (1 mM) and basic 
fibroblast growth factor (bFGF; 4 ng/ml) (all supplements were purchased from Invitrogen). 
Every 3-4 days pluripotent colonies were enzymatically de-attached by incubation with 1 
mg/ml Collagenase IV (Invitrogen) for 15 min at 37°C in 5% CO2 incubator conditions. 
Additionally, colonies were mechanically de-attached from the feeder-layer by tapping to 
guarantee a more efficient yield of colonies. After centrifugation (100 x g, 4°C) and 
dissociation in 20%-DMEM by gentle pipetting 3-4 times to reduce colony size, colony 
fragments were distributed 1:4 or 1:6 into wells containing fresh confluent feeders. 
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2.1.7.2 Cardiac Differentiation 
The protocol was adopted from Schwanke et al. [Schwanke, Wunderlich et al. 2006]. In brief, 
R366.4 and MF12 RESCs were enzymatically and mechanically dissected as described in 
paragraph 2.1.7.1. For initiation of differentiation, the colony fragments were resuspended in 
RESC differentiation medium consisting of Iscove's Modified Dulbecco's Medium 
(IMDM+GlutaMAX™) supplemented with FBS (Hyclone or Invitrogen, 20% v/v), β-ME 
(100 µM), non-essential amino acids (1x), L-glutamine (1 mM). Before colony fragments 
were seeded, 12-well culture dishes were coated with 0.5 ml Agarose (1% Agarose (w/v) in 
IMDM-GlutMAX™). Next, colony fragments of pluripotent RESCs of 1 well of a 6-well 
plate were equally distributed on the 12-well plate and incubated at 37°C, 5% CO2 in RESC 
differentiation medium. After 7 days RESCs formed 3-dimensional cell aggregates that were 
transferred to 0.1% Gelatine (w/v in PBS +/+) coated culture dishes and further incubated 
(37°C, 5% CO2). Medium was renewed every 2-3 days [Schwanke, Wunderlich et al. 2006]. 
 In addition to the protocol described in the previous section, the rESC colony 
fragments on agarose coated 12-well plates were treated with activinA (100 ng/ml) for the 
first 24 hrs of differentiation followed by BMP4 (10 ng/ml; both factors were purchased from 
PeproTech (Hamburg, Germany) until day 7 as adopted from Laflamme and colleagues 
[Laflamme, Chen et al. 2007]. No medium was changed within the first 7 days, while in the 
remaining time until harvesting of EBs for experiments, medium was changed every 2-3 days.  
2.1.7.3 END-2-Feeder protocol 
END-2 cells are derivatives of the murine embryonic carcinoma cell line P19 and were shown 
to potently induce endodermal and mesodermal differentiation [Mummery, van Achterberg et 
al. 1991]. Co-cultivation of pluripotent cells with END-2 cells markedly increases their 
differentiation efficacy into cells of the cardiac lineage. Therefore we applied an established 
END-2 co-cultivation protocol to our R366.4 and MF12 RESC culture in an approach to 
increase the yield of spontaneously beating clusters [Mummery, Ward-van Oostwaard et al. 
2003]. RESC colony fragments were dissected as described in the RESC passage section 
(2.1.7.1). Colony fragments of one well of a 6-well plate were transferred to a 6 cm culture 
dish for co-culture with mitomycin C (10 µg/ml) mitotically inactivated END-2 cells (60,000 
cells/cm2). END-2 cells were kindly provided by Prof. C. Mummery (Department of Anatomy 
and Embryology, Leiden University Medical Center). 
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2.1.8 Human embryonic and induced pluripotent stem cells (hESCs and hiPSCs) 
2.1.8.1 Propagation 
Human pluripotent ES and iPS cells  were propagated by manual dissection every 5-7 days. 
For propagation approximately 50 colonies were dissected using the grid-cut method. Thereby 
individual un-differentiated colonies were cut into 9-16 equally sized pieces using a sterile 
needle [Costa, Sourris et al. 2007]. Colony pieces were collected and transferred to a fresh 
3.5 cm culture dish, and maintained in knockout-Dulbeccos Modified Eagle Medium (KO-
DMEM) containing Serum Replacement (SR, 20%, v/v), L-glutamine (2 mM) and non-
essential amino acids (NEAA; 1x), β-ME (100 µM), bFGF (4 ng/ml) at 37°C in 5% CO2 
incubator conditions. Medium was changed every 2 days. Remaining pre-differentiated 
colonies were used for differentiations. H1 and H9 hESCs were provided by Prof. J.A. 
Thomson, (Wisconsin Regional Primate Research Center, University of Wisconsin, Madison, 
USA) and WiCell research Institute, Madison, USA, iPSCs were provided by Dr. Dr. T. Saric 
and Dr. A. Fatima (Institute for Neurophysiology, University of Cologne, Germany). 
2.1.8.2 Cardiac Differentiation 
hESCs and hiPSCs were differentiated into CMs using END-2 protocols [Mummery, van 
Achterberg et al. 1991, Mummery, Ward-van Oostwaard et al. 2003, Fatima, Xu et al. 2011]. 
CM containing clusters of all human cell lines used herein were kindly prepared by C. 
Böttinger. 
2.1.9 EB size assay 
Pictures of EBs taken on the respective days using Axiovert 10, Axiovert 25 or Axiovert 200 
microscopes (Carl Zeiss, Jena, Germany) were analyzed using the commercial Carl Zeiss 
software AxioVision LE 4.5 (Carl Zeiss, Jena, Germany). Depending on the microscope and 
magnification of objectives, pictures were calibrated to analyze EB cross-sections as a 
measure for cell proliferation and growth.  
2.1.10 Ratio of beating clusters 
For quantification of beating ratios, the EBs were plated on 6-well plates (15-25 EBs per well) 
at day 6 and the drug was refreshed following the respective protocol until the end of the 
experiment. 6-well culture dishes were coated with 0.1% gelatine to improve attachment of 
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the EBs. Using a microscope total numbers and numbers of EBs containing beating clusters 
were counted by eye and ratios were calculated. 
2.2 Flow cytometry 
2.2.1 Cell preparation 
100-200 EBs were harvested at corresponding days, washed three times with phosphate-
buffered saline (PBS, 0 mM Ca2+; 0 mM Mg2+) and enzymatically dissociated to a single-cell 
suspension using 2 ml trypsin/EDTA (0.05%) for 10 min at 37°C in a water bath with shaking 
every 2 min. The trypsin reaction was inhibited by addition of 10 ml IMDM + FBS (20%). 
Cell suspension was further dissociated by up- and down-pipetting and filtered by passing 
through a 40 µm cell strainer before cells were counted (life-dead staining with trypan blue). 
Approximately 0.5*106 cells were washed in PBS and subsequently resuspended in  
1 ml cell-wash solution (BD Biosciences, Franklin Lakes, USA).  
2.2.2 Measurement 
Quantification of eGFP expressing ESCMs was performed by flow cytometry using a 
FACScan flow-cytometer (BD Biosciences, Franklin Lakes, USA). For each sample 10,000-
50,000 living cells were gated. Dead cells were stained with propidium iodide (PI, Sigma). 
Data was analyzed using Cyflogic (v 1.2.1, Turku, Finland). 
2.3 Immunohistochemistry 
2.3.1 Cryosliced EBs  
20-40 EBs from the culture were fixated in 4% paraformaldehyde (Roth, Karlsruhe, 
Germany) for 30 min at room temperature and incubated in 30% sucrose solution over night 
at 4°C prior to embedding in Tissue Tek® O.C.T.™ Compound (Sakura® Finetek Japan Co., 
Tokyo, Japan). Embedded EBs were shock frozen, stored at -80°C and subsequently 
cryosliced. The 8 µm cryosections were then placed on silanized Histobond cover slips (Paul 
Marienfeld GmbH, Lauda-Königshofen, Germany) for the staining procedure. 
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2.3.2 Single cells/ whole EBs  
Two days prior to staining EBs were plated on 1% gelatine coated cover slips. For single cell 
stainings, EBs were enzymatically dissociated first. EBs/cells were cultivated in 12-well 
culture dishes and incubated at 37°C and 5% CO2 in the respective differentiation medium 
(for mouse or human ESCMs).  After EBs/cells were allowed to attach, they were fixated with 
4% paraformaldehyde for 30 min at room temperature.  
2.3.3 Permeabilization and immunostaining procedures 
All preparations, cryosliced sections, whole EBs and single cells were permeabilized using 
permeabilisation solution (0.25% TritonX, 0.5 M NH4Cl). After washing with PBS, the 
preparations were incubated with 1:10 Roti®Block (Roth, Karlsruhe, Germany) to prevent 
cross binding of antibodies. Incubation with primary antibodies was performed overnight at 
4°C on a horizontal shaker. After six washing steps with phosphate-buffered saline (PBS, 0 
mM Ca2+; 0 mM Mg2+), samples were incubated with secondary antibody for 2 hrs at 4°C. 
Nuclei were always co-stained with nucleic acid stain Hoechst (1:1,000; subtype H 33342; 
Sigma Aldrich; Prod# B2261). Stained samples were embedded in Prolong Gold (Invitrogen, 
Carlsbad, USA) and imaged using a Zeiss Axiovert 200 (Carl Zeiss, Jena, Germany). For 
analysis the Carl Zeiss software AxioVision LE 4.5 was used. Primary and secondary 
antibodies and corresponding dilutions are stated in section VIII. of the appendix. 
2.4 Molecular biology 
2.4.1 RNA Isolation 
Approximately 100-1,000 EBs were harvested from mass culture for RNA Isolation 
depending on the differentiation day. Samples of EBs were collected on days 1-4, 6, 8, 10 
after initiation of differentiation and on day 14 with and without puromycin treatment. 
Together with samples of undifferentiated αPIG44 ES cells and mouse embryonic fibroblasts 
(MEFs) all samples were collected in 1 ml TriZol® Reagent (Invitrogen, Carlsbad, USA) and 
frozen at -80°C. Following manufacturer’s instructions RNA was isolated. Briefly, cells were 
homogenized by passing the cells through a sterile syringe and a needle and incubated for 5 
min at room temperature to permit complete dissociation of nucleoprotein complexes. 200 ml 
chloroform was added and samples were vigorously shaken by hand for 15 sec before they 
were again incubated at room temperature for 2-3 min and subsequently centrifugated at 
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10,500 rpm for 15 min at 4°C. The aqueous phase was transferred into a fresh tube. For 
precipitation of RNA the aqueous phase was mixed with 500 µl isopropanol and incubated for 
10 min at room temperature. Samples were centrifuged at 10,500 rpm for 10 min at 4°C and 
the supernatant was removed. To wash the RNA the pellet was resuspended in 1 ml 75% 
ethanol by vortexing before it is again centrifuged (8,500 rpm, 5 min, 4°C). Finally, the pellet 
was air-dried and resuspended in DEPC water for storage at -20°C. RNA concentration was 
determined using the NanoDrop UV/Vis spectrophotometer (Thermo Scientific). 
2.4.2 DNase I digestion of RNA isolations 
For more reliable quantification of the gene expression we additionally digested isolated RNA 
using deoxyribonuclease I (DNase I), Amplification Grade (Prod#: 18068-015; Invitrogen, 
Carlsbad, USA), even though the isolation kit used in this work guarantees a yield of RNA 
devoid of genomic DNA. The digest strictly followed the manufacturer’s guidelines with 15 
min incubation at room temperature followed by DNase I inactivation at 65°C for 10 min in 
the presence of 2.5 µM EDTA. The final inactivation step was carried out in a peqSTAR 96 
Universal Thermocycler (PEQLAB Biotechnologie GmbH, Erlangen, Germany). 
2.4.3 cDNA Synthesis 
cDNA was synthesized from 2 µg of RNA using the SuperScript®ViloTM cDNA Synthesis Kit 
(Invitrogen, Carlsbad, USA). Synthesis strictly followed manufacturer’s instructions with the 
reverse transcriptase reaction step at 42°C for 60 min and the final inactivation step both 
being performed in a peqSTAR 96 Universal Thermocycler (PEQLAB Biotechnologie 
GmbH, Erlangen, Germany). 
2.4.4 Semiquantitative-RT-PCR 
cDNA of samples collected at different stages of differentiation and undifferentiated ES cells 
were analyzed for expression levels of different genes using semiquantitative reverse-
transcription PCR (sqRT-PCR). PCR reactions containing JumpStart™ REDTaq® ReadyMix™ 
Reaction Mix (Invitrogen) or Fermentas™ Dream Taq™ PCR Master Mix (2X) were set up 
following manufacturer’s instructions. False positive results caused by amplification of 
genomic DNA were excluded by choosing intron spanning primer pairs (see Table “Primers” 
in the appendix). PCRs were carried out in a peqSTAR 96 Universal Thermocycler (PEQLAB 
Biotechnologie GmbH, Erlangen, Germany). A standard PCR consisted of an initial 
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denaturation for 2 min at 98°C, an optimized number of cycles consisting of three steps: 1.) 
denaturation for 30 sec at 98°C, 2.) annealing for 45 sec at primer specific temperatures, 3.) 
extension 30-60 sec depending on product length at 72°C. PCRs ended with a 10 min final 
extension step at 72°C and were analyzed with 1.5% agarose gel electrophoresis. Primers 
were designed using the Primer3-based online tool NCBI Primer Blast [Ye, Coulouris et al. 
2012]. Exon junctions were identified online by mouse BLAT search (programmed by Jim 
Kent; http://genome.ucsc.edu/ [Kent 2002]). 
2.4.5 Quantitative-RT-PCR 
Quantitative real-time PCR analysis was carried out using the ABI-7500 Fast PCR system 
(Applied Biosystems, Weiterstadt, Germany). The PCR reaction consisted of 12.5 µl SYBR 
Green PCR master mix (QuantiFAST, Qiagen, Hilden, Germany), 1 µl of primer pair (0.2 µM 
each) and 1 µl of cDNA template made up to a final volume of 25 µl. The standard conditions 
for PCR were used, 95°C/5 min Taq activation, 40 cycles of 95°C/10 sec and 60°C/30 sec. A 
melting curve was produced to verify single PCR product amplification. The mRNA levels 
were normalized against β-actin levels and calculated using a relative quantitation with the 
cycle threshold (ct) method by 7500 Fast System SDS software 1.4.0. (Applied Biosystems, 
Weiterstadt, Germany). The primer sequences used in the PCR analysis are shown in the table 
“Primers” in the appendix. qPCR reactions were carried out in technical triplicates for each 
sample. Negative controls were reactions containing H2O as template. Results are shown as 
mean±SD. Statistical analysis was done using paired Student’s t-test. P-values of ≤0.05 (*) 
were considered significant. 
2.4.6 Agarose gel electrophoresis 
Amplified DNA fragments from PCR reactions were loaded on agarose gels for 
electrophoretic separation. Gels were prepared using 1.5% (w/v) agarose in TAE buffer (40 
mM Tris-base, 20 mM acetic acid, 1 mM EDTA). EtBr (Roth, Karlsruhe, Germany) was 
added to stain DNA. Because loading buffer was already contained, the used PCR kits 
allowed direct sample loading onto the gels. Samples were loaded together with a 100-10,000 
bp ladder as a fragment size standard and run for 50-60 min at 100 V. Finally, pictures were 
taken by exposing gels to UV-light. 
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2.5 Extracellular recordings using Microelectrode Arrays (MEA) 
Extracellular recordings of field potentials (FPs) with MEAs were performed using the 
Multichannel Systems 1060-Inv-BC amplifier and data acquisition system (Multichannel 
Systems, Reutlingen, Germany). Substrate-integrated MEA culture dishes contain 60 
Titanium Nitride coated gold electrodes (30 µm diameter) arranged in an 8x8 electrode grid 
with an inter-electrode distance of 200 µm, allowing simultaneous recording of extracellular 
FPs from all electrodes at a sampling rate of 1 to 50 kHz by the use of the MEA amplifier 
system. Standard measurements were performed at a sampling rate of 2 kHz in IMDM. For 
the extracellular recordings we used either beating EBs directly from the mass culture or EBs 
that were prior plated on 1% gelatine-coated 6-well culture dishes at day 6  of differentiation 
(or day 7 for rESCMs). For measurements with hESCMs and hiPSCMs beating clusters from 
the END2 culture were used. Beating clusters were mechanically dissected and transferred to 
MEA dishes and subsequently allowed to attach for 2 days in the incubator at 37°C with 5% 
CO2. To assure best attachment of beating clusters, MEA chambers were coated using a 1:200 
dilution of fibronectin (1 mg/ml) in gelatine (0.1%). During measurements temperature was 
kept constant at 37°C. Applying a specialized self-programmed software tool based on 
LabView (National Instruments, Austin, USA) MEA data was analyzed. The tool allows 
analysis of MEA traces for interspike intervals (ISI) and intervals between FPmin and FPmax 
referred to as FPDur (Fig. 2.1). ISIs were considered to be the time interval between two 
consecutive FP minima (FPmin), thus providing a read out for beating frequency. Furthermore, 
FPDur intervals were analyzed under the influence of several drugs. FPDur was shown to 
correlate with APD90 values of action potentials as derived from current-clamp measurements 
[Halbach, Egert et al. 2003, Stett, Egert et al. 2003, Halbach 2006].  
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2.6 Impedance measurement 
2.6.1 Cell preparation 
Day 14 puromycin purified αPIG44 EBs (4 day purification; see paragraph “Puromycin 
purification of cardiomyocytes“) were harvested and washed twice with PBS (0 mM Ca2+; 0 
mM Mg2+) to avoid dead cells and debris. The supernatant was aspirated (with floating 
debris). 5 ml Trypsin/EDTA (0.05%) and DNase (5 Units) were added followed by incubation 
at 37°C in a water bath for 20-30 min. For better dissociation EBs were gently mixed by 
shaking every 2 min. After the incubation, remaining clusters were allowed to settle, and the 
supernatant was removed before filtration through 40 µm cell strainer. 5-times the volume of 
the supernatant 20%-IMDM (cold) was added to inhibit trypsin activity. Trypsin was removed 
by centrifugation (100 x g) and the single cell pellet was resuspended in 20%-IMDM. This 
first batch of cells was kept on ice and the Trypsin/EDTA (0.05%) and DNase (5 Units) step 
was repeated for 15 min with the remaining pellet of un-dissociated clusters. At the end of the 
second dissociation round the supernatant was filtered, trypsin was removed by 
centrifugation, and the pellet was also re-suspended in 20%-IMDM. Both filtered single-cell 
suspensions were combined. Keeping cells cold helps secure the quality of the yielded single 
cardiomyocytes. Finally, cells were counted (life-dead staining with trypan blue) and 60,000 
cells/well were seeded on specially designed 96-well microtiter plates (E-plate 96; ACEA 
 
Figure 2.1: Depiction of common FP features 
The interval between two consecutive FPmin represents the inter-spike interval (ISI [sec]) and is the reciprocal 
value of the beating frequency [Hz]. The interval between FPmin and FPmax is referred to as the FPDur. 
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BIOSciences Inc., San Diego, USA) containing integrated gold microelectrodes. Cells were 
allowed to settle for 1 hr at room temperature before the measurement was started.   
2.6.2 Measurement procedure 
For cytotoxicity testing we used the xCELLigence RTCA Cardio system (ACEA 
BIOSciences Inc., San Diego, USA) allowing continuous real-time monitoring of cell 
viability by non-invasive impedance recording [Atienza, Yu et al. 2006, Xi, Wang et al. 
2011]. The xCELLigence RTCA Cardio system consists of four hardware components: a 96-
well microtiter plate (E-Plate 96); the RTCA Cardio station accommodating the E-Plate which 
is kept in a tissue culture incubator; The RTCA Control Unit which is necessary to operate the 
software and to acquire the data; the RTCA Analyzer connecting the Cardio station with the 
Control Unit by a cable through the sealed door of the incubator. 
 Dissociated CMs were treated in 3 different groups (16 wells per group, n=16): 1) 
control (untreated); 2) reserpine treatment starting at day 14 (10 µM; reserpine was added at 
the day of seeding); 3) reserpine treatment starting at day 17 (10 µM; reserpine was added 3 
days after seeding to test if the drug itself changes adhesion and therefore the cell index (CI)). 
Medium was first changed after approximately at day 17 (~56 hrs) to guarantee good initial 
cell adhesion. Further medium changes were performed every 24 hrs during the remainder of 
the measurement. Within the first 56 hrs the CI of each well was recorded every 20 min. After 
that CIs were recorded continuously every 15 min until day 23 of differentiation. Data were 
recorded and analyzed using the RTCA Cardio 1.0 software (ACEA BIOSciences Inc., San 
Diego, USA). 
2.7 Data analysis 
For data analysis Student’s paired or unpaired t-test and one-way ANOVA was applied, 
respectively. Error bars represent the standard error of the means (s.e.m.) if not stated 
otherwise. P-values ≤0.05 (*) were considered significant. For statistical analysis GraphPad 
InStat Version 3.10 software and GraphPad Prism® (GraphPad Software, Inc., San Diego, 
USA) were used. 
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3 Results 
3.1 The role of catecholamines in cardiac lineage commitment in mouse ES 
cells 
3.1.1 Cell culture and morphology 
D3 αPIG44 ES cells harbor a vector expressing eGFP and a puromycin resistance gene under 
the control of a murine αMHC promoter. The pluripotent cells were passaged 3 times a week 
and propagated on a NEO-feeder layer. Fig. 3.1 depicts a representative ES cell colony as 
used for differentiation.  
3.1.2 Reserpine application protocols 
To study the effect of reserpine on the differentiation of αPIG44 ES cells we first tested 
several application schemes. Fig. 3.2 illustrates the different approaches of reserpine 
application used for this work. Two different approaches were used: (1) different frequency of 
drug refreshment: ‘d2’ (green arrows): application on days 0, 2, 4, 6, 8, 10, 12; and ‘d4’ 
(yellow arrows): application on days 0, 2, 4, 10; (2) different duration of reserpine application 
(Fig. 3.2 grey arrows): ‘until day 14’ (top) and ‘until day 6’ (bottom). In all cases reserpine or 
DMSO were applied starting on day 0. Fig. 3.2 further shows representative day 11 EBs of the 
three groups plated on 0.1% gelatine coated culture dishes on day 6 (Fig. 3.2 A-C).  
 
Figure 3.1: Colony of pluripotent D3 αPIG44 ES cells  
Representative pluripotent αPIG44 ESC colony (scale bar: 50 µm). Published in [Lehmann, Nguemo et al. 
2013]. 
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Analysis of the different application protocols led to the conclusion that there are no 
developmental differences between the untreated and the DMSO-treated group. In comparison 
to these two groups, the reserpine-treated group showed a significantly reduced outcome in 
cardiomyocyte numbers. Because no differences between the ‘d2’ and ‘d4’ differentiation 
protocol was observed, all further experiments were performed following the ‘d4’ protocol.  
Also the chronic application until day 14 and the application until day 6 led to reduced cardiac 
development. It will be stated in the corresponding sections, if reserpine was only applied 
until day 6. 
 As a read-out for cardiomyocyte differentiation in the presence of reserpine, we first 
estimated the size of green eGFP-expressing CM-containing clusters within EBs, which is 
representative of the quantity of CMs. Therefore we used phase-contrast and fluorescence 
microscopy. Fig. 3.3 shows representative pictures of EBs at day 2, 4, 10 and 14. Day 2 and 
day 4 EBs of control and DMSO EBs were morphologically indistinguishable from reserpine-
treated EBs. First eGFP expressing CMs could be observed at day 7-9 in control and DMSO-
 
Figure 3.2: Scheme of culture protocols 
Cell culture schedules: Arrows indicate the days of addition of DMSO (1:1,000) or reserpine (10 µM in 1:1,000 
DMSO) as used for the ‘d2’ (green) and ‘d4’ (yellow) protocols. For the ‘d2’ protocol, medium was renewed at 
day 6 and 12, while for the ‘d4’ protocol, medium changes were combined with drug application (d6 and d12): 
(A-C) Control (untreated), solvent control (DMSO; 1:1,000) and reserpine-treated (10 µM in 1:1,000 DMSO) 
day 11 EBs plated on 0.1% gelatine-coated culture dishes (scale bars: 200 µm). Published in [Lehmann, 
Nguemo et al. 2013].  
 Results 
35 
 
treated EBs, whereas, in reserpine-treated EBs the cardiac differentiation was strongly 
reduced even at day 10. Day 14 EBs were puromycine purified to emphasize the reduction of 
CMs after reserpine treatment and only drastically reduced numbers of minimum-sized 
cardiac clusters could be observed (indicated by green arrow).  
3.1.3 Reserpine reduces numbers of beating clusters 
To investigate whether the reduction of cardiomyogenesis, as suggested by the reduced 
numbers of eGFP expressing CMs in Fig. 3.3, led to altered functionality, we quantified the 
ratios of beating clusters. We therefore plated EBs of the three groups on 0.1% gelatine coated 
culture dishes at day 6 and kept treating them following the respective protocol. Counting was 
performed visually and ratios of beating to non-beating EBs were calculated (Fig. 3.4). 
Analysis of the visual counting shows the first appearance of beating clusters with low 
incidence at day 12 of differentiation in reserpine-treated EBs in ‘d2’ and ‘d4’ protocols 
(12.2±9.8%, n=6 and 3.2±7.8%, n=7, respectively), whereas the untreated and DMSO-treated 
groups already show a considerable percentage of beating EBs (untreated ‘d2’: 29.3%±5.7, 
‘d4’: 35.8±7.3%; DMSO-treated ‘d2’: 27.0±8.0%, ‘d4’: 42.6±11.3%). Reserpine-treated EBs 
show their maximum of beating EBs at day 17 of differentiation (‘d2’: 36.6±9.2% and ‘d4’: 
 
Figure 3.3: eGFP positive cardiomyocyte containing EBs representative of the time course of 
differentiation  
Phase contrast/fluorescence overlay images of control, DMSO- (solvent control) and reserpine-treated EBs at 
day 2, 4, 10 and 14 of differentiation (day 14 EBs were purified with puromycine). Green: eGFP positive CMs. 
The reserpine-treated purified cardiac cluster is typically small in size and is highlighted by a green arrow (scale 
bars: d2+d4 50 µM; d10+d14 200 µm). Published in [Lehmann, Nguemo et al. 2013]. 
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34.2±15%) before the number declines after day 20 as in the untreated and DMSO-treated 
group. It has to be noted that the visual counting and the eGFP expression pictures from day 
14 (Fig. 3.3) are opposed, but beating clusters were counted regardless of their size or number 
of CMs contained in them. Since ‘d2’ and ‘d4’ protocols lead to a comparable effect of 
delayed start of beating during ES cell differentiation, it was decided to follow the ‘d4’ 
protocol for further experiments. 
 
3.1.4 Quantification of CMs in EBs using flowcytometry 
For more detailed quantification of the difference of eGFP expressing CMs in control, DMSO 
and reserpine-treated EBs we performed flow cytometry experiments. We grew the EBs using 
the ‘d4’ protocol in mass cultures. Additionally, we investigated whether the period and 
duration of reserpine application affected cardiac differentiation. Therefore, we treated ES 
cells with reserpine either until day 14 (‘until d14’ application) or only until day 6 (‘until d6’ 
application). On day 10 and 14 of differentiation about 100-200 EBs were harvested and 
enzymatically dissociated. Fig. 3.5A shows representative eGFP/propidium iodide (PI) dot 
 
Figure 3.4: Visual counting of beating clusters  
Percentages of beating vs. non-beating EBs were calculated based on visual counting of plated EBs at 
days 10-20. The number of experiments (n) is given on top of each panel. Published in [Lehmann, Nguemo et 
al. 2013]. 
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plots of flow cytometry experiments. Population percentage values of the particular single 
measurement are given in each plot. Fig. 3.5B shows the analysis of the results. Percentages 
of eGFP positive CMs in treated EBs were normalized toward percentages in control EBs. 
Using the ‘until d14’ application (Fig. 3.5B, left), at day 10 no significant differences were 
found between untreated and DMSO-treated EBs (100% vs. 87.3±9%, n=11 independent 
differentiations, p>0.05). In line with the morphological findings (Fig. 3.3), we found that in 
reserpine-treated EBs eGFP expressing CMs were reduced to 28.4±13.8% at day 10 (n=11, 
***p<0.001). At day 14 of differentiation reserpine-treated EBs contained 8% less eGFP 
positive CMs than control EBs (92±32% vs. 100%, n=7 differentiations, p>0.05). Also 
DMSO-treated EBs did not show significant differences as compared to controls (118±18%, 
n=7, p>0.05). Using the ‘until d6’ application scheme demonstrated a similar outcome (Fig. 
3.5B, right). At day 10 no significant difference was observed between control and DMSO 
(100% vs. 109±17%, n=7, p>0.05), while after reserpine treatment the percentage of CMs was 
reduced to 36±12% (n=6, **p<0.01). As in the ‘until d14’ experiments, percentages of CMs 
were not significantly different between the three groups on day 14 (n=4, p>0.05).  
 PI was used to stain dead cells. Analyzing the values of the PI staining derived from 
our experiments (not shown) we did not observe significant differences of PI positive events 
after reserpine treatment, suggesting no significant alterations of cell viability by reserpine. 
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3.1.5 Reserpine inhibits expression of cardiac marker proteins 
Reduced numbers of eGFP positive cells after reserpine treatment in combination with a 
strongly delayed initiation of contraction (Fig. 3.5) using different application protocols 
strongly suggests that reserpine negatively affects cardiomyogenesis. To further investigate if 
this observation was paralleled by alterations on different cardiac protein levels we stained 
EBs using anti-αActinin and anti-cardiac TroponinT (cTnT) antibodies. Herewith it was 
possible to rule out the possibility that the application of reserpine unspecifically inhibited the 
 
Figure 3.5: Flowcytometry for CM quantification 
(A) Representative eGFP/PI dot plots of single measurements of enzymatically dissociated EBs of the 
control group (left) or treated with DMSO and reserpine either until day 14 or until day 6. Percentages of 
eGFP and PI events are given in each plot. Measurements were performed at day 10 (top row) and day 14 
(bottom row) of differentiation. (B) Normalization of the percentage of CMs within EBs toward control 
EBs. ‘until d14’: d10 (n=11, *** p<0.001); d14 (n=7, p>0.05). ‘until d6’: d10 (DMSO n=7, Res n=6, ** 
p<0.01), d14 (n=4, p>0.05). Published in [Lehmann, Nguemo et al. 2013]. 
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eGFP fluorescence or the contraction of the differentiating CMs, thus showing that reserpine 
in fact influences cardiomyogenesis per se.  
 Fig. 3.6 shows that in control and in DMSO-treated day 11 EBs αActinin (red; top 
panel) and cTnT (red; bottom panel) are co-localized with eGFP (green). In contrast, in 
reserpine-treated day 11 EBs αActinin, cTnT and eGFP are hardly expressed, supporting our 
previous results of reduced cardiomyogenesis. 
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3.1.6 Effects of reserpine on proliferation and cell viability  
3.1.6.1 EB cross-section area measurements  
Evaluating whether reserpine affects the viability of ES cells during their differentiation 
would help to exclude that reserpine inhibits proliferation or might have cytotoxic and/or 
 
Figure 3.6: Immonhistochemical staining for cardiac markers  
Immunocytochemical staining of cryosliced (top) and plated (bottom) EBs at day 11 of differentiation: eGFP 
positive cardiomyocytes (green), Hoechst 33342 stained nuclei (blue) and cardiac αActinin (red; top panel) or 
cardiac TroponinC (red; bottom panel). Top rows represent overlay pictures. Scale bars: 50 µm. Published in 
[Lehmann, Nguemo et al. 2013]. 
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apoptotic effects. In a first approach we measured the cross-section areas of spherical EBs at 
different days of differentiation. Fig. 3.7 represents the analysis of cross section areas of 127-
230 EBs from each group of 3-4 independent differentiations at different stages during 
differentiation. We found no significant difference between the groups at day 2 with a mean 
area of 0.040±0.019 mm2 in the untreated, 0.045±0.020 mm2 in the DMSO-treated group and 
0.046±0.024 mm2 after reserpine treatment. Neither untreated (0.088±0.0064 mm2), DMSO-
treated (0.086±0.0075 mm2), nor reserpine-treated EBs (0.077±0.0067 mm2) showed 
significant differences at day 4 of differentiation. Also at day 10 EB size did not differ 
significantly (0.222±0.0154 mm2, 0.246±0.0362 mm2, and 0.270±0.0126 mm2, respectively, 
p>0.05). Based on these results the cells of all three groups grow at the same proliferation 
rate.  
3.1.6.2 Impedance measurements 
After we found that reserpine did not influence proliferation of cells during the developmental 
process, we further evaluated whether the reserpine-induced reduction of CMs in EBs was 
due to reserpine-induced cytotoxicity on CMs per se. For this purpose we used puromycine-
purified control cardiac clusters which were enzymatically dissociated at day 14 (see section 
2.6). Using the xCELLigence RTCA Cardio system enabled us to analyze the impedance of 
 
Figure 3.7: Cross-section areas during the course of differentiation  
Cross-section measurements of EBs on days 2, 4, and 10 from independent differentiation experiments (n=3-4; 
±s.e.m.; p>0.05). Published in [Lehmann, Nguemo et al. 2013]. 
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CM monolayers. Impedance values were measured over a number of electrodes (as shown in 
pictures of Fig. 3.8B) and converted into the cell index (CI). The CI as an arbitrary unit 
reflects cell number, morphology, and attachment. For example, if a drug induces cytotoxicity 
fewer cells would be attached or less strongly attached to the bottom of the cell culture well 
covering less electrodes, and the CI would decrease over time [Xi, Yu et al. 2008, Chen, Cui 
et al. 2012, Otero-Gonzalez, Sierra-Alvarez et al. 2012, Weiland, Berger et al. 2012]. In this 
experiment we investigated if reserpine exerts cytotoxic effects on pure CMs which would 
decrease the CI over time. It should be noted that for this series of experiments medium and 
reserpine was refreshed every 24 hrs. 
 The results of the cytotoxicity experiment are depicted in Fig. 3.8. For each group 16 
wells (n=16) of CMs were plated and the graph in Fig. 3.8A represents their averaged values. 
The CI of all three groups was monitored for ~222 hrs, corresponding to differentiation days 
14-24. The impedance monitoring revealed that CI values increased exponentially before 
reaching a plateau within the first 48 hrs (d14-d16) and the plateau suggested that the cells 
grew a confluent layer. CI values of the single wells were within a close range indicating that 
the wells contained equal numbers of cells (data not shown). Finding no differences between 
the control and the ‘Res after d14’ group indicated that reserpine does not inhibit CM 
adhesion. In a second phase, a yet untreated group was exposed to reserpine (starting after 
~72 hrs/ ‘Res after d17’). Within the second phase of the monitoring the CI slowly increased 
in all groups. This finding strongly suggests that reserpine had no cytotoxic effect on CMs, 
which was further underlined by the fluorescence microscopy pictures in Fig. 3.8B, clearly 
showing eGFP expressing CMs after reserpine application despite more frequent reserpine 
refreshment (every 24 hrs instead of every 4 days). 
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3.1.7 Reserpine effects on gene expression - Quantitative Real Time-PCR (qRT-PCR) 
The results of the previous paragraphs provided evidence for an effect of reserpine on 
cardiomyogenesis. For mRNA expression level analysis we tested ES cells, d1-d14 EBs, 
 
Figure 3.8: Impedance measurements to exclude cytotoxic effects of reserpine on CMs 
(A) Cell index (CI)/time plot of puromycine purified day 14 CMs monitored between d14 (0 hrs) – d24 
(~222 hrs) of differentiation. The plot represents averaged CI values ± SD (n=16).  Two reserpine application 
protocols were used: ‘Res after d14’: reserpine was applied at the day of seeding (d14); ‘Res after d17’: 
reserpine was applied on the third day after seeding (d17) to allow attachment without the drug. (B) phase-
contrast/fluorescence overlay (left) and fluorescence (right) pictures of the CM layers at day 24 (scale bars: 200 
µm). 
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puromycine purified EBs and mouse embryonic fibroblasts (MEFs) by qRT-PCR. All qRT-
PCRs were performed in collaboration with Dr. Vilas Wagh at the University of Cologne, 
Institute for Neurophysiolgy. Used primers are listed in section VII. “Primers” of the 
appendix. 
3.1.7.1 Pluripotency genes 
To investigate if reserpine affected expression of genes important for development prior to 
cardiac development, we studied the expression of the pluripotency genes Zfp42 (Rex1), Oct4 
and Nanog as well as the differentiation marker Fgf-5 (Fig. 3.9). As a pluripotency gene, Rex1 
should be down-regulated upon the start of differentiation. Interestingly, reserpine-treated ES 
cells down-regulated the gene considerably faster, thus indicating that treated cells lose their 
pluripotency properties earlier. Oct4 and Nanog, however, did not show such strong 
differences. Fgf-5 is strongly expressed just prior to gastrulation followed by a dramatic cease 
in expression once formation of the primary germ layers is complete [Hebert, Boyle et al. 
1991]. Fgf-5 expression showed early up-regulation in both groups. But, while in the 
untreated group Fgf-5 was dramatically down-regulated after day 4, this down-regulation 
could only be observed after day 6 in the reserpine group. Expectedly, as compared to ES 
cells pluripotency genes were strongly down-regulated in MEFs. Fgf-5 expression was similar 
in ES cells and MEFs.  
 
Figure 3.9: qRT-PCR results of Zfp42 (Rex1), Oct4, Nanog and Fgf-5  
Relative quantities (RQ) were calculated using the ∆∆ct-method and are plotted on a log2 scale. Published in 
[Lehmann, Nguemo et al. 2013]. 
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3.1.7.2 Cardiac and mesodermal marker genes 
The expression of the cardiac specific genes myosin heavy chain (Myh6) and atrial myosin 
light chain 2 (Mlc2a) should elucidate how strong reserpine affected the CM differentiation 
on the gene expression level. qRT-PCR results of the cardiac genes revealed (Fig. 3.10) that 
Myh6 showed a ~250-fold reduced level of expression in reserpine-treated EBs at day 10. 
Mlc2a did not even seem to be expressed until day 6-8 and expression levels never reached 
control EB levels (up to ~130-fold reduced expression at day 14). These results underline the 
finding of reserpine-inhibited cardiac differentiation. Purified CMs of the control and the 
treated group showed almost equal levels of gene expression. Expectedly, MEFs did not 
express these cardiac genes.  
 Investigating whether only cardiac genes or also mesodermal or early CM gene 
expression is altered, we tested the expression of the specific markers homebox protein 
Nkx2-5, T-brachyury (T-bra), and Gata binding factor 4 (Gata4) (Fig. 3.10). Initial 
transcription of Nkx2-5 was found to be delayed by approximately 2 days (day 8 instead of 6) 
in reserpine-treated EBs. Peaking at day 10 in both groups, Nkx2-5 expression was still 
significantly lower in reserpine-treated EBs at each time point. Accordingly, initiation of T-
bra expression was also delayed by about one day. The maximum expression of T-bra was 
reached at day 6 in reserpine-treated EBs instead of day 4 in control EBs. In purified day 14 
CMs T-bra and Gata4 expression showed higher levels in the reserpine group, whereas 
Nkx2-5 expression was not altered between the groups. In MEFs Nkx2-5, Gata4 and T-bra 
only showed weak expression. 
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3.1.7.3 Catecholamine synthesis genes 
Reserpine-induced depletion of catecholamines has serious effects on cardiac differentiation. 
However, it is not known whether reserpine also influences the expression of the genes of 
catecholamine synthesis. Therefore the expression of tyrosine hydroxylase (Th), aromatic L-
amino acid decarboxylase (Ddc), dopamine-β-hydroxylase (Dbh) and phenylethanolamine N-
methyltransferase (Pnmt) was examined using qRT-PCR (Fig. 3.11). In controls no significant 
expression of Th and Ddc was detected until day 6, while Dbh and Pnmt expression was not 
detected before day 8-10. In contrast, reserpine-treated EBs showed up-regulation of Th, Ddc 
and Dbh already on day 2. Pnmt showed low expression and decreasing levels during 
differentiation in reserpine-treated EBs, whereas in controls up-regulation of Pnmt expression 
started after day 8 and was kept up-regulated until day 14. In reserpine-treated purified day 14 
EBs, expression of Th, Ddc and DBH was also increased, while Pnmt was expressed on a low 
level in both, controls and reserpine-treated EBs. MEFs expressed the genes on ES cell levels 
or below. 
 
Figure 3.10: qRT-PCR results of cardiac marker genes Myh6, Mlc2a and mesodermal markers Nkx2-5, 
T-bra and Gata4  
Relative quantities (RQ) were calculated using the ∆∆ct-method and are plotted on a log2 scale. Published in 
[Lehmann, Nguemo et al. 2013]. 
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3.1.7.4 Endodermal and Ectodermal marker genes  
Given that the number of CMs was strongly reduced by reserpine although EB sizes were 
unaltered, compensatory or alternative lineage differentiation is conceivable. To investigate 
this possibility we further tested the expression of endodermal and ectodermal marker genes.  
As endodermal marker genes we used Sox17, Foxa2, alpha-fetoprotein (Afp), 
hepatocyte nuclear factor 4a (Hnf4a) and albumin (Alb) (Fig. 3.12A). The most prominent 
discrepancies amongst the tested endodermal markers were observed in the expression 
patterns of the transcription factors Sox17 and Foxa2. Most striking is the early up-regulation 
observed for both genes on day 6 instead of day 8 and day 2 instead of day 4, respectively. 
However, the expression of later endoderm-derived liver tissue-inducing genes Afp, Hnf4a 
and Alb revealed no such effect of reserpine. In MEFs, expression of all endodermal marker 
genes tested here, except for Foxa2, is on a level of pluripotent ES cells or below. These 
results suggest that reserpine may also affect certain aspects of early endodermal 
development. 
Investigating ectodermal marker gene expression of microtubule-associated protein 2 
(Map2), β-III-tubulin (Tubb3), and Nestin (Nes) (Fig. 3.12B), it was found that in control EBs 
Map2 expression started around day 4 and stayed at a constant level between day 6 and 14. In 
reserpine-treated EBs Map2 expression stated already at day 1 and was 25-50-times increased 
within the first three days compared to controls. Map2 expression levels were increased 
during the whole period. Tubb3, a valuable neuronal marker [Katsetos, Legido et al. 2003], 
was expressed from day 6 on in reserpine-treated cells, whereas in control EBs it appeared to 
 
Figure 3.11: qRT-PCR results of catecholamine synthesis genes Th, Ddc, Dbh and Pnmt  
Relative quantities (RQ) were calculated using the ∆∆ct-method and are plotted on a log2 scale. Published in 
[Lehmann, Nguemo et al. 2013]. 
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be absent. Nes, a neural progenitor marker [Frederiksen and McKay 1988, Lendahl, 
Zimmerman et al. 1990], was expressed from day 10 on. Aberrant from expression patterns of 
Map2 and Tubb3, Nes expression was rather low in reserpine-treated EBs. 
3.1.8 Expression of α- and β-adrenergic receptor subtypes 
α- and β-ARs are the cellular targets of catecholamines and were therefore studied using 
sqRT-PCR comparing their time course expression in control and reserpine-treated EBs. 
Fig. 3.13 shows that in control EBs the β1- and the β2-AR expression started on day 6, while 
after reserpine treatment first expression was detected on day 4. However, on day 10 β1- and 
β2-ARs were absent in reserpine-treated EBs. Interestingly, β3-ARs were expressed in ES 
cells and their expression levels were found to be increased in reserpine-treated EBs. All 
α1-ARs were clearly expressed on day 10 in the control group, while no expression of α1-ARs 
was found in reserpine-treated EBs. A distinct transient expression of α1A and α1D was 
 
Figure 3.12: qRT-PCR results of endodermal and ectodermal /neuronal marker genes 
(A) endodermal markers Sox17, Fox2a, Hnf4a, Alb and Afp; (B) ectodermal marker Map2 and neuronal markers 
Tubb3 and Nes. Relative quantities (RQ) were calculated using the ∆∆ct-method and are plotted on a log2 scale. 
Published in [Lehmann, Nguemo et al. 2013]. 
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detectable between days 4-8 after reserpine treatment, which even appeared to be higher than 
the expression in the control group. α1B was not expressed at any time in reserpine-treated 
EBs. Expression of the α2A receptor was similar in both groups, while α2B expression strongly 
differed. In control EBs expression of α2B receptors started by day 6 while in reserpine-treated 
EBs no expression was detectable. Like the β1- and β2 receptors, α2C was expressed 
transiently by day 4-6, but was absent on day 10 in reserpine-treated EBs, while in control 
EBs its expression started at day 6 and increased until day 10. Thus, reserpine induced 
alterations in AR-expression. Particularly remarkable was the absence of most ARs in day 10 
reserpine-treated EBs, while others were expressed prematurely (β1, β2, α1A, α1D and α2C).  
3.1.9 Positive effects on neuronal differentiation 
As already indicated by qRT-PCRs of ectodermal and neuronal markers (see paragraph 
3.1.7.4 and Fig. 3.12B), reserpine treatment promoted differentiation of the neuronal lineage. 
Using a cell culture protocol originally optimized for cardiomyogenic differentiation, we 
frequently observed the appearance of cells with a neuronal morphology in the presence of 
reserpine (Fig. 3.14). These cells appeared already at day 11 and were mostly observed in the 
periphery of EBs. Control EBs never showed similar cells. 
 
Figure 3.13: Time course of α- and β-AR subtype expression  
Semiquantitative reverse-transcription PCRs (sqRT-PCRs) from ES cells (ES), control and reserpine-treated 
EBs during differentiation day 2 to day 10 representative of the mRNA expression of α- and β-AR subtypes 
(β1, β2, β3, α1A, α1B, α1D, α2A, α2B, α2C; Gapdh was used as house-keeping control). L: DNA Ladder. Amplified 
fragment sizes are stated on the right of each pane. Primers are listed in section VII. “Primers” of the appendix. 
Published in [Lehmann, Nguemo et al. 2013]. 
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3.1.10 Immunohistochemical stainings for β-III-tubulin and DBH  
To confirm our molecular biology and microscopy findings, immunohistochemical stainings 
with antibodies specific for TUBB3 (β-III-tubulin) and DBH were carried out (Fig. 3.15). In 
all day 11 EBs TUBB3 positive cells were found. However, we observed differences in cell 
morphology between control and reserpine-treated EBs. While the cells in control EBs were 
of round or elongated shape, reserpine-treated EBs contained a high number of neuronal-like 
cells with elongated outgrowth, presumably axons and dendrites (Fig. 3.15, top). This finding 
clearly underlined our phase contrast microscopy observations. DBH expressing cells were 
found in all three groups showing slightly increased numbers in reserpine-treated EBs (Fig. 
3.15, bottom). The cells were of round shape as previously described for intracardiac 
adrenergic (ICA) cells [Huang, Friend et al. 1996]. Taken together our qRT-PCR and 
immunocytochemistry experiments investigating the presence of the DBH enzyme showed 
congruent findings (Fig. 3.11 and Fig. 3.15): 1. qRT-PCR for Dbh at day 10 proved elevated 
expression levels in reserpine-treated EBs confirming the IHC results (from day 11 EBs); 2. 
Reserpine-treated purified day 14 CMs showed a distinctly increased Dbh expression, 
suggesting that Dbh synthesizing cells were present. 
 
Figure 3.14: Neuronal cells in reserpine-treated EBs  
Representative phase contrast image of a day 11 reserpine-treated EB showing cells with typical neuronal 
morphology (scale bar: 50 µm). Published in [Lehmann, Nguemo et al. 2013]. 
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3.1.11 Functional expression of the adrenergic and muscarinic system 
For functional analysis, contracting eGFP positive EBs were collected to perform 
extracellular recordings of field potentials (FPs) using microelectrode arrays (MEAs). 
Reserpine itself already confers a negative chronotropic effect when applied on CMs, because 
of its catecholamine depleting action and consequent lack of β1-AR stimulation. Therefore, 
the cell culture conditions applied to generate the EBs we used for functional analysis 
 
Figure 3.15: Immunohistochemical staining with anti-β-III-tubulin and anti-DBH antibodies  
Immunolocalization of (top) neuronal marker β-III-Tubulin (red) and (bottom) catecholamine synthesis 
enzyme dopamine-β-hydroxylase (DBH; violet) in day 11 EBs: eGFP positive cardiomyocytes (green), 
Hoechst 33342 stained nuclei (blue). Top row represents overlay pictures. Scale bars: 50 µm. Published in 
[Lehmann, Nguemo et al. 2013]. 
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contained reserpine only until day 6 for two reasons: 1. To slightly increase the number of 
beating clusters, 2. To avoid the direct effects of reserpine on CMs and their beating rates 
enableing us to analyze developmental changes in their beating properties. Whether the ‘until 
day6’ protocol led to decreased cardiac differentiation comparable to the ‘unitl d14’ protocol 
was verified by flowcytometry quantification of eGFP positive CMs (Fig. 3.5). We found that 
the ‘until day6’ protocol yielded slightly increased CM numbers compared to the ‘until d14’ 
protocol. Moreover, we observed moderately more contracting EBs. Yet, the ‘until day6’ 
protocol obviously still strongly inhibits cardiac differentiation compared to the untreated 
protocol (see Fig. 3.5; ‘until d6’). Therefore, we were able to derive sufficient numbers of 
contracting EBs for functional analysis using the ‘until day6’ protocol.  
 The β-adrenergic and muscarinic systems are crucial for heart function in vivo. 
Investigating whether both systems are functionally active in vitro, the respective specific 
receptor agonists, isoprenaline (1 µM ISO) and carbachol (1 µM CCH) were applied. We 
analyzed their effect on beating frequencies of untreated and reserpine-treated day 15-16 EBs 
(Fig. 3.16). An EB adhesively grown on a MEA culture chamber for two days and recorded 
FP traces of all 60 electrodes are depicted in Fig. 3.16A. Fig. 3.16B shows 10 sec FP traces 
(on top) and dot plots of the beating frequencies of representative 60 sec intervals (bottom) 
during the course of the experiment. Each dot represents a calculated frequency derived from 
values of inter-spike intervals (ISIs). Only rhythmically beating EBs were considered for 
analysis (n=4 for each group from 3 independent differentiations). Drugs were co-applied as 
follows: 1) baseline: no drug (3 min), 2) ISO (1 µM; 6 min), 3) CCH (1 µM; 6 min), 4) 
washout with repeated medium changes to confirm drug effects through frequency recovery 
effect.  
 EBs averaged beating frequencies during the conditions 1-4 of: 3.89±0.75 Hz, 
5.67±1.06 Hz, 4.47±1.14 Hz, and 5.13 ±1.11 Hz. In comparison, reserpine-treated EBs 
averaged frequencies of 2.23±0.34 Hz, 2.87±0.36 Hz, 2.58±0.41 Hz, and 2.62±0.38 Hz (Fig. 
3.16C). Altogether, reserpine-treated EBs showed lower beating frequencies than control EBs 
at baseline conditions, adding to the reserpine-induced inhibitory effect on cardiac 
differentiation [Banach, Halbach et al. 2003, Kuzmenkin, Liang et al. 2009, Pfannkuche, 
Liang et al. 2009]. Statistical analysis further showed that only in control EBs (and not in 
reserpine EBs) ISO treatment led to a significant positive chronotropic effect (Fig. 3.16 C+D, 
× p<0.05). This observation suggested a weaker responsiveness of reserpine-treated EBs 
towards β-adrenergic stimulation. Finding that under ISO conditions absolute frequency 
values were significantly different between both groups further added to the suggestion of 
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weaker responsiveness (Fig. 3.16C, * p<0.05). Nevertheless, this significant difference 
between the two groups disappeared when values were normalized (Fig. 3.16D). 
 
Figure 3.16: Comparison of β-adrenergic and muscarinic modulation of beating rate in control and 
reserpine-treated ES cell-derived cardiomyocytes 
(A) Spontaneously contracting EB plated on MEA chamber for two days. (B) Representative beating 
frequencies demonstrating effects of ß-adrenergic agonist isoprenaline (ISO, 1 µM) and muscarinic agonist 
carbachol (CCH, 1 µM) on cardiac clusters generated under control (top panel) and reserpine-treated (bottom 
panel) conditions. Original FP traces (10 sec) of each indicated condition are showcased (on top of each plot). 
(C+D) Statistical analysis of absolute and normalized FP frequencies from MEA measurements (n=4). (˟ 
p<0.05: significant difference between baseline and 1 µM ISO in ctrl EBs; * p< 0.05: significant difference 
between ctrl and reserpine-treated EB under ISO). Published in [Lehmann, Nguemo et al. 2013]. 
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3.1.12 Prove of reserpine’s catecholamine depleting action 
Even though the exact mechanism of reserpine action is not fully understood yet, it has been 
established that reserpine is a potent drug inhibiting vesicular transport of catecholamines by 
the vesicular monoamine transporter (VMAT) leading to a depletion of catecholamine stores 
and at the same time preventing re-uptake of catecholamines [Carlsson, Lindqvist et al. 1957, 
Bezard, Imbert et al. 1998, Bezard and Przedborski 2011]. Extracellular and intracellular 
catecholamines are quickly degraded by the action of the enzymes MAO and COMT. Since 
reserpine inhibits vesicular transport and, thus, synthesis of NE and EPI as well as secretion of 
the catecholamines DA, NE and EPI, it leaves no extracellular catecholamines for paracrine 
action (reviewed in [Eisenhofer, Kopin et al. 2004]).  
 To investigate the gradual depletion of catecholamines and the subsequent negative 
chronotropic effect on the beating rate, we performed extracellular recordings of FPs with 
MEAs on untreated day 11-12 beating clusters in EBs. Two days prior to measurements EBs 
were plated and medium was renewed after the first 24 hrs. Fig. 3.17 depicts representative 
FP measurements. Baseline beating was recorded for 3 min (2.5 Hz – 4 Hz) before reserpine 
(10 µM) was added. EBs were kept in the presence of reserpine until the maximum negative 
chronotropic effect was reached or until a complete halt of contraction was observed. We 
never observed a complete stop of beating within the first 8 min, while beating frequencies 
were already clearly reduced in all EBs tested. Of all EBs (n=16), 7 stopped beating, while 9 
showed significant negative chronotropy (1 Hz or below) until 30 min after reserpine 
application. 5 EBs showed arrhythmia. Co-applying adrenergic receptor agonists ISO (1 µM; 
Fig. 3.17A), EPI (100 nM; Fig. 3.17B) and NE (100 nM; Fig. 3.17C) quickly recovered the 
beating frequencies in 13 of the EBs. Washout proved that effects were drug induced. All 
results are summarized in Table 1. 
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Figure 3.17: Effect of catecholamines on spontaneously beating clusters of EBs after acute application of 
reserpine 
Representative FP frequencies of day 11 to 12 beating cardiac clusters under the acute presence of reserpine (10 
µM) and after co-application of adrenergic receptor agonists (A) ISO (1 µM), (B) epinephrine (EPI, 100 nM) 
and (C) norepinephrine (NE, 100 nM). EBs were incubated with reserpine until maximum negative chronotropic 
effects were observed (between 8-30 min) before application of the adrenergic agonists. Depicted are frequency-
time plots of representative 60 sec intervals during the experiment. 10 sec FP traces are showcased on top of 
each plot. Note: After rescue with epinephrine no washout could be recorded. Full summary of all EBs 
measured is shown in Table 1. Published in [Lehmann, Nguemo et al. 2013]. 
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Table 3.1: Summary of reserpine application experiments and adrenergic receptor (AR) 
agonist stimulated recovery (from Fig. 3.17A-C) 
Reserpine  AR Agonist Washout 
N= Negative Stop No effect Arrhythmia Yes No Undefined Yes No Undefined 
chronotropy 
Res + ISO 7 4 3 0 3 5 1 1 5 2 0 
Res + EPI 5 3 2 0 2 5 0 0 2 3 0 
Res + NE 4 2 2 0 0 3 1 0 2 2 0 
Overview 16 9 7 0 5 13 2 1 12 7 0 
 
Shown are the numbers of control EBs and their responses during: 1. Reserpine: Acute Reserpine application 
(i.e. EBs responding by negative chronotropy, stop of beating, no effect and arrhythmia). 2. AR Agonist: AR 
Agonist stimulation following reserpine application (EBs which reacted with positive (yes), neutral (no) or very 
weak (undefined) chronotropy). 3. Washout: After repeated medium changes (showing recovery toward baseline 
beating rate). Published in [Lehmann, Nguemo et al. 2013]. 
3.1.13 Isoproterenol (ISO) partially rescues the long-term effects of reserpine 
The results of the “short-term” rescue experiments (Fig. 3.17) showed that reserpine-induced 
catecholamine depletion and resulting effects on cardiac functionality can be reversed by 
application of endogenous adrenergic agonists (ISO, EPI and NE). Yet, it remains to be 
investigated whether adrenergic agonists are able to rescue the long-term effects of reserpine 
on ESCM differentiation.   
 We developed cell culture conditions to perform a “long-term” rescue experiment. 
One of the major limiting factors for long-term catecholamine-containing culture conditions is 
the fact that catecholamines may induce apoptosis in cardiac cells by activation of the β-
adrenergic receptors after only 24 hrs of incubation [Communal, Singh et al. 1998, 
Communal, Singh et al. 1999]. Moreover, due to their susceptibility to oxidation 
catecholamines are very unstable molecules. For these reasons long-term rescue experiments 
were performed using ISO as β-adrenergic agonist instead of the natural agonists EPI or NE. 
To avoid apoptotic cell death, we added ISO and also reserpine only until day 6. Whereas 
reserpine was applied at day 0 and refreshed at day 2, ISO, after application on day 0, had to 
be refreshed every 24 hrs until day 6 to keep ISO availability in the medium constant during 
that period. 
 Fig. 3.18 shows phase contrast/fluorescence overlay pictures. For evaluation of the 
long-term rescue effect of ISO (1 µM) on CM development the occurance of eGFP positive 
cells in day 10, day 14 and day 14 purified EBs was tracked. Untreated control EBs 
represented a normal differentiation with a normal yield of eGFP positive CMs (Fig. 3.18, left 
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column). Day 14 purified control EBs mainly consisted of eGFP positive CMs. Treating 
differentiating ES cells with ISO (1µM) during the first six days of culture did at least not 
reduce the eGFP positive CM yield after 10 days (data not shown). Reserpine treatment 
during the same period of differentiation expectedly decreased CM yield and cluster size in 
every setting (d10, d14, d14+puro, Fig. 3.18, middle column). Combined application of 
reserpine (10 µM) and ISO (1 µM) induced a distinct reversal of the strongly reduced CM 
yield in reserpine-only treated EBs (Fig. 3.18, right column). Comparing puromycin purified 
CM clusters at day 14, the rescue effect became most obvious (middle and right bottom; green 
arrows indicate CM clusters). ISO induced rescue led to an estimated 2- to 3-fold increase of 
CM containing EBs as compared to only reserpine treatment. Taken together, the results 
suggested that the reserpine effect could at least partially be reversed using the β-adrenergic 
agonist ISO and, thus, it can be claimed that catecholamines play an essential role in cardiac 
development of ESCs. The result may suggest that the effect is, at least in part, transduced by 
the β-adrenergic receptor system and its downstream effectors. 
 
Figure 3.18: Long-term rescue experiment with ISO  
EBs were cultured in the presence of reserpine and combined presence of reserpine and β-adrenergic agonist 
ISO. Fluorescence pictures depict eGFP positive CM clusters (green) at different stages of differentiation and 
after purification of EBs with puromycin (bottom row). Green arrows indicate small eGFP positive clusters. 
Scale bars: 200 µm.  
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Reserpine applied during ES cell development induced two obvious changes of 
differentiation: 1. reduced CM differentiation, and 2. increased neuronal differentiation (Fig. 
3.14+3.15). Whether the latter effect can also be reversed by ISO application was further 
investigated as depicted in Fig. 3.19. Untreated control, reserpine until day 6 and ISO + 
reserpine until day 6 treated EBs were plated on culture dishes at day 7 and were allowed to 
attach before phase contrast pictures were taken at day 10. Comparing control to 
reserpine-treated EBs clearly showed neuronal cells only in the reserpine group. Combined 
application of reserpine and ISO yielded comparable numbers of neuronal cells as in only 
reserpine-treated EBs. Thus, the neuronal inducing reserpine effect did not seem to be 
mediated by the paracrine β-adrenergic receptor signaling pathway. 
3.1.14 α- and β-AR antagonists mimic the reserpine effect 
Catecholamines specifically target all α- and β-AR subtypes (α1A, α1B, α1D, α2A, α2B, α2C, β1, 
β2, β3). As the sqRT-PCR results (Fig. 3.13) showed, reserpine application alters the 
expression of most α- and β-AR subtypes and the reserpine effects are, therefore, certainly not 
limited to β-ARs and their downstream effectors. If that had held true, the ISO rescue 
experiment (paragraph 3.1.13) would have shown complete recovery when ISO and reserpine 
were co-applied. To investigate whether the α- or β-AR system is responsible for 
cardiomyogenesis, we established differentiation conditions containing the α-AR specific 
antagonist phentolamine and the β-AR specific antagonist propranolol. This experiment 
further helps to distinguish between catecholamine-induced AR-dependent effects and 
possible unspecific reserpine actions on cardiac differentiation.  
 
Figure 3.19: Isoprenaline long-term rescue effect on neuronal development  
The same EBs as in Fig. 3.18 were plated on culture dishes to track appearance of neuronal cells at day 10. In 
both, reserpine only (Res) and Res+Iso-treated EBs, neuronal cells in outgrowths of plated EBs were 
observed.Scale bars: 100 µm. 
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 In Fig. 3.20 the results of the antagonisation experiments are depicted as 
phasecontrast/fluorescence overlay pictures at days 8-14. Control EBs showed the normal 
yield of eGFP expressing CMs starting on day 8. The reserpine-treated group was expectedly 
strongly reduced in their number of CMs. In the groups treated with either 10 µM 
phentolamine or 5 µM propranolol, numbers of CMs were slightly decreased already at day 8. 
Phentolamine had a stronger negative effect on cardiomyogenesis than propranolol. Co-
application of phentolamine and propranolol led to even stronger inhibition of 
cardiomyogenesis, mimicking the effect of reserpine. The co-application led to delayed 
appearance of eGFP positive CMs. Starting from day 10 cardiac clusters could be observed, 
but were reduced in size and number as compared to control EBs. Nevertheless, EB size and 
shape of all groups was comparable suggesting normal growth and proliferation.  
 The bottom panel of Fig. 3.20 shows further control experiments. Doubling the 
concentration of propranolol shows that the negative effect on cardiomyogenesis was 
concentration-dependent. Furthermore, doubling phentolamine concentration inhibited ES cell 
growth and proliferation. Prolonged application of the drugs until day 10 also led to reduced 
cardiomyogenesis, while EB growth was not changed. Co-application of double 
concentrations of both drugs expectedly also led to significant reduction in EB growth which 
was most likely due to phentolamine action. Thus, α-ARs affect stem cell growth and 
proliferation or their viability. However, in conclusion these experiments show that α- as well 
as β-ARs are critically involved in cardiomyogenesis. 
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Figure 3.20: Blocking of α- and β-ARs mimics the reserpine-induced effect on cardiomyogenesis 
Top: Fluorescence pictures of EBs treated with the unspecific α- and β-blockers phentolamine and propranolol 
and the combination of both showing the respective expression of eGFP positive CMs on days 8 to 14 of 
differentiation. Bottom: Additional control experiments. For details see text (Scale bars: 200 µm). Published in 
[Lehmann, Nguemo et al. 2013]. 
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3.2 MEA-based QT-screen using pluripotent stem cell derived CMs  
Development of drugs is cost intensive. Several drugs had to be withdrawn from the market 
even after implementation into clinical settings and recommendations, because they were 
found to cause severe and sometimes even fatal cardio-active side effects.  
 After establishment of the MEA and ES cell system as valuable drug-screening tool, it 
was approached to screen known pharmaceutical compounds for those unwanted side effects. 
Such a system would not only help to reduce costs, but also to largely reduce the need for 
laboratory animals. Therefore, we sought to use the advantages of the MEA technique in 
combination with rhesus monkey and human ES cell- as well as iPS cell-derived CMs. Using 
human ES and iPS-derived cardiomyocytes (iPSCMs) eliminates the risk of false conclusions 
due to species differences compared to rhesus monkey stem cell-derived CMS (rESCMs).  
3.2.1 Rhesus monkey cell culture 
As described in paragraph 2.1.3, rESCs were propagated in the presence of bFGF twice per 
week to maintain them in a pluripotent state and to prevent spontaneous differentiation. The 
undifferentiated state of pluripotent ESCs is characterized by strong expression levels of the 
enzyme alkaline phosphatase (AP) [Pease, Braghetta et al. 1990]. To guarantee identical 
pluripotent states of the rESC colonies used for propagation as well as differentiations we 
performed AP stainings as shown in Fig. 3.21. Both, R366.4 and MF12 rESCs stained 
positively for AP and were therefore shown to present a pluripotent state.  
 
Figure 3.21: Alkaline phosphatase staining of R366.4 and MF12 rESCs  
Alkaline phosphatase staining (violet) of rESC lines R366.4 and MF12 showing their pluripotent state as used  
for propagation on ICR-feeder layers and used for differentiation (scale bars: 200 µm). 
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3.2.2 rESC differentiation using mass culture and END2 protocols 
Initially a cardiac differentiation protocol for R366.4 rESCs was published by C. Schwanke et 
al. in 2006 [Schwanke, Wunderlich et al. 2006]. Differentiation of MF12 rESCs into CMs 
(rESCMS) was known to follow the same protocol. However, the published protocol only 
yielded insufficient numbers of CMs and beating clusters for drug-screening purposes. 
Therefore alternative differentiation protocols were tested. In a first approach we applied a 
modified mass culture protocol with horizontal shaking as used for mESCM differentiation. 
Secondly, we approached to improve the CM yield by differentiating the cells on END2 
feeder layers as commonly used for hESCM differentiations. Fig. 3.22 shows microscopy 
pictures of both approaches. Due to the mechanical stress caused by the constant shaking, the 
mass culture protocol did not result in any improvement, with large numbers of dead cells and 
very little numbers of EBs of sufficient size. Still, some EBs that were plated grew to normal 
size. Nevertheless, EBs did not start contracting. Also application of an END2 protocol did 
not improve the outcome. From human ESCM END2 differentiation we know that derived 
EBs are rather small, but rhesus EBs were even smaller in comparison and no contractions 
could be observed. 
3.2.3 rESC differentiation applying activinA/BMP4 
Several groups showed enhancement of murine as well as human ES cell cardiac 
differentiation by the addition of the growth factors activinA and bone morphogenic protein 4 
(BMP4)  [Laflamme, Chen et al. 2007, Nostro, Cheng et al. 2008, Yang, Soonpaa et al. 2008, 
Kattman, Witty et al. 2011, Xu, Police et al. 2011, Sa and McCloskey 2012]. It became 
 
Figure 3.22: Optimization of rESCM differentiation by mass culture and END2 differentiation protocols 
Representative brightfield microcopy pictures of plated EBs derived from R366.4 (left) and MF12 (right) rESC 
differentiation using a mass culture protocol and an END2 feeder protocol, respectively (scale bars 200 µM). 
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evident that each cell line still required individual adaption of the concentrations as well as the 
stages and durations of application of both growth factors. Fig. 3.23 depicts brightfield 
microscopy observations of R366.4 and MF12 rESC differentiations with and without 
activinA and BMP4. We found that especially the R366.4 line could efficiently be directed 
into the cardiac lineage by activinA and BMP4, yielding increased numbers of beating 
clusters compared to the protocol published by Schwanke and co-workers. Also MF12 rESC 
differentiation into CMs was enhanced by growth factor application. Still, compared to the 
MF12 rESCMs, R366.4 contracting rESCMs could be observed as early as day 10-11. Thus, 
we decided to perform MEA QT-screen measurements with R366.4 rESCMs. 
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3.2.4 Summary of the optimized differentiation  
Fig. 3.24 summarizes the optimization approach with activinA and BMP4 showing a scheme 
of the resulting rESCM activinA/BMP4 differentiation protocol the way it was used for 
subsequent MEA measurements. In brief, we combined the differentiation protocol of 
 
Figure 3.23: Optimization of rESCM differentiation protocols by activinA and BMP4  
Representative pictures of R366.4 (left) and MF12 (right) EBs during rESC differentiation using the protocol 
published by C. Schwanke et al. (w/o ActivinA+BMP4; [Schwanke, Wunderlich et al. 2006]) and the same 
protocol modified by stage-specific addition of activinA and BMP4 (ActivinA+BMP4). EBs were plated on 1% 
gelatine-coated culture dishes on day 7of differentiation and pictures were taken on different days as stated. 
Asterisks (*) indicate spontaneously contracting EBs (scale bars 200 µM). 
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Schwanke et al. [Schwanke, Wunderlich et al. 2006] with an incubation of rESCs with 
activinA for the first 24 hrs followed by addition of BMP4 until day 7. During this period EBs 
were cultivated in culture dishes coated with 1% agarose preventing adhesion to ensure proper 
EB formation. After day 7, EBs were collected and transferred to 1% gelatine-coated multi-
well culture dishes and further cultivated for MEA measurements. 
3.2.5 Efficiency of the optimized differentiation 
Fig. 3.25 shows the quantification of the efficiency of our differentiation protocol. The graph 
represents the number of contracting EBs appearing as a ratio of the total number of EBs 
derived from our protocol at different stages of the culture. The combined group is 
representative of all differentiations using the activinA/BMP4 protocol (as shown in Fig. 
3.24). Between day 10 and 14 about 9% of the EBs started contracting, while between days 
15-19 we yielded 5.9%. On days 20-24 another 5.4% EBs were observed that started 
 
Figure 3.24: Scheme of the rESC cardiac differentiation protocol using growth factors activinA and BMP4 
for MEA QT-screen  
Scheme of the optimized rESC activinA/BMP4 differentiation protocol (scale bars: rESC colony, 100 µm; 
beating cluster, 200 µm). Further shown is a R366.4 spontaneously contracting EB plated on a MEA chamber 
and a picture representative of the 8x8 grid of FP traces recoded from that EB by the recording software 
MCRack® (Multichannel Systems, Reutlingen, Germany). 
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contracting relatively late after the initiation of differentiation. Altogether, we were able to 
reach about 20% differentiation efficiency using our protocol. Yet not fully understood, 
preliminary experiments using NEO-MEF feeders instead of ICR-feeders (as proposed by 
Schwanke et al., 2006) for propagation of undifferentiated rESC colonies indicate a strong 
increase in the differentiation efficiency. Using NEO-feeders yielded over 40% efficiency of 
contracting EBs, compared to 4.1% between days 10-14 when rESCs were propagated on 
ICR-feeders. In both groups hardly any new contracting EBs appeared after day 24.  
 
3.2.6 rESCMs express cardiac αActinin  
In addition to the quantification of the differentiation efficiency, we performed 
immunohistochemical stainings of rESCM containing EBs with cardiac-specific anti-αActinin 
antibodies. The result of fluorescence microscopic observations of a cryosliced rESC-derived 
EB is depicted in Fig. 3.26. It was found that CMs yielded using the activinA/BMP4 protocol 
stained positive for the cardiac marker αActinin. 
 
Figure 3.25: Efficiency of rESC differentiation into contracting EBs 
The graph represents the ratio of contracting to total EBs derived from the activinA/BMP4 protocol between 
days 10 and 39 after initiation of differentiation in percent. Shown are the newly appearing contracting EBs in 
each phase during cultivation. It further shows preliminary results of the yield of contracting EBs depending on 
the feeder MEFs (ICR or NEO, respectively) that were used for rESC propagation. 
 
 Results 
67 
 
3.2.7 Negative FPDur/ frequency (FP/f) correlation in hESCMs under physiologic conditions 
We know from human physiology that QT-time and RR-intervals are positively correlated, 
i.e. the longer the RR-interval the longer QT-time and vice versa. In turn this means that the 
higher the frequency the shorter the QT-interval (negative correlation), because the RR-
interval is the multiplicative inverse of the frequency. Similarly, the action potential duration 
(APD) is negatively correlated with the action potential frequency. Therefore, we hypothesize 
that under physiological conditions also the FP duration (FPDur) must be negatively correlated 
with the frequency [Halbach, Egert et al. 2003, Halbach 2006].  
 To investigate FPDur/frequency (FP/f) correlations we first performed MEA 
measurements with hESCMs and iPSCMs at untreated conditions and further stimulated with 
the β-adrenergic agonist ISO, inducing a positive chronotropic effect. Because ISO mimics 
the natural sympathetic adrenergic stimulation of CMs, this stimulation can still be considered 
physiological. Resulting FP/f correlations should therefore provide a “normal” baseline for 
further experiments that investigate effects of drugs with QT-time and repolarization 
prolonging effects (e.g. E4031, Sotalol, etc.). 
 In Fig. 3.27 MEA recordings of day 30-35 H1 hESCMs treated with ISO are shown. 
Each panel depicts the same data set plotted under different aspects. And, each dot represents 
the value pairs of FPDur and frequency values averaged over a 60 sec interval under the stated 
conditions. Fig. 3.27A represents absolute FP/f values. Comparing all baseline (blue 
trapezoid) with ISO value pairs (pink, red, turquois) shows that ISO application induced a 
shift of the value pairs to the top left section of the chart, thus, indicating a negative FP/f 
correlation. This negative correlation persisted within each single EB measurement (Fig. 
3.27B). At baseline conditions beating frequency was between 1 to 1.5 Hz, while maximum 
 
Figure 3.26: Anti-αActinin immunohistochemical staining of an rESC-derived contracting EB  
Representative fluorescence picture of a cryosliced day 15 R366.4 rESC-derived contracting EB. The slice was  
stained with a mouse-anti-αActinin primary antibody (red) and Hoechst 33342 for nuclei staining (blue). Scale 
bars: 50 µm. 
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rates under ISO did not exceed 2.5 Hz, which was considered physiologic beating. However, 
using absolute values revealed an EB-to-EB variation typical for biological preparations. To 
circumvent the variation, FP/f values were normalized per EB toward their baseline value 
(untreated condition) as depicted in Fig. 3.27 C+D. Normalization made recordings from 
different EBs far more comparable and shows that a single drug affects different EBs in a 
relatively similar way in respect to their FP/f correlation. In this case FP/f correlations were 
negative to the almost same degree in each EB. Furthermore, when averaged, the FP/f values 
also showed negative correlation and further suggest that the correlation was almost linear 
within a physiological beating frequency range (~1 to 2.5 Hz). Taken together we show that, 
1) FPDur and frequency are negatively correlated, and 2) Averaging of normalized FP/f value 
pairs represents the FP/f correlation of a population of EBs. Therefore, only averaged and 
normalized FP/f plots will be used for presentation of further data. 
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Figure 3.27: Negative FP/f correlation in H1 hESCMs under physiological positive chronotropic 
conditions  
Day 30-35 H1 hESCMs were treated with different concentrations of β-adrenergic agonist ISO and analyzed by 
extracellular MEA recordings. Each dot represents the averaged value pairs of FPDur and frequency analysis of a 
representative 60 sec interval under the different conditions (baseline, ISO application, washout). All 
FPDur/frequency plots represent the same data set, but different aspects: A+C: absolute and normalized single 
values sorted by treatment, respectively; B+D: absolute and normalized single values sorted by measurement, 
respectively; D: normalized and average values of all measurements. For details see text. 
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3.2.8 Negative FP/f correlation in hiPSCMs under physiologic conditions 
The negative FP/f correlation was now shown in H1 hESCMs. However, to show that this 
negative correlation was not only a cell line- or cell type-specific phenomenon, but a general 
relationship, we performed MEA recordings to investigate the influence of the frequency on 
the FPDur in further pluripotent cell derived CMs. Fig. 3.28 shows the results of ISO 
application on FP/f correlations in NP0017, NP0014c5 and Royan hiPSCMs (cells were 
kindly provided by Dr. Dr. T. Saric and Dr. A. Fatima, University of Cologne, Institute of 
Neurophysiology). In accordance with the results of H1 hESCMs under the influence of ISO, 
also hiPSCMs showed negative FP/f correlations. 
 
Figure 3.28: Negative FP/f-correlation in hiPSCMs under physiological positive chronotropic conditions 
FPDur/frequency plots representative of ISO treatment of NP0017, NP0014c5 and Royan d25-35 hiPSCMs. 
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3.2.9 Negative FP/f correlation during negative chronotropic stimulation 
So far we showed by positive chronotropic stimulation that FPDur and frequency of EBs 
correlated negatively. However, it remained unclear whether the negative correlation persisted 
when EBs are stimulated in the opposite direction. Therefore, we used carbachol (CCH), a 
muscarinergic agonist, to induce a negative chronotropy in H1 hESCMs. Fig. 3.29 shows the 
FPDur/frequency plot of averaged and normalized values of MEA recordings during the 
application of increasing concentrations of CCH. The results showed that under the influence 
of 1 µM and 10 µM CCH, the frequency was decreased by ~40% while the FPDur increased by 
~25%. Thus, the negative FPDur/frequency correlation persisted also after negative 
chronotropic stimulation. 
 
3.2.10 FP/f correlation during successive positive and negative chronotropic stimulations 
It was further necessary to know if the negative FPDur/frequency correlation could be observed 
during consecutive positive and negative chronotropic stimulation. For that reason we treated 
H1 hESCMs first with ISO (positive chronotropic) and subsequently with the β-blocker 
Metoprolol (negative chronotropic). MEA analysis, shown in Fig. 3.30, again revealed the 
negative FPDur/frequency correlation and thus strongly indicates that FPDur and frequency are 
dependent on each other. 
 
Figure 3.29: Negative FP/f correlation in hESCMs under physiologic positive chronotropic conditions 
FPDur/frequency plots representative of CCH treatment of H1 d25-35 hESCMs. 
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3.2.11 Effects of class III antiarrhythmic drugs on FP/f correlations in hESCMs and rESCMs 
According to our findings and publications by others [Reppel, Igelmund et al. 2007, Caspi, 
Itzhaki et al. 2009], we hypothesized that drugs such as class III (Vaughan Williams 
classification) antiarrhythmic agents (K+ channel blockers) should change the FP/f 
correlation. Since class III antiarrhythmic drugs increase AP and FP durations, we assumed a 
less negative or even positive FP/f correlation. To test this hypothesis, we recorded FPs of 
EBs during E4031 and sotalol treatment. Fig. 3.31 depicts the results of MEA measurements 
in H1 hESCMs and R366.4 rESCMs treated with increasing concentrations of both class III 
agents. Unlike during ISO treatment, FPDur increased during E4031 treatment even though the 
frequency increased. This was reflected by a positive FP/f correlation in H1 and R366.4. FP/f 
value pairs shifted to the top right of the diagram in a concentration-dependent manner (Fig. 
3.31A+B). Also sotalol induced a positive FP/f correlation, even though the effect was rather 
weak in H1 (Fig. 3.31C+D). Furthermore, washout partially recovered this effect.  
 
Figure 3.30: Negative FP/f correlation in hESCMs under physiologic positive and negative chronotropic 
conditions  
FPDur/frequency plots representative of ISO and Metoprolol co-application in H1 d25-35 hESCMs. 
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To demonstrate that positive FP/f correlations are generally detected in the presence of 
substances altering QT-time, we performed further series of measurements using different of 
such drugs. Accordingly, Fig. 3.32 shows the FP/f plots. Amiodarone belongs to the group of 
class III antiarrhythmics while quinidine actually is a class I (Na+-blocker) antiarrhythmic 
drug. However, quinidine also blocks K+-channels and, thus, exhibits QT-prolonging activity. 
Both drugs were applied with increasing concentrations in R366.4 rESCMs and H1 hESCMs, 
respectively (Fig. 3.32A+B). We found that amiodarone induced a positive FP/f correlation at 
concentrations above 25 µM and that it could be washed out.  Quinidine, however, only 
showed a mild effect on FP/f correlation. Lidocain, being a class Ib antiarrhythmic drug (Na+-
blocker), is known to decrease the QT-time and APDur by extending the depolarization on one 
Figure 3.31: Positive FP/f correlation in hESCMs and rESCMs induced by class III antiarrhythmic drug 
application 
FPDur/frequency plots representative of E4031 (A+B) and sotalol (C+D) application in H1 and R366.4 d25-35 
ESCMs, respectively.  
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side, but even more shortening the repolarization. To investigate if this effect can be detected 
with the help of FP/f correlations we performed yet another series of measurements. Lidocain 
was the only antiarrhythmic compound were we could not confirm QT-time and APDur 
observations, which suggests that further measurements are needed for final validation. 
Finally, we treated MF12 rESCMs with E4031 showing that this cell line also reacted with a 
positive FP/f correlation upon treatment with a class III antiarrhythmic agent (Fig. 3.32D).  
 
 
Of the MEA data presented in the previous sections, three important conclusion can be drawn: 
1) A screen for potential APDur increasing and QT-time-prolonging compounds is feasible 
based on positive and negative FP/f correlations; 2) The screen is independent of the type of 
 
Figure 3.32: Positive FP/f correlation in hESCMs and rESCMs induced by different antiarrhythmic drug 
applications 
FPDur/frequency plots representative of amiodarone (A), quinidine (B), lidocaine (C) and E4031 (D) application 
using different pluripotent ESC derived CMs (R366.4, H1, H9 and MF12, respectively). 
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pluripotent cell lines and species (rhesus monkey or human) the ESCMs were derived from; 
3) The experiments showed that hiPSCMs are well suited for this purpose.  
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4 Discussion 
4.1 Role of catecholamines in cardiac lineage commitment in mouse ES 
cells 
Catecholamines have been found to be essential not only for the regulation of adult heart 
function but also for embryonic heart development [Kobayashi, Morita et al. 1995, Thomas, 
Matsumoto et al. 1995, Zhou, Quaife et al. 1995, Ebert and Taylor 2006]. Approaching to 
investigate the role of catecholamines in stem cell development pluripotent murine D3 
αPIG44 ES cells were treated with reserpine, a drug blocking storage and re-uptake of 
catecholamines thereby depleting their extracellular availability [Carlsson, Lindqvist et al. 
1957, Schuldiner 1994, Bezard, Imbert et al. 1998, Bezard and Przedborski 2011]. The results 
clearly showed reduced and delayed cardiomyogenesis and further suggested a critical role of 
catecholamines in stem cell differentiation. Yet, reserpine did not negatively affect cell 
proliferation as was demonstrated by EB size evaluation and impedance monitoring. Apart 
from reduced cardiac lineage direction, application of reserpine also affected the time course 
and expression quantities of pluripotency, catecholamine synthesis as well as germ-layer 
marker genes. Of special interest was the finding of high numbers of spontaneously 
differentiating neuronal cells in reserpine-treated EBs, which was further strengthened by 
qRT-PCR results showing increased ectodermal and neuronal marker gene expression. 
Further supporting the finding of reserpine-induced delayed cardiac development, we 
observed significantly reduced beating rates in reserpine-treated EBs [Kuzmenkin, Liang et al. 
2009, Pfannkuche, Liang et al. 2009]. Co-applying reserpine with NE, EPI and isoproterenol, 
a β-adrenergic agonist, we found a rescue of the reserpine induced effect on cardiac function, 
suggesting at least a partial involvement of the adrenergic system in cardiac development. 
Moreover, we co-applied reserpine with ISO during the first 6 days of differentiation finding 
distinctly rescued numbers of eGFP expressing CMs. Interestingly we could show that α- and 
β-AR antagonists mimic the effect of reserpine in terms of reduced cardiac development, 
leading to the assumption that not only β-ARs but also α-ARs are crucial for 
cardiomyogenesis. In conclusion, the current work presents evidence for a reserpine-induced 
reduction of cardiomyogenesis via catecholaminergic signal transduction, i.e. α- and β-
adrenoceptors.  
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4.1.1 Effects of reserpine on cardiac differentiation 
To directly identify the influence of catecholamines on cardiomyogenesis, determining 
catecholamine levels in the EBs would have been desirable. Since catecholamines possess an 
extremely short half-life due to their susceptibility to oxidation, we indirectly demonstrated 
the role of catecholamines by ISO rescue and AR antagonization. For the same reason we 
were not able to answer the question, if cardiomyogenesis could be enhanced by AR 
stimulation. To investigate this beneficial effect, further experiments will have to be 
performed using adrenergic agonists with increased chemical stability. 
Showing severe developmental defects, several studies have been performed 
investigating the effect of genetic knock-outs of catecholamine synthesis enzymes in mouse 
models. In 1995, Thomas et al. published their results of DBH knock-out mice being unable 
to synthesize NE and EPI [Thomas, Matsumoto et al. 1995]. Strikingly, all of the homozygous 
embryos died in utero when bred from homozygous mothers and only 5% of homozygous 
embryos from heterozygous mothers reached adulthood. This survival probably depended on 
placental catecholamine transfer from their mothers. They further suggested that mortality 
was caused by a lack of NE rather than EPI, because it could be prevented by treatment with 
dihydroxyphenylserine which can be converted to NE without the activity of DBH. The 
majority of DBH-/- embryos died of probable cardiovascular failure even before formation of 
adrenal glands and maturation of the sympathetic nervous system, suggesting different 
primary sources of catecholamine biosynthesis between embryos and adult mice [Thomas, 
Matsumoto et al. 1995]. The idea of an important role of catecholamines in embryonic 
development was strengthened by establishing mouse models deficient of intact TH being 
unable to synthesize the catecholamines DA, NE and EPI. Two independent publications 
provided strong evidence for catecholamines being essential for fetal development and 
postnatal survival [Kobayashi, Morita et al. 1995, Zhou, Quaife et al. 1995]. Both groups 
reported significant fetal mortality after E12.5 and E11.5, respectively, with even increasing 
mortality rates during the progression of development, very low postnatal survival (maximum 
P21 [Zhou, Quaife et al. 1995]) and runting of the neonates. Whereas Kobayashi et al. could 
not identify any “gross deformity” in any of the organs at least in embryos, Zhou et al. 
suggested cardiovascular failure as the cause of embryonic fatality after TH knockout 
[Kobayashi, Morita et al. 1995, Zhou, Quaife et al. 1995]. Nevertheless, L-DOPA rescue 
[Zhou, Quaife et al. 1995] and genetic rescue with human TH [Kobayashi, Morita et al. 1995] 
confirmed their finding of the essential developmental role of catecholamines. Both groups 
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suggested a paracrine action of catecholamines at a developmental stage before neuronal 
innervation is established. 
Deleting PNMT, the enzyme catalyzing the biosynthetic step from NE to EPI, on the 
other side, did not lead to embryonic mortality contrasting the effects of TH and DBH 
deletions [Ebert, Rong et al. 2004]. This finding added to the assumption that NE is the most 
critical catecholamine regarding cardiac development. Our reserpine treatment model strongly 
resembles a DBH knock-out situation. Our observation of strongly inhibited cardiac 
differentiation after reserpine induced catecholamine depletion appears plausible and 
underlines the comparability of our stem cell model with in vivo models with respect to the 
influence of catecholamines. Nevertheless, we cannot conclude whether NE or EPI is more 
important. Reported severe effects on embryo survival in knock-out models is also reflected 
in the gene expression studies shown here (Fig. 3.9-3.13). Interestingly, we also showed that 
depleting catecholamines, further leads to unexpected miscellaneous timely and quantitative 
alterations of the expression of different groups of genes, related to e.g. pluripotency, germ 
layer development, catecholamine biosynthesis and α- and β-ARs. Such changes could 
certainly also lead to severe embryonic malformations and death as described in the afore-
mentioned in vivo knock-out models. 
 While our in vitro ES cell culture system allows defined experimental conditions, the 
situation in terms of cell/cell interplay, hormonal regulation, and maternal/fetal interaction is 
far more complex in vivo [Schlumpf and Lichtensteiger 1979]. Placental transfer of 
catecholamines from the heterozygous mothers to homozygous embryos might rescue at least 
some embryos from prenatal death or may uphold, at least in part, the cardiac differentiation 
program [Kobayashi, Morita et al. 1995, Thomas, Matsumoto et al. 1995, Zhou, Quaife et al. 
1995]. The importance of placental transfer was nicely shown by Thomas et al. in 1995. They 
reported that 12% of their DBH-/- embryos from heterozygous mothers survived until birth, 
whereas all DBH-/- embryos from homozygous mothers died before E13.5 [Thomas, 
Matsumoto et al. 1995]. The same study also nicely showed that heterozygous embryos 
(DBH+/-) from homozygous mothers synthesized NE almost at wild-type levels. Whether 
maternal or embryonic catecholamines are more important for development remains unclear. 
However, if maternal catecholamine levels would per se supersede the levels released by the 
embryo, embryonic cardiac development would be strongly dependent on the mother’s 
catecholamine levels (e.g. stress exposure, etc.). Therefore, it is hypothesized here, that a local 
regulatory system might control catecholamine concentrations within the blastocyst and/or the 
embryo, at least during the earliest steps of cardiac development. 
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It was also found that excessive exposure of catecholamines or β-adrenergic agonists 
leads to congenital heart failure in chick embryos [Hodach, Gilbert et al. 1974]. Since, only 
early application (E4 to E5) led to these malformations in chicken, and embryonic mortality 
appeared between E9.5 and E13.5 in murine catecholamine biosynthesis gene knock-out 
models, a “critical period” for catecholamine action was suggested. During this period 
embryos are “hypersensitive” to exposure with catecholamines (reviewed in [Ebert and Taylor 
2006]. This suggested that depletion as well as over-application of catecholamines leads to 
alteration of cardiac development in vivo. Reserpine applied continuously (‘until day 14’) but 
also only until day 6 in our respective culture protocols is already enough to induce strongly 
reduced cardiac development. This obviously suggests, that in our in vitro ES cell system the 
critical period was before day 6. Even though the in vivo knock-out models (TH and DBH 
knock-out) suggested the critical period in terms of embryonic lethality to be between E9.5 
and E13.5 [Kobayashi, Morita et al. 1995, Thomas, Matsumoto et al. 1995, Zhou, Quaife et 
al. 1995], the mechanistic changes leading to that certainly appear before E9.5. Hence, the 
critical periods would be more or less overlapping in the in vivo and the in vitro model of this 
work. Thus, reduced cardiac development in ESCs could be based on the “critical period” for 
catecholamine action. In this period catecholamines whether in very low or in excessive 
concentrations were simply shown to negatively alter cardiac development in vivo. Based on 
our results, we suggest that in the ES cell differentiation model this critical period is likely to 
be within the first 6 days of differentiation. 
 In the present study we showed results from qRT-PCR experiments quantifying the 
expression of catecholamine synthesizing enzymes (see Fig. 3.11). Expression of the genes 
Th, Ddc and Dbh began on day 2 when reserpine was present. Pnmt, on the other side, did not 
seem to be expressed in reserpine-treated EBs at all or were at least strongly down-regulated. 
In control EBs, expression of neither of these enzymes could be detected before day 6 or day 
8. Already in the 1930’s people hypothesized that catecholamines are important regulators of 
heart rate even at early pre-innervation stages of development [Markowitz 1931] and further 
suggested a humoral control of the heart rate in embryos before inception of the nervous 
system [Hsu 1933]. In accordance, catecholamines (NE and EPI) were detected in chicken 
hearts as early as day 3 of incubation. In whole chick embryos, L-DOPA and DA were even 
present from day 1 on [Ignarro and Shideman 1968]. Consequently, the question arose what 
the source of the catecholamines at this pre-innervation stage of development would be. In rat 
[Ebert and Thompson 2001], mouse [Ebert, Rong et al. 2004] and human [Huang, Friend et 
al. 1996] hearts or primary cardiomyocyte isolates, intrinsic cardiac adrenergic (ICA) cells 
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were found. These ICA cells are present long before neuronal β-adrenergic innervation occurs 
and were described to have important functions in embryonic heart development and also 
neonatal cardiac β-adrenergic functionality. Initially it was suggested that ICA cells would 
only be related to cardiac conduction system development [Ebert and Thompson 2001], 
whereas a further study by Ebert and colleagues in 2008 proposed that also atrial and 
ventricular myocytes originate from the same kind of cells [Ebert, Rong et al. 2008].  
 Reserpine-induced depletion of catecholamines leading to reduced cardiomyogenesis 
indicates that catecholamines stimulate cardiomyogenesis. Moreover, our results showed 
higher expression of catecholamine biosynthesis genes while reserpine is present. Those 
results suggested higher levels of L-DOPA, DA, and NE, which would in turn contradict the 
hypothesis of catecholamines having inducing effects on cardiomyogenesis. 
Immunohistochemical staining with DBH antibodies (Fig. 3.15) revealed the increased 
presence of catecholaminergic cells in reserpine-treated EBs and strengthened the qRT-PCR 
results (Fig. 3.11). As described for ICA cells [Huang, Friend et al. 1996],  catecholaminergic 
DBH expressing cells are small, roundish and were found in isolated groups but basically do 
not look like neuronal cells. Our DBH expressing cells look like ICA cells, but are not 
surrounded by cardiac cells in the reserpine-treated group. Nevertheless, the reserpine reduced 
vesicular transport and resulting lower levels of NE and EPI may have activated expression of 
the preceding enzymes (e.g. Th, Ddc and Dbh) in a feedback regulation/activation loop, as 
commonly seen in anabolic biosynthetic pathways. Hence, the catecholamine synthesizing 
enzymes are up-regulated, while effectively, catecholamine levels are low through the action 
of reserpine, and for that reason cardiac development may be hampered.  
 Higher numbers of ICA cells as seen in immunohistochemical stainings (Fig. 3.15) 
could have a similar reason. So far, it is unclear which mechanisms control ICA cell growth 
and proliferation. We show that ICA cells are present, but hypothesize that they are 
catecholamine-depleted by the action of reserpine. Therefore the catecholamines’ cardiac-
inducing effect in reserpine-treated EBs is lacking. Increased ICA cell proliferation could as 
well be induced by a missing feed-back inhibition mechanism. While reserpine depletes ICA 
cells of catecholamines and changes the cells’ gene expression, in compensation it could 
induce a signal cascade that induces ICA cell proliferation above the normal level, leading to 
our observation of slightly increased numbers of those cells. 
 The previous discussion about the presence and the role of ICA cells is interesting in 
respect to a recent publication, providing evidence of those cells reducing 
ischemia/reperfusion injury [Huang, Nguyen et al. 2009]. 
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4.1.2 Underlying mechanisms 
Activation of adrenergic receptors activates highly complex intracellular signaling cascades. 
ARs are well known to belong to the G protein-coupled receptor superfamily (GPCRs) [Caron 
and Lefkowitz 1993]. Upon catecholamine binding to their specific receptor subtypes, 
dissociation of the G-protein heterotrimers regulates a variety of second messengers, e.g. 
cAMP, cGMP, Ca2+, inositol 1,4,5-trisphosphate (IP3), nitric oxide (NO), arachidonic acid 
(AA), etc. Subsequently, protein kinases and phosphatases regulate the phosphorylation status 
of proteins involved in almost all areas of cellular function. These functions can roughly be 
divided into short-term and long-term modulating effects. Short-term effects include for 
example ion channel activity, receptor sensitivity, general metabolism or neurotransmitter 
synthesis and release, whereas, long-term modulations include synthesis of channels, 
receptors and intracellular messengers, synaptogenesis and generally gene expression 
(reviews: [Keys and Koch 2004, Zheng, Han et al. 2004]). However, many details of the 
adrenergic network are still unclear.  
 During the course of differentiation, CMs undergo various changes regarding their 
functional properties [Hescheler, Fleischmann et al. 1999, Janowski, Cleemann et al. 2006, 
Kuzmenkin, Liang et al. 2009, Pfannkuche, Liang et al. 2009]. As has been shown before, 
also the frequency with which CMs contract varies strongly between the developmental 
stages. Murine ESCMs have been demonstrated to increase their beating rates during the 
course of development [Banach, Halbach et al. 2003, Kuzmenkin, Liang et al. 2009]. The 
MEA experiments presented in Fig. 3.16 show that reserpine-treated EBs contracted with 
reduced frequencies and underlined our overall finding of delayed cardiac differentiation. 
Upon ISO stimulation, absolute values of beating rates of control EBs were significantly 
higher (Fig. 3.16C) than beating rates of reserpine-treated EBs, whereas, normalization of the 
beating rates did not lead to a significant difference (Fig. 3.16D). Even more, the normalized 
ISO stimulated frequency in reserpine-treated EBs is lower and could, therefore, imply a 
decreased responsiveness and an immature β-adrenergic system in these cells [Kuzmenkin, 
Liang et al. 2009, Pfannkuche, Liang et al. 2009]. The conclusion of this functional MEA 
experiment was also reflected by the sqRT-PCR results for β-AR expression (Fig. 3.13). Both 
findings further support the hypothesis that reserpine delays cardiac differentiation, but they 
also show that reserpine treatment changes the expression of β-ARs (and α-ARs) providing a 
first idea for the underlying mechanism. 
Discussion 
82 
 
 The sqRT-PCRs and the MEA experiments pointed toward a possible role of ARs in 
ESCM differentiation. To further elucidate the mechanism underlying the reserpine-induced 
developmental effect, short-term rescue experiments were performed (Table 1 and Fig. 3.17). 
First, we used MEAs to confirm that reserpine depletes the catecholamine stores, thereby 
gradually reducing the beating rate of spontaneously beating clusters. Recovery of the beating 
rate, by application of β-adrenergic agonist ISO and natural AR agonists NE and EPI, showed 
that the reserpine effect on beating rates is catecholamine-dependent. Thus, the experiment 
confirmed that reserpine depletes intracellular catecholamine stores and suggested that the 
reduced cardiac development may depend on reduced levels of catecholamines causing a lack 
of AR stimulation (mainly β1-ARs in the heart). Also the increase in neuronal cells may be 
dependent on reduced catecholamine levels. However, whether the α-AR, the β-AR system or 
both systems together are responsible for the effects could not be concluded. 
The previous findings laid the basis for the long-term rescue experiment. Cultivating 
ES cells in medium containing reserpine and ISO at least partially reversed the inhibiting 
effect of reserpine on cardiac development (Fig. 3.18). Thus, it can be hypothesized, that β-
AR signaling partially modulates cardiac development. Since the specific β-AR subtypes are 
coupled to different G-protein complexes (activating as well as inhibiting) application of the 
unspecific β-AR agonist ISO could induce partially opposite intracellular effects that might 
inhibit complete rescue. It is possible that more complete rescue might be accomplished with 
subtype-specific β-AR agonists. In this regard, it has to be further considered that ISO has a 
limited half-life. Due to their even shorter half-life, the native β-AR agonists, NE and EPI, 
were tested for their potential rescue effects, however without providing revealing results. 
Also sqRT-PCRs (see Fig 3.13) did not explain which β-AR subtype determines cardiac cell 
fate, because expression of all subtypes was somewhat changed after reserpine treatment. 
 Evidence from previous work implied the conclusion that the β1- and the α2-
adrenoreceptor systems are the most likely candidates for developmental inhibition. In vivo 
knockout experiments showed that those ARs negatively impact embryonic development 
when being deleted [Rohrer, Desai et al. 1996, Hein, Altman et al. 1999, O'Connell, Ishizaka 
et al. 2003]. This work showed, that applying phentolamine and propranolol to antagonize α- 
and β-adrenergic receptor signaling negatively affects cardiomyogenesis, mimicking the 
negative effects of reserpine (Fig. 3.20). This observation was in line with the above 
mentioned knockout experiments. The results shown here strongly suggest catecholamine-
induced α- and β-AR-mediated signaling to be critical for cardiac development in ES cells. 
This finding may, at least partially, be extrapolated to the in vivo situation. Our sqRT-PCR 
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results point toward α1D, α2C and the β-ARs as possible candidates promoting the 
catecholamines’ effects on cardiomyogenesis, because their expression patterns showed the 
most obvious deviations. However, also α2A being prematurely expressed might be a 
candidate,  in line with AR knockout models [Rohrer, Desai et al. 1996, Hein, Altman et al. 
1999, O'Connell, Ishizaka et al. 2003]. Most striking was the rather unexpected strong 
expression of β3 in reserpine-treated EBs. Except for α2A and β3, all ARs are absent at day 10 
after reserpine treatment. Therefore our data suggest that a wide-spread role of 
catecholamines on the differentiation of a variety of cell types (all those expressing ARs) is 
conceivable.  
4.1.3 Effects on neuronal Differentiation 
Beside the reserpine-induced inhibition of cardiomyogenesis, the present work also provides 
evidence for alterations in ectodermal gene expression (Fig. 3.12B). Even in our cell culture, 
being optimized for cardiac differentiation, reserpine-treated ES cells obviously develop into 
EBs containing remarkable numbers of neuronal cells (Fig. 3.14, 3.15 and 3.19). Of the genes 
tested, especially Map2 is significantly up-regulated already at day 1 of differentiation. Tubb3 
also shows higher expression levels compared to untreated EBs. Together with the 
immunohistochemical staining with β-III-tubulin antibodies and the phase contrast 
microscopy pictures, the inducing effect of reserpine on neuronal development is quite 
striking [Theurkauf and Vallee 1982, Harada, Teng et al. 2002, Katsetos, Legido et al. 2003]. 
The neuronal cells found in reserpine-treated EBs are not only increased in their number, but 
also appear more mature based on their morphology with typical axonal and dendritic 
outgrowths. So far, not many details of the effects of catecholamines on neuronal 
development are described. 
In vivo studies with heterozygous TH mutant mice (TH+/-) with moderate 73-80% of 
wild-type NE levels revealed impairments in different learning and memory tasks but no 
morphological changes in brains [Kobayashi, Noda et al. 2000]. Another in vivo study by 
Kobayashi and colleagues worked with genetically modified mice resulting in a complete loss 
of TH expression only in dopaminergic neuronal cells [Kobayashi and Sano 2000]. With 
resulting significantly lower levels of dopamine produced in the brain (probably during the 
embryonic and maturation phase), three weeks after birth these mice were described to have 
brain weights reduced to 87% compared to control mice. These mutant mice showed impaired 
spontaneous locomotor activity and cataleptic behavior. Kobayashi et al. concluded that the 
abnormalities in motor control resulted from the combined loss of the two major 
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dopmaninergic pathways, the nigrostriatal and the mesocorticolimbic pathway and not from a 
loss of dopaminergic cells in the brain [Kobayashi and Sano 2000]. In line with the in vivo 
experiments by Kobayashi et al. and based on our findings, catecholamine biosynthetic 
enzymes and their products, especially DA and NE, are also important for the development of 
neuronal cells. The data shown here suggest that in ES cell culture catecholamines seem to 
exhibit a negative regulatory effect when present. We hypothesize that reserpine 
reduces/depletes catecholamine concentrations and may therefore abolish this negative 
regulating effect, thus leading to increased neurogenesis. 
Another possible reason for the positive effect of reserpine on neuronal development 
could be based on a more global drug effect. As discussed in a review of Zorn and colleagues, 
endoderm and mesoderm are derived from a transient progenitor cell population known as the 
mesendoderm [Zorn and Wells 2009]. In parallel to these progenitors, the ectodermal lineage 
arises and in the further course of development differentiates into neuronal cells (besides other 
cell types). Several publications provided good evidence for Nodal being an important central 
switch responsible for mesendodermal on one side (induced by Nodal) or ectodermal cell fate 
on the other side (induced when Nodal is inactivated) [Vallier, Reynolds et al. 2004, Ben-
Haim, Lu et al. 2006, Camus, Perea-Gomez et al. 2006, Mesnard, Guzman-Ayala et al. 2006]. 
Strikingly, our results indicated that reserpine affects early developmental gene expression, of 
e.g. Rex1 and Fgf5 and, thus, suggested a very early effect during cell fate decision (Fig. 3.9). 
Thus, the reserpine-induced mesodermal inhibition could indirectly promote neurectodermal 
development by altering the regulation of a central switch such as Nodal. However, further 
experiments are necessary to ultimately prove this hypothesis. 
Furthermore, Fgf5 has not only been described to be a marker for the embryonic 
gastrulation, but it has also been suggested that its expression is somehow linked to 
ectodermal germ layer cells during this stage [Hebert, Boyle et al. 1991]. Thus, Fgf5 is 
certainly involved in gastrulation, which is the process in which a population of cells is 
transformed into a three-layered structure forming the three germ layers. Our results show that 
6 days after the start of differentiation a remarkably stronger expression of Fgf5 was detected, 
when cells were treated with reserpine (Fig. 3.9). This finding suggests that the reserpine 
effects were influencing cell fate decisions very early during development and strengthens the 
hypothesis that the reduction in mesodermal differentiation might be compensated by 
increased ectodermal differentiation.  
Adding to this hypothesis a publication by the group of Toyooka provided evidence 
that Rex1-/Oct3/4+ cells undergo differentiation into neurectoderm more efficiently than 
 Discussion 
85 
 
Rex+/Oct3/4+ cells [Toyooka, Shimosato et al. 2008]. qRT-PCR results presented here 
indicated that between day 2 and day 4 Rex1 was strongly down-regulated in reserpine-treated 
cells, whereas Oct4 expression was similar in control and reserpine-treated cells. This 
Rex1/Oct4 ratio found in reserpine-treated cells resembled a Rex1-/Oct3/4+ situation, thus, 
maybe promoting more efficient differentiation into neurectoderm. 
4.1.4 Conclusions 
In the first part of this thesis murine ES cells were treated with reserpine to elucidate a 
possible role of catecholamines in cardiomyogenesis. This data describes the effect of 
reserpine-induced catecholamine depletion and suggests several important conclusions: 
1) Catecholamine depletion strongly reduces cardiac development, 2) it induces alterations of 
diverse gene expressions not only limited to cardiomyogenesis, 3) Catecholamines are crucial 
for development already at very early developmental stages, even before neuronal 
innervations, 4) Catecholamine depletion leads to alterations of cardiomyocyte 
electrophysiology, and 5) the α- as well as β-adrenergic signaling cascade seem to be 
involved in early stage catecholamine action. It can be assumed that the results shown here 
will help provide a deeper insight into the role of catecholamines and adrenergic signaling in 
ES cell differentiation. Our reserpine-catecholamine-depletion model shows alterations in 
cardiac as well as neuronal developmental processes. This will potentially help to identify 
new targets for directed stem cell differentiation protocols. Finally, the results indicate that 
high dose α- and β-blocker therapy during early pregnancy needs clear indications [Meidahl 
Petersen, Jimenez-Solem et al. 2012]. 
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4.2 MEA-based QT-screen using pluripotent stem cell-derived CMs  
In the second part of the thesis it was approached to establish a pharmacological screening 
tool, suitable for the detection of possible cardio-active side effects such as repolarization 
prolongation. The advantages of extracellular recordings with MEA were combined with the 
properties of pluripotent cells to provide large numbers of CMs and the good comparability of 
this in vitro model with the in vivo situation of diseased hearts. Similar to QT-times from 
ECGs and AP durations from intracellular recordings, we also hypothesized FPDur from 
MEAs to be strongly frequency dependent. Applying several compounds with known 
pharmacological effects we concluded that: 1) under physiological conditions the FP/f 
correlation is negative; 2) if class III antiarrhythmic agents are present, FP/f correlations are 
shifted to less negative or positive values; 3) these findings represent a general correlation 
since they were  confirmed in rESCMs, hESCMs as well as hiPSCMs.  
4.2.1 Optimization of rESC culture and differentiation  
Optimization of the rES cell culture and their differentiation towards CMs was initially a 
crucial step. Using our newly established activinA/BMP4 protocol it was possible to derive 
sufficient numbers of beating clusters. This protocol clearly improved the yield of CMs as 
compared to the other protocols tested. While activinA/BMP4 treatment for directed 
differentiation of hESCMs was published before [Laflamme, Chen et al. 2007], to our 
knowledge here it was shown for the first time that these factors have the same pro-
cardiomyogenic effect on rESCs.   
 Nevertheless, rESC cardiac clusters derived using our protocol showed certain 
downsides compared to hES or hiPS cardiac clusters. Most adverse was the low ratio of CMs 
within rESC EBs. hES and hiPS were differentiated using END2 protocols and generally 
yield comparatively small EBs, yet containing a more beneficial ratio of CMs. Low CM ratios 
in rESC EBs negatively affect FP signal amplitudes and make EBs prone to arrhythmia and 
sensitive to minor temperature oscillations. Arrhythmic behavior was most likely caused by 
the increased force that is needed from CMs to agitate the non-CM cells the EBs are 
predominantly composed of. Because arrhythmic beating reduces the quality of MEA 
recordings and those EBs were therefore not used for analysis, numbers of potentially good 
rESCM EBs were still not very high.  
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4.2.2 Qualitative classification of drug effects by FP/f correlation 
In this work it was shown that the FPDur is dependent on frequency. It was further shown that 
under physiologic conditions FP/f correlations are negative, while they became more positive 
when K+-channel blocking class III agents were present. A graphical method representing 
normalized and averaged FPDur/frequency plots was chosen to illustrate changes of FP/f 
correlations under the influence of different types of drugs. The idea was to classify drug 
effects on the basis of FP/f correlations.  
 
 
Fig. 4.1 illustrates the drug effect classification idea. As stated before, FPDur and beating 
frequency recorded under the influence of a drug were normalized toward the respective 
baseline values (untreated condition). Due to normalization, the baseline FP/f value pair is 
always located at coordinates x=1/y=1 of the FP/f plot (blue rhombus). Given a hypothetical 
1:1 linear correlation of FPDur and beating frequency, FP/f values pairs should align along the 
green line under physiological conditions revealing a negative FP/f correlation. Positive 
chronotropy should shift the value pairs along the green line in the direction of (1), while 
negative chronotropy should shift the pairs in the direction of (2). However, as was shown 
with ISO measurements, in reality the steepness of the lines varied (Fig. 3.27). The variation 
 
 
Figure 4.1: Illustration of drug effect classification based on positive and negative FP/f correlations  
The FPDur/frequency plot is subdivided into quadrants (dottet lines) to classify FPDur/frequency value pairs. 
Normalized baseline value pairs are represented by the blue rhombus (center). The green line indicates a 
negative FP/f correlation shift, as detected under physiological positive (1) or negative (2) chronotropic 
stimulation. The red line indicates a positive FP/f correlation shift. Class III antiarrhythmic drugs E4031 and 
sotalol shifted value pairs to the top right quadrant (3) indicating frequency independent FPDur increase (and 
APDur/QT-time prolonging drug effects), while frequency independent FPDur decrease would be expected in 
quadrant (4). Arrows indicate the drug-induced shift. For further details see text. 
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of the steepness was due to FP signal morphology variation, but also caused by biological 
variations within the analyzed parameters. Therefore, classification of drug effects should 
rather be made based on the quadrant in which the value pairs align. Four quadrants are 
indicated by dotted lines in Fig. 4.1. During positive chronotropic stimulation (ISO), FP/f 
value pairs were found in the top left (1), while under negative chronotropic stimulation value 
pairs were found in the bottom right quadrant (2) (also see Fig. 3.27-3.30). Similarly, in our 
hypothetical conditions, positive FP/f correlation indicating value pairs would align along the 
red line or in the top right (3) or bottom left (4) quadrant. E4031 and sotalol measurements 
(Fig. 3.31) nicely showed that classification on the basis of the quadrants is feasible. 
Nevertheless, it is not expected that all potentially harmful agents tested within a high-
throughput screen induce effects as strong as classical K+-channel blockers like E4031 and 
sotalol. Therefore, the sensibility of such a screen needs to be further improved.  
4.2.3 Limitations and suggested improvements 
Improvement of sensibility of the screening approach presented here can be achieved in 
several ways. Probably most important is standardization of the experimental setup and 
measurement procedure, including the used cell lines, the differentiation protocol, the model 
system and the measurement routines. Those points will be discussed in more detail hereafter. 
 The results of the work demonstrated that our screen worked independent of the used 
cell lines (R366.4+MF12 rESCMs, H1+H9 hESCMs and several hiPSCMs). As mentioned 
before, work with hES cells poses ethical problems but provides cells from human origin as 
compared to rES cells. hiPS cells avoids ethical as well as problems resulting from inter-
species differences. Furthermore, hiPSCMs have been shown to possess functional properties 
very similar to hESCMs and primary CMs [Zhang, Wilson et al. 2009, Germanguz, Sedan et 
al. 2011]. Therefore we suggest that from todays point of view iPSCMs are most applicable 
for such a screen. For drug screening a hiPS cell line representative of humans of all genders, 
races and ages will have to be established to be used as a standard.  
 Optimized and standardized cell culture conditions are absolutely crucial for reliable 
screening, not only to ensure the availability of sufficient numbers of CMs, but also, to 
guarantee that the CMs derived from a pluripotent origin are of the same kind (atrial, 
ventricular or conduction system) and at the same stage of development at all times to make 
results comparable. Several publications showed that CMs undergo continuous change during 
in vitro differentiation [Maltsev, Ji et al. 1999, Reppel, Boettinger et al. 2004, Pfannkuche, 
Liang et al. 2009]. This consequently means that all CMs used, not only have to be in the 
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same state, but also, that this state has to closely resemble or be the same as the mature state 
of CMs [Dolnikov, Shilkrut et al. 2006, Khan, Lyon et al. 2013]). For that reason detailed 
understanding of the maturation processes is essential.  
 Interestingly, early stage ES cell-derived CMs were found to resemble failing cardiac 
myocytes [Brito-Martins, Harding et al. 2008]. It was hypothesized  that re-expression of an 
embryonic gene profile and function might serve as a rescue program [Liang, Halbach et al. 
2010]. Characteristics of heart failure are cytosolic Ca2+ overload, structural changes of the 
myofilaments as well as alteration in neurohormonal regulation [Kho, Lee et al. 2012]. 
 Pharmacological screening can potentially be used to identify drugs that help to reduce 
symptoms of certain heart diseases. Several hiPS disease models have already been 
established [Moretti, Bellin et al. 2010, Fatima, Xu et al. 2011, Itzhaki, Maizels et al. 2011, 
Jung, Moretti et al. 2012], and, in the future, can be used to identify and optimize patient-
specific therapy strategies. 
 However, to further improve our drug-screening model it would have to be considered 
which grade of purification the cells should have for MEA measurements. In the current work 
an EB based culture and measurement was used. EBs not only consist of CMs, but to a major 
proportion of non-cardiac cells. In the EB cell-cell interactions upon drug application cannot 
be controlled and can cause bias. Therefore, a homogenous tissue-like construct of identical 
cells would be preferable. The demand for large amounts of specialized cells is increasing and 
technologies will be developed to provide the cells in the near future [Hattori, Chen et al. 
2010]. During this project initial experiments were conducted using monolayers of purified 
CMs for MEA measurements. Though those monolayers were grown from mouse ESCMs, 
they still showed great promise in regard to their applicability and signal quality (data not 
shown) and will be potentially the optimal format for the MEA-based drug-screen. The major 
disadvantage of EBs, especially of the rES EBs, was the low ratio of CMs to non-cardiac 
cells. This ratio directly influences the signal amplitude of FPs [Halbach 2006]. In turn, low 
signal amplitudes lead to poor signal-to-noise ratios which exacerbated data analysis and 
subsequently lead to increased impreciseness particularly of FPDur. Additionally, CM 
monolayers are preferable to EBs in respect to possible conduction analysis. Describing 
conduction speeds between distant areas of the monolayer adds extra information of drug-
effects to the same experimental setup. 
 Another way of improvement of the screening sensibility can be achieved by 
establishing a suitable quantification. The method we used to evaluate drug-effects is based 
on graphical FP/f correlation classification. This approach provided rather qualitative than 
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quantitative results. One possible solution for quantification was the adaption of heart-rate 
adjustment of QT-times (QTc) as used clinically for ECG normalization. Also tested and 
evaluated in humans, we calculated in analogy to QTc, frequency-corrected FPDur values using 
the clinically most relevant Bazett’s formula [Bazett 1920]. Furthermore, we calculated QT-
corrections after Fridericia’s formula [Fridericia 1920] and a formula derived from the 
“Framingham Heart Study” involving more than 5,000 patients [Sagie, Larson et al. 1992]. 
All these formulas were empirically determined on the basis of a non-linear relationship of 
QT- and RR-intervals. However, all QT-time correction algorithms were questioned because 
of inaccuracy in respect to their universal applicability of the resulting QTc’s [Ahnve 1985, 
Sagie, Larson et al. 1992].  Many other groups have proposed further linear and non-linear 
correction algorithms, but all of them failed to represent corrections covering subjects of all 
genders, races, health conditions and genetic backgrounds within the complete heart-rate 
frequency band. There is also ongoing debate about the maximum normal QTc, ranging from 
400-440 msec [Schouten, Dekker et al. 1991], to determine their predictive value. Even 
though not shown in this work, our corrected FPDur quantification approach partially showed 
consensus with the graphical results. However, depending on the correction algorithm we also 
found contradictions between the applied corrected quantifications (Bazett vs Fridericia vs 
Framingham), but also between graphical and quantitative approach. Altogether, the graphical 
approach provided a more universal picture of the expected drug effects and was therefore to 
be preferred. 
4.2.4 Conclusions 
In summary, we showed here that FPDur is dependent on the beating frequency in MEA 
recordings with pluripotent stem cell-derived CMs irrespective of their species or cell line 
background. We further provided evidence of a negative FP/f correlation under physiologic 
conditions and shift to a positive correlation in the presence of class III antiarrhythmic drugs. 
Based on these findings we propose a graphical classification model for potential 
cardio-active drugs. Yet, with the discussed standardization of our system in respect to cell 
lines, cell culture conditions, the format of the CM tissue-construct, etc., we suggest the 
possibility of a quantifiable drug-screening system based on the proposed principle of FP/f 
correlation. Finally, our observations can provide the basis for establishing a high- or 
medium-throughput screen combining the advantages of hiPSCMs and the MEA technology.
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VII Primers 
Gene Forward-primer Reverse-primer 
Zpf42(Rex1) GAGACTGAGGAAGATGGCTTCC CTGGCGAGAAAGGTTTTGCTCC 
Oct4 CAGCAGATCACTCACATCGCCA GCCTCATACTCTTCTCGTTGGG 
Nanog GAACGCCTCATCAATGCCTGCA GAATCAGGGCTGCCTTGAAGAG 
Fgf5 AGAGTGGGCATCGGTTTCCATC CCTACAATCCCCTGAGACACAG 
Map2 GCTGTAGCAGTCCTGAAAGGTG CTTCCTCCACTGTGGCTGTTTG 
Tubb3 CATCAGCGATGAGCACGGCATA GGTTCCAAGTCCACCAGAATGG 
Nes AGGAGAAGCAGGGTCTACAGAG AGTTCTCAGCCTCCAGCAGAGT 
Sox17 GCCGATGAACGCCTTTATGGTG TCTCTGCCAAGGTCAACGCCTT 
Fox2a TGGAGCTGTGTATGGTCCTGAG GTTGGGTAAGGGAAGCCAGGAA 
Hnf4 TGCGAACTCCTTCTGGATGACC CAGCACGTCCTTAAACACCATGG 
Alb CAGTGTTGTGCAGAGGCTGACA GGAGCACTTCATTCTCTGACGG 
Afp GCTCACATCCACGAGGAGTGTT CAGAAGCCTAGTTGGATCATGGG 
Th TGCACACAGTACATCCGTCATGC GCAAATGTGCGGTCAGCCAACA 
Ddc GGAGCCAGAAACATACGAGGAC GCATGTCTGCAAGCATAGCTGG 
Dbh GAGACTGCCTTTGTGTTGACCG CGAGCACAGTAACCACCTTCCT 
Pnmt1 CAGGAGCCTTTGACTGGAGTGT TCGATAGGCAGGACTCGCTTCA 
Myh6 GCTGGAAGATGAGTGCTCAGAG CCAGCCATCTCCTCTGTTAGGT 
Mlc2a AGGAAGCCATCCTGAGTGCCTT CATGGGTGTCAGCGCAAACAGT 
Nkx2.5 TGCTCTCCTGCTTTCCCAGCC CTTTGTCCAGCTCCACTGCCTT 
Gata4 GCCTCTATCACAAGATGAACGGC TACAGGCTCACCCTCGGCATTA 
T-bra ATCCACCCAGACTCGCCCAATT CTCTCACGATGTGAATCCGAGG 
ACTB CATTGCTGACAGGATGCAGAAGG TGCTGGAAGGTGGACAGTGAGG 
Adrb1 GACGCTCACCAACCTCTTCA ACTTGGGGTCGTTGTAGCAG 
Adrb2 TGAAGGAAGATTCCACGCCC CCGTTCTGCCGTTGCTATTG 
Adrb3 AGGCACAGGAATGCCACTCCAA GCTTAGCCACAACGAACACTCG 
Adra1a GAGTTTGAGGGCTCAGCAGT AGTGACTCTCAACTTGGCCG 
Adra1b AGAACCCTTCTACGCCCTCT GGAGCACGGGTAGATGATGG 
Adr1d ATCGTGGTCATGTACTGCCG GACGCCCTCTGATGGTTTCA 
Adra2a CAGGTGACACTGACGCTGGTTT GACACCAGGAAGAGGTTTTGGG 
Adra2b CCCTCATCTACAAGGGCGAC TTCGGGATCTTCAGGGGTCT 
Adra2c TCACCGTGGTAGGCAATGTG GCGGTAGAACGAGACGAGAG 
Gapdh GGCTCATGACCACAGTCCAT ACCTTGCCCACAGCCTTG 
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VIII Antibodies 
Primary antibodies Manufacturer; Prod# dilution 
   
anti-α-Actinin  Sigma-Aldrich; A7811 1:800 
anti-cardiac Troponin I  Chemicon; MAB3438 1:1,000 
anti-cardiac Troponin T  Thermo Scientific; MS-295-P1 1:1,000 
anti-HCN4  Alomone Labs; APC-052 1:300 
anti-β-III-Tubulin  GeneTex; GTX27751 1:1,000 
anti-NCAM  GeneTex; GTX19782 1:200 
sheep-anti-dopamine-β-hydroxylase GeneTex; 19353 1:200 
   
Secondary antobodies 
  
goat-anti-mouse Alexa Fluor 555  Invitrogen; A21081 1:1,000 
donkey-anti-sheep Alexa Fluor 647 Molecular Probes; A-21448 1:200 
   
Nuclear Staining 
  
Hochst H33342 Sigma Aldrich; B2261 1:1,000 
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IX Materials 
a) Cell culture supplements & consumables 
DMEM Invitrogen, Carlsbad, USA 
IMDM Invitrogen, Carlsbad, USA 
IMDM-GlutaMAXTM Invitrogen, Carlsbad, USA 
Knockout™ DMEM Invitrogen, Carlsbad, USA 
Knockout™ Serum Replacement Invitrogen, Carlsbad, USA 
FBS (Standard) Invitrogen, Carlsbad, USA 
MEM NEAA (100x) Invitrogen, Carlsbad, USA 
β-ME Invitrogen, Carlsbad, USA 
L-glutamine Invitrogen, Carlsbad, USA 
Pen/Strep Invitrogen, Carlsbad, USA 
Trypan blue Invitrogen, Carlsbad, USA 
Trypsin/EDTA (0.05%/0.25%) Invitrogen, Carlsbad, USA 
Collagenase IV Invitrogen, Carlsbad, USA 
PBS (+/+)/(-/-) Invitrogen, Carlsbad, USA 
Geneticin® Selective Antibiotic (G418 
Sulfate)  
Invitrogen, Carlsbad, USA 
Puromycin Dihydrochloride Invitrogen, Carlsbad, USA 
Gelatin (porcine) Sigma-Aldrich, St. Louis, USA 
HyCloneTM FBS Thermo Fisher Scientific Inc., Waltham, USA 
CryoTubes 1.8 ml Nunc® Thermo Fisher Scientific Inc., Waltham, 
USA 
Nylon cell strainer (100µm) BD FalconTM Biosciences, Bedford; USA 
culture dishes (3.5, 6, and 10 cm) BD FalconTM Biosciences, Bedford; USA 
tubes (15 ml, 50 ml) BD FalconTM Biosciences, Bedford; USA 
bacteriological culture dishes (3 and 10 
cm) 
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
multi-well culture dishes Greiner Bio-One GmbH, Frickenhausen, 
Germany 
pipettes (1 ml - 50 ml) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
tubes (1.5 ml) Greiner Bio-One GmbH, Frickenhausen, 
Germany 
pipette tips SARSTEDT AG & Co., Nümbrecht, Germany 
facs tubes   5 ml SARSTEDT AG & Co., Nümbrecht, Germany 
syringes & needles B. Braun, Melsungen, Germany 
 
b) Growth factors 
activin A PeproTech, Hamburg, Germany 
BMP4 PeproTech, Hamburg, Germany 
bFGF PeproTech, Hamburg, Germany 
LIF (ESGRO® Leukemia Inhibitory Factor) Merck Millipore, Billerica, USA 
c) Molecular Biology Kits & Consumables 
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DNA-Ladder (100 bp-10kb) Fermentas 
DNase I, Amplification Grade Invitrogen, Carlsbad, USA 
Fermentas™ Dream Taq™ PCR Master Mix 
(2X) 
Thermo Fisher Scientific Inc., Waltham, 
USA 
JumpStart™ REDTaq® ReadyMix™ Reaction 
Mix 
Invitrogen, Carlsbad, USA 
Mµlti GuardTMBarrier Tips (10µl, 100µl, 
1000µl) 
Sorenson Bioscience Inc. 
PCR tubes  Bio-Rad Laboratories GmbH, München 
Germany 
QuantiFAST SYBR Green PCR master mix  Qiagen, Hilden, Germany 
SuperScript®ViloTM cDNA Synthesis Kit  Invitrogen, Carlsbad, USA 
TriZol® Reagent Invitrogen, Carlsbad, USA 
 
d) Immunohistochemistry Materials 
Cover slips (10 mm) Paul Marienfeld GmbH,  
Lauda-Königshofen, Germany 
Prolong Gold  Invitrogen, Carlsbad, USA 
Roti®Block  Roth, Karlsruhe, Germany 
silanized Histobond cover slips  Paul Marienfeld GmbH,  
Lauda-Königshofen, Germany 
Tissue Tek® O.C.T.™ Compound  Sakura® Finetek Japan Co., Tokyo, Japan 
 
e) Drugs & Chemicals 
Amiodarone Sigma-Aldrich, St. Louis, USA 
CCH Sigma-Aldrich, St. Louis, USA 
DMSO Sigma-Aldrich, St. Louis, USA 
E4031 Sigma-Aldrich, St. Louis, USA 
EDTA Sigma-Aldrich, St. Louis, USA 
EtBr (1%) Roth, Karlsruhe Germany 
ISO Sigma-Aldrich, St. Louis, USA 
Lidocain Sigma-Aldrich, St. Louis, USA 
NH4Cl Sigma-Aldrich, St. Louis, USA 
paraformaldehyde Roth, Karlsruhe, Germany 
Phentoleamine Sigma-Aldrich, St. Louis, USA 
Propidium Iodide Sigma-Aldrich, St. Louis, USA 
Propranolol Sigma-Aldrich, St. Louis, USA 
Resepine Sigma-Aldrich, St. Louis, USA 
SeaKem LE Agarose Roth, Karlsruhe Germany 
Sotalol Sigma-Aldrich, St. Louis, USA 
Sucrose Sigma-Aldrich, St. Louis, USA 
Tris Roth, Karlsruhe, Germany 
TritonX 100 Sigma-Aldrich, St. Louis, USA 
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f) Devices & Softwares 
Microscopy  
Axiovert 10/25/200 Carl Zeiss AG, Jena, Germany 
AxioVision LE 4.5 Carl Zeiss AG, Jena, Germany 
  
Flowcytometry  
Facs Flow solution BD Biosciences, Franklin Lakes, USA 
Cell-wash solution BD Biosciences, Franklin Lakes, USA 
FACScan flow-cytometer  BD Biosciences, Franklin Lakes, USA 
Cyflogic v 1.2.1 Turku, Finland 
  
sqRT-PCR  
peqSTAR 96 Universal Thermocycler  PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
  
qRT-PCR  
ABI-7500 Fast PCR system  Applied Biosystems, Weiterstadt, Germany 
7500 Fast System SDS software 1.4.0.  Applied Biosystems, Weiterstadt, Germany 
NanoDrop 1000 Thermo Fisher Scientific Inc., Waltham, 
USA 
  
MEA  
Multichannel Systems 1060-Inv-BC amplifier Multichannel Systems, Reutlingen, 
Germany 
MEA culture dishes Multichannel Systems, Reutlingen, 
Germany 
MCRack Multichannel Systems, Reutlingen, 
Germany 
MC DataTool Multichannel Systems, Reutlingen, 
Germany 
LabView National Instruments, Austin, USA 
  
Impedance measurement  
E-plate 96 ACEA BIOSciences Inc., San Diego, USA 
xCELLigence RTCA Cardio system  ACEA BIOSciences Inc., San Diego, USA 
RTCA Cardio 1.0 software  ACEA BIOSciences Inc., San Diego, USA 
  
Data processing/Data anlysis  
GraphPad InStat Version 3.10 (trial version) GraphPad Software, Inc., San Diego, USA 
GraphPad Prism®  GraphPad Software, Inc., San Diego, USA 
Microsoft Office 2003+2010 Microsoft, USA 
Origin7 OriginLab Corporation, Northampton, USA 
CorelDraw X5 Corel Corporation, Ottawa, Kanada 
Adobe Photoshop C3 Adobe Systems Incorporated, San Jose, 
USA 
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ImageJ National Institutes of Health, USA 
EndNote Thomson Reuters, New York, USA 
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